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Abstract 
 
Asthma is the most common chronic inflammatory airway disorder globally. Its prevalence is in 
increase. Accumulated evidence has demonstrated the importance of airway smooth muscle cells 
(ASM) in asthma pathophysiology. ASM cells participate in asthma pathogenesis through an altered 
contractile, proliferative and secretory function in asthmatic airways. It has been demonstrated 
that ASM cells can express functional toll like receptor-2 (TLR2) and activation of TLR2 is 
believed to be involved in the amplification of airway inflammatory responses during infectious 
exacerbation. Further, under various conditions of stimulation, ASM cells release several 
inflammatory mediators; such an example is cyclooxygenase-2 (COX-2). COX-2 can be rapidly 
and robustly expressed in response to a diverse range of pro-inflammatory cytokines and 
mediators. Increased levels of COX-2 protein and its prostanoid metabolites serve as key 
contributors to pathophysiology in respiratory diseases typified by dysregulated inflammation. 
We, therefore, aim in this thesis to investigate the underlying molecular mechanisms of TLR2 
receptor activation and upregulation of COX-2 protein levels in ASM cells in the context of 
airway inflammation induced by exacerbated bacterial infection. 
The inflammasome is a multimeric protein complex thought to be responsible for inflammation 
associated respiratory diseases, including asthma, via processing and secretion of pro-
inflammatory cytokine interlukin-1β (IL-1β). Hence, in Chapter 3 we aim to reveal the molecular 
mechanisms underlying TLR2-induced activation of the nucleotide-binding domain and leucine-
rich repeat protein–3 (NLRP3) inflammasome and investigate associated cytokines secretion in 
ASM cells in vitro. Since asthma exacerbations are associated with elevated concentrations of 
secreted IL-1β, we addressed whether the NLRP3 inflammasome is activated under in vitro 
  Abstract 
XXXI 
 
conditions that mimic infectious (bacterial) exacerbations in asthma. Primary cultures of ASM 
cells were treated with infectious stimuli (mimicked using the TLR2 agonist Pam3CSK4, a 
synthetic bacterial lipopeptide) in the presence of an inflammatory stimulus, tumour necrosis 
factor  (TNF). The data demonstrate that in ASM cells the Pam3CSK4-mediated 
augmentation of TNFα-induced IL-6 and IL-8 mRNA and protein concentrations is not mediated 
by IL-1β secretion via NLRP3 inflammasome activation. The data support that NLRP3 
inflammasome is not activated in ASM upon TLR2 ligation. 
Life-threatening asthma exacerbation is the most common and very serious concern for those 
asthma patients who suffer further respiratory tract infections. β2-adrenergic receptor (β2-AR) 
agonists are the first line therapy in the  treatment of asthma. Recent studies, however, have 
revealed that β2-agonists lose bronchodilatory efficacy because the receptor-mediated molecular 
pathways responsible for their beneficial actions are desensitized by infection. In Chapter 4, we 
determine whether infectious stimuli interact to further enhance ASM cell inflammatory 
responses and examine the role o f  COX-2 in this context. In an in vitro model of bacterial 
infection in ASM cells, we show that activation of TLR2 by Pam3CSK4 in the presence TNF, 
leads to the secretion of significant amounts of COX-2 mRNA and protein. Subsequently, the 
level of COX-2 product, PGE2 is increased. β2-agonists exert their bronchodialatory effects upon 
binding with β2-AR receptors that result in the secretion of cyclic adenosine monophosphate 
(cAMP). They also show anti-inflammatory effects via releasing critical anti-inflammatory 
protein mitogen activated protein kinase phosphatase-1 (MKP-1). We found that an increased 
level of TLR2 agonist-induced PGE2 reduces cAMP production as well as anti-inflammatory 
protein, MKP-1, secretion in response to short-acting (salbutamol) and long-acting (formoterol) 
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β2-agonists. Taken together, these results show that, like viruses, bacteria induce prostanoid-
dependent β2-AR desensitization on ASM cells. 
Elevated COX-2 protein secretion was suggested to play a role in asthma exacerbation that also 
corroborate with our previous study (Chapter 4), we were therefore interested in exploring the 
effects of COX-2 upregulation by some other inflammatory mediators. Chapter 5 investigate the 
effects of sphingosine-1-phosphate (S1P), a bioactive sphingolipid that plays an important role in 
pathophysiology of asthma, on COX-2 upregulation alone and in combination with TNF in 
bronchial ASM cells and provide the first demonstration of β2-AR desensitization by S1P in 
vitro. ASM cells were pretreated with S1P for up to 24 h and the temporal kinetics of COX-2 
mRNA expression and PGE2 secretion were measured. It was found that S1P significantly 
enhanced COX-2 expression and PGE2 secretion and this was repressed by the selective COX-2 
inhibitor, celecoxib, the corticosteroid dexamethasone, or siRNA knockdown of COX-2 
expression. We also found that TNFα upregulates S1P-induced COX-2 protein expression and 
augments PGE2 in an additive manner. Further experiments investigated the effects of S1P-
induced COX-2 upregulation and PGE2 secretion on heterologous β2-AR desensitization as 
measured by inhibition of cAMP production in response to the short-acting β2-agonist, 
salbutamol, and the long-acting β2-agonist, formoterol. The data suggest that S1P has the 
potential to repress β2-adrenergic activity via increasing COX-2 mediated PGE2 production in 
ASM cells. 
Evidence suggests that pivotal cytokine, IL-17A, is found in elevated levels in respiratory 
diseases, including severe asthma, and directs pulmonary immunity and inflammation. In 
Chapter 6 we examine the impacts of IL-17A on COX-2 mRNA expression, protein upregulation 
and subsequent PGE2 secretion from ASM cells. Using an in vitro inflammatory model with 
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TNF we show that IL-17A has no effect when added alone but it substantially augments TNF-
mediated responses in ASM cells. Interestingly, we found that IL-7A had no effect on COX-2 
mRNA expression; rather it enhances TNF-induced COX-2 protein stability. Moreover, in this 
study we reveal that TNF-induced COX-2 is subject to proteasomal degradation, the first 
evidence demonstrating post-translational regulation of COX-2 protein stability and confirmed 
by blocking TNF-induced COX-2 proteasomal degradation by using two inhibitors of the 
proteasome - bortezomib and MG-132. Therefore, we have shown that IL-17A acts to increase 
TNF-induced PGE2 by enhancing COX-2 protein stability, but not COX-2 gene expression. 
This study also examined the impact of IL-17A on β2-AR desensitization on ASM cells and 
found that IL-17A did not show any effect on β2-AR desensitization when treated alone or in 
combination with TNF that differs from our previous studies. 
PGE2 is a multifunctional protein that exerts its effects via four receptor subtypes, EP1-4. In 
Chapter 7, the aim was to investigate the role of specific EP receptors (EP2 and EP4) in the 
context of airway inflammation. To explore the underlying molecular mechanisms of PGE2-
induced β2-AR desensitization we used two different protocols, short (serum starvation after 48 h 
of cells plating) and standard (serum starvation after one week of cells plating). In the short 
protocol, it appears that the EP2 receptor may be involved in β2-AR receptor desensitization, 
whereas in the standard protocol it does not. However, the preliminary data of this chapter 
warrants further work to clarify which class of receptor is involved in β2-AR receptor 
desensitization. 
In conclusion, studies conducted in this thesis provide greater understanding of molecular 
mechanisms underlying TLR2 receptor activation and COX-2 protein upregulation in ASM cells. 
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Our increased understanding about these pathways can be exploited as a source of therapeutic 
target for respiratory diseases in future drug development. 
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Chapter 1 
General Introduction 
 
1.1 Asthma 
Asthma is a common and chronic lung disease characterized by airway inflammation, 
remodelling, and hyperresponsiveness to contractile stimuli that promote airway constriction and 
wheezing. According to the World Health Organization (WHO), asthma is of major public health 
importance as it is one of the most common and increasingly prevalent chronic diseases in the 
world. An estimated 334 million people worldwide suffer from asthma, with 250,000 annual 
deaths attributed to the disease. The most alarming statistic  is that the number of people with 
asthma will grow by more than 100 million by 2025 (Masoli et al., 2004; Asher and Pearce, 
2014). Its social and economic impact is therefore substantial. Despite significant understanding 
of the fundamental mechanisms of asthma pathogenesis and other inflammatory airway diseases, 
therapeutic approaches to control the disease still remain a significant unmet need. Hence, it is 
vitally important to conduct extensive research on asthma control and mechanisms.  
Asthma is considered to be a significant cause of morbidity and mortality as it affects 5% of 
adults and 10% of children; these numbers are expected to increase further (Woolcock and Peat, 
1997). Even though it is considered that asthma is most commonly an early childhood disease, it 
can develop at any stage in life, including adulthood. According to The Global Asthma Report 
2014, asthma was estimated as the 14th most important disorder in terms of global years lived 
with disability. Disability from chronic diseases, including chronic respiratory diseases, is 
becoming an increasingly important issue for all health systems. It is therefore important to 
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continue the monitoring of asthma prevalence and severity globally, and actions should be taken 
to reduce the burden of asthma accordingly. 
Asthma has significant impact on the quality of life in terms of  restriction of activities, 
interrupted sleep, disturbed routines, increased stress and poor school performance in children 
(O'Connell, 2004). It is also a costly health problem and the economic burden of asthma is 
enormous, creating very large expenses for the patient, family and society both nationally and 
internationally. It is estimated that for children and adults with asthma, the annual cost is US$14 
billion in direct costs (those associated with medical treatment for the illness) and indirect costs 
(those associated with nonmedical output losses resulting from the consequences of the illness) 
(O'Connell, 2004). Promoting cost-effective management in order to reduce asthma-associated 
morbidity and mortality via optimal treatment is now a challenging issue worldwide. 
 
1.2 Asthma pathogenesis: role of ASM cells 
Asthma is a complex and chronic inflammatory disease that results from overactive 
inflammatory signalling pathways. Inflammation plays the pivotal role in the pathophysiology of 
asthma, causing airway muscles to be tighten and swollen. These changes cause the airway to 
become narrow, making it difficult for air to pass through. In asthma the airway tubes become 
smaller or narrower mostly due to underlying inflammation or swelling. This leaves less space 
inside the airway tubes. Increased sticky mucus production blocks the airways, and contraction 
of muscles around the airways, or bronchospasm, makes the airway tighter (Figure 1.1). Asthma 
symptoms vary from person to person and can be minor to severe and may also change over 
time. Typical asthma symptoms include loss or shortness of breath, frequent coughing especially 
at night, wheezing, chest tightness, pain and pressure. Acute and chronic asthma is characterized 
  Chapter 1 
4 
 
by airway inflammation, airway hyperresponsiveness (AHR) and airway remodelling (Im and 
Ammit, 2014). Possible factors that may lead to the development of asthma include diet, climate, 
community health care standards, genetic factors, and occupational exposure to certain dusts or 
chemicals (Moffatt et al., 2007; Postma et al., 2011). The most common characteristic features of 
asthma are described below: 
Bronchoconstriction: One of the most prominent physiological events that trigger clinical 
symptoms leading to narrowing of the airway and ultimately limiting airflow is 
bronchoconstriction. In severe asthma exacerbation, bronchial smooth muscle contraction 
(bronchoconstriction) occurs quickly to narrow the airways in response to a range of stimuli, 
including allergens or irritants (Ishmael, 2011). 
Airway Inflammation: Airway inflammation is an important feature of asthma which is further 
exaggerated by bronchoconstriction. The extent of clinical severity of asthma depends on airway 
inflammation that eventually leads to airway hyperresponsiveness. Inflammation is also a major 
cause of airway swelling that further interferes in airflow. Airway inflammation appears to be 
central to the pathogenesis of all of these clinical manifestations of asthma that trigger the 
activation of a number of inflammatory cells including mast cells, eosinophils, neutrophils, T- 
lymphocytes, epithelial cells and macrophages (O'Byrne, 1996). 
Airway remodelling: In addition to the inflammatory features mentioned earlier, the airway 
wall of patients with asthma is usually characterised by a number of structural changes that are 
grouped together under the common term “airway remodelling” (Beckett and Howarth, 2003). 
Airway remodelling causes activation of a wide range of structural cells with subsequent 
permanent changes in the airway. This ultimately leads to airflow limitation and airway 
sensitivity and, most importantly, patients become less responsive to therapy. Asthma severity 
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depends on the structural changes of the airway, which include, airway wall thickening, 
subepithelial fibrosis, increase in myocite muscle mass, airway smooth muscle hypertrophy and 
hyperplasia, blood vessel proliferation and dilation, mucus hypersecretion, epithelial hypertrophy 
and mucus metaplasia. 
 
 
Figure 1.1 Pathological mechanisms of asthma (Doeing and Solway, 2013). 
 
Cell biology studies suggest that asthma is a complex multicellular disease, involving atypical 
responses of many different types of lung cell (Locksley, 2010). Among the many cells of the 
lung, epithelial cells and airway smooth muscle (ASM) cells are considered as two major cell 
types that are ultimately responsible for the most common symptomatic pathology in asthma. 
Epithelial cells act as the first line barrier against external stimuli and initiate airway 
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inflammation and participate in mucus production, whereas ASM cells cause symptomatic 
airway narrowing by rapid  and extensive contraction (Erle and Sheppard, 2014). Moreover, in 
asthmatic conditions it is found that ASM cell mass is increased which can potentiate asthma 
exacerbation (Khan, 2013). 
ASM cells are considered to play a key role in the pathophysiology of asthma. Several studies 
suggest that ASM cells are responsible for secreting a number of inflammatory mediators 
including chemokines, cytokines, extra cellular matrix (ECM) proteins and a wide range of 
growth factors (Maruoka et al., 2000; Ammit et al., 2001; Hirst, 2003). The inflammatory 
mediators secreted by ASM cells lead to an early response consisting of bronchoconstriction, 
plasma exudation, mucus secretion, neural effects and attraction and activation of inflammatory 
cells, as well as long-lasting effects such as structural changes of airways or airway 
remodelling. Previous reports also support that ASM cells are not only involved in airway 
narrowing, but also play a role in the remodelling and inflammation of the airways observed in 
asthma (Hirst, 2003; Lazaar and Panettieri, 2005; Zuyderduyn et al., 2008). Moreover, during 
infectious exacerbations in asthma ASM cells participate in the amplification of inflammatory 
responses via augmented cytokine production. Hence, targeting ASM cells to understand the 
cellular and molecular mechanisms associated with asthma exacerbation may offer new and 
important therapeutic targets in treating this common lung disease. 
 
1.3 Asthma management 
Asthma is a chronic disease that has no cure. Though asthma cannot be cured, with good 
management, people with asthma can lead normal, active lives. Asthma symptoms can be 
improved by adapting a proper management plan that includes both non-pharmacological and 
  Chapter 1 
7 
 
pharmacological approaches. Non-pharmacological approaches include avoiding asthma triggers 
where possible and following lifestyle advices, such as, not smoking, eating a healthy diet, 
keeping up-to-date with immunization, responding to worsening symptoms, regular health 
reviews or monitoring with doctors and, most importantly, seeking emergency care when 
needed.  
Asthma medicines are used to stop, control or prevent asthma symptoms in order to reduce the 
number and severity of asthmatic episodes and to improve airflow. Pharmacologically, asthma is 
treated largely via long term control („preventer‟) and quick relief medicine („reliever‟) 
(Martinez and Vercelli; Peters et al., 2006). Steroidal anti-inflammatory drugs are considered as 
key preventer lifesaving medications that prevent asthma attacks by reducing swelling and 
mucus production in the airways. Bronchodilators or β2-agonists are the standard relievers that 
relieve symptoms of asthma by relaxing the airway muscles to help to open up the airways. Two 
types of β2-agonists have been characterized. Short-acting β2-agonists (SABAs) - provide quick 
relief of asthma symptoms but the effects last only 4-6 h and long acting β2-agonists (LABAs) - 
last about 12 h and are considered to be maintenance drugs. However, asthma can be well 
controlled with combination therapies that contain both a corticosteroid and a bronchodilator, 
particularly a long acting β2-agonist (Currie et al., 2005; Selroos, 2007). Some other asthma 
medications also available are listed in Figure 1.2. 
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Figure 1.2 Approaches for asthma management. 
 
Long term use of asthma medicines often leads to unwanted side effects including nausea, 
headache, skeletal muscle tremor, skin and muscle atrophy, disturbed wound healing, 
osteoporosis, growth failure, steroid psychoses, depression, peptic ulcers, upper gastrointestinal 
bleeding, pancreatitis and severe immunosuppressant effects (Lulich et al., 1986; Schacke et al., 
2002). Further, the levels of asthma control vary with drug dose over time and environmental 
factors. Initial asthma treatment depends on the severity of asthma and follow-up treatment 
depends on how well the asthma action plan is controlling the symptoms and preventing asthma 
attacks (Reddel et al., 2015). Asthma treatment for certain groups of people, such as children, 
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pregnant women, or those for whom exercise brings on asthma symptoms are adjusted to meet 
their special needs. 
It is apparent that in spite of extensive social awareness and asthma education, the management 
of acute severe asthma is variable and often unsuccessful, as the current pharmacological 
approach to combat asthma is commonly associated with a number of side effects. Treatments 
may even lose their effect or become insensitive under certain conditions. One such condition is 
asthma exacerbation (Oliver et al., 2014). It is therefore crucial to re-evaluate the drugs currently 
available, both in terms of their clinical use and our understanding of their modes of action, 
along with the development of new potent prophylactic agents.  
 
1.4 Asthma exacerbation 
Most people with asthma exhibit various degrees of inflammation in their airways and their 
airways become much more sensitive to certain irritants; commonly known as „triggers‟. 
Triggers worsen the condition of already inflamed airways, thus provoking an asthma attack 
commonly known as „asthma exacerbation‟. Each individual tends to have different asthma 
triggers. Common asthma triggers include, pollens, dust, animals, air pollution, food additives, 
strong perfumes, exercise, cigarette smoke, some medicines e.g.: aspirin, changes in temperature 
and humidity, psychological influences e.g. extremes of emotion, workplace irritants e.g.: paint 
and varnish fumes, flour, wood dust and, most importantly, respiratory viral or bacterial 
infections (Wark and Gibson, 2006). Asthma exacerbation is associated with accelerated loss of 
lung function (Dougherty and Fahy, 2009). During acute exacerbation the signalling pathways 
involved in airway inflammation and remodelling are activated more easily resulting in 
progressive loss of lung function, including shortness of breath, coughing, wheezing and chest 
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tightness. Severe asthma exacerbation can even cause death. Hence, patients experiencing 
asthma exacerbation need immediate treatment, close observation and frequent assessment of 
lung function. 
Viral and bacterial infections are the most common causes of respiratory infection that 
eventually lead to asthma exacerbation. Respiratory viral or bacterial infections work in an 
additive or synergistic manner that cause normal asthmatic symptoms to become exacerbated. 
There is a strong association between respiratory infections and the risk and pathogenesis of 
asthma exacerbation and it is believed that recognition of respiratory microorganisms by pattern 
recognition receptors can inadvertently initiate or exacerbate an unrelated inflammatory 
condition (Edwards et al., 2012). In a recent review article Oliver et al. explored the relationship 
between viral infections and asthma exacerbation and explained why current therapeutics do not 
fully inhibit virus-induced exacerbations, for example, β₂-adrenergic desensitisation and 
corticosteroid insensitivity as well as which aspects of virus-induced inflammation are likely to 
be attenuated by current therapy  (Oliver et al., 2014).  
Exacerbations can range from mild to life-threatening, and they contribute substantially to urgent 
healthcare utilization. Although the frequency of exacerbations can be reduced by good medical 
management and asthma action plans, infectious exacerbations cannot be completely eliminated. 
It is more likely that when lung function worsens asthmatic patients require greater amounts of 
their asthma medicines, to achieve asthma control. Treatment options are currently limited, and 
thus, further research into the molecular basis of infectious exacerbation is urgently required. 
During infection pathogens interact with airway cells mostly via Toll-like receptors (TLRs), a 
family of pattern-recognition receptors that recognize pathogen-associated molecular patterns 
(PAMPs) (Koziol-White and Panettieri, 2011; Manetsch et al., 2012b). Therefore, investigation 
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of the molecular mechanisms downstream of TLR signalling may identify new approaches to 
restrain infectious exacerbations in chronic airways disease. 
 
1.5 TLR receptors 
TLRs are a class of pathogen-recognition receptors that can recognize specific molecular 
structures found in microbes. They are important for the innate and adaptive immune response to 
pathogen and damage associated molecular patterns (PAMPs, DAMPs). Respiratory tract 
infection by various pathogens, including bacteria, viruses and fungi, are a frequent cause of 
inflammatory airway disease exacerbation. Thereby, activation of TLRs in the airways can play a 
key role contributing to infectious asthma exacerbations. Interestingly, in addition to their ability 
to detect external pathogens, TLRs are also apparently able to mediate responses to a variety of 
endogenous host molecules including reactive oxygen species (ROS), high mobility group box 
(HMGB) protein and surfactant protein A via a number of signalling pathways (Frantz et al., 
2001; Biragyn et al., 2002; Park et al., 2004). The capability of TLRs to respond to an 
extraordinarily diverse range of exogenous and endogenous stimuli makes them exclusively 
potential targets in infective and non-infective inflammatory responses in the airway diseases. 
TLR proteins belongs to a family of type I transmembrane receptors characterized by an NH2-
terminal extracellular leucine-rich repeat domain (LRR) and a COOH-terminal intracellular tail 
containing a conserved region called the Toll/IL-1 receptor (TIR) homology domain (Basu and 
Fenton, 2004). The extracellular domain contains a varying number of LRR, which are believed 
to be primarily responsible for ligand binding. Additionally, these domains may also play a key 
role in TLR dimerization, whereas  the intracellular TIR domain involves protein-protein 
interactions between TLR proteins and their downstream signal transduction components (Basu 
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and Fenton, 2004).Upon ligand binding, TLRs activate several downstream signalling pathways, 
including activator protein-1 (AP-1), nuclear factor kappaB (NF-κB) or mitogen-activated 
protein kinases (MAPKs), resulting in the production of pro-inflammatory cytokines, 
chemokines and other inflammatory mediators (Akira and Takeda, 2004). 
 
 
 
Figure 1.3 TLR receptors and their specific ligands (Medzhitov, 2001). 
 
The TLR family consists of 11 members (TLR1-TLR11) that recognize distinct PAMPs found in 
bacteria, fungi, viruses, helminths and protozoa (Sukkar et al., 2006). TLRs recognize a variety 
of PAMPs (Figure 1.3) and show distinct function in innate immune recognition. The amino acid 
sequences of the human TLRs reveal that members of the TLR family can be divided into five 
subfamilies: the TLR3, TLR4, TLR5, TLR2 and TLR9 subfamilies (Takeda et al., 2003). Our 
target of interest, TLR2, belongs to the TLR family that includes TLR1, TLR6, TLR10, TLR14 
and possibly the avian TLR15 (Roach et al., 2005). It is located at the cell surface and upon 
binding with its ligands, dimerises with TLRs of the same family. Heterodimerization capacity of 
TLR2 receptor with other TLRs of the same family enabled TLR2 to detect a broader range of 
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bacterial PAMPs (Zahringer et al., 2008). Most cells of the human innate and adaptive immune 
system express TLR2 and its heterodimers (Flo et al., 2001; Dasari et al., 2005; Bekeredjian-
Ding and Jego, 2009; Chang, 2010; Meyer-Bahlburg and Rawlings, 2012). Human ASM cells 
express mRNA of a number of TLRs and this expression was shown to be increased upon 
stimulation with pro-inflammatory stimuli (Morris et al., 2005; Sukkar et al., 2006; Lee et al., 
2010). Considering the fact that TLR2 has been implicated in a number of lung-associated 
immune responses, understanding and targeting these pathways may allow regulation of the 
excessive proinflammatory responses during infectious exacerbation. 
 
1.6 TLR2 receptor activation in ASM cells 
TLR2 receptors are expressed on ASM cells and their activation leads to a variety of cellular 
responses, including the production of the neutrophil chemoattractant chemokine IL-8 (Sukkar et 
al., 2006) and IL-6 (Chiou and Lin, 2009), key cytokines responsible for airway inflammation. In 
ASM cells activation of TLR2 receptors are involved in the intensification of airway 
inflammatory responses during infectious exacerbations in asthma via increased cytokine 
production (Manetsch et al., 2012b). Some other effects of TLR2 activation are described below: 
 
1.6.1 Effects on inflammasome activation 
Respiratory infections are key factors underlying asthma exacerbation. Inflammasomes are 
multiprotein complex signalling molecules that are activated by a range of substances produced 
during infections, tissue damage or metabolic imbalances. Inflammasomes are typically 
composed of three components; NOD-like receptor (NLR) proteins, the adaptor molecule 
apoptosis-associated speck-like protein containing a CARD (ASC) domain and caspase-1 
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[reviewed in (Im and Ammit, 2014)]. Upon activation caspase-1 promotes the maturation and 
secretion of the proinflammatory cytokines interleukin (IL)-1β and IL-18 (Schroder and 
Tschopp, 2010). A growing body of evidence has suggested that the nucleotide-binding domain 
and leucine-rich repeat protein–3 (NLRP3) inflammasome is important in chronic airway 
diseases such as asthma and chronic obstructive pulmonary disease (COPD) (Birrell and Eltom, 
2011; dos Santos et al., 2012). 
TLR ligation associated proinflammatory signalling pathways are found important for both 
inflammasome activity and pro-IL-1β availability (Figure 1.4). Microbial sensing through TLRs 
to activate the NLRP3 inflammasome to release IL-1β has been demonstrated in various cells 
(Kanneganti et al., 2006; Netea et al., 2009; Segovia et al., 2012; Lim et al., 2013). Interestingly, 
evidence suggests that TLR activated regulation of NALP3 inflammasome-mediated IL-1β 
production in mononuclear phagocytes appears to be cell-type specific. For example, TLR 
stimulation alone is sufficient to induce inflammasome-mediated IL-1β production in monocytes 
(Netea et al., 2009; Carta et al., 2011), the same as in both bone marrow–derived and splenic 
dentritic cells that secrete substantial amounts of inflammasome-mediated IL-1β upon TLR 
activation in absence of secondary signals (Nguyen et al., 2007; He et al., 2013) . However, in 
many cellular models the activation of the inflammasome requires a secondary signal in order to 
release active IL-1β. In in vitro culture system adenosine triphosphate (ATP) often added in 
order to stimulate this activation step (Latz et al., 2013). Tissue macrophages require both 
primary and secondary signals for inflammasome-mediated IL-1β secretion (Netea et al., 2009). 
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Figure 1.4 TLR2 activated inflammasome and subsequent IL-1β secretion. Ligation of 
TLR2 ligand with the receptor activates inflammaosmes (NLRP3, Caspase-1 and ASC) that 
further promotes maturation and secretion of IL-1β from cytoplasm to outside the cell 
 
To date, however, most NLRP3 inflammasome studies have been limited to airway epithelium 
and macrophages. The ability of ASM cells to produce and secrete pro-inflammatory mediators, 
including cytokines and chemokines, has been established by many studies. Hence, exploring the 
possible involvement of the NLRP3 inflammasome and IL-1β activation in the enhanced 
synthetic function of ASM cells in response to invading pathogens via TLR2 receptor 
stimulation would be very worthwhile. 
 
1.6.2 Effects on COX-2 upregulation 
Cyclooxygenase (COX), also known as prostaglandin H/G synthase, is the rate-limiting enzyme 
responsible for the production of prostanoids from arachidonic acid, hydrolyzed from cell 
membrane phospholipids catalyzed by phospholipase A2. Two isoforms of COX have been 
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identified: COX-1 and COX-2, each encoded by different genes. COX-3 also exists but the 
enzyme is encoded by the same gene of COX-1 so may be considered a variant rather than a true 
isoform. COX-1 is believed to be expressed constitutively as a “housekeeping” enzyme, whereas 
COX-2 can be either inducible or constitutive, depending on the tissue. As an inflammation-
associated enzyme, COX-2 has long been regarded as playing a pivotal role in the pathogenesis 
of airway inflammation in respiratory diseases such as asthma and COPD. Table 1.1 summarises 
the role of COX-2 in different airway cells. A diverse range of mediators present in the airway 
microenvironment have been demonstrated to induce COX-2 and increase COX-2-mediated 
prostanoid products in cells implicated in airway inflammation. Stimulation of TLR4 by 
lipopolysaccharide (LPS) is the prototypical pathogen mimic approach that has been long 
recognised to induce COX-2 in lung models in vitro and in vivo (Swierkosz et al., 1995). More 
recently, rhinoviral infection of epithelial cells in vitro has been shown to increase viral genetic 
material and activation of TLRs on ASM cells. This cross-talk activates TLR3 and TLR 7/8-
induced COX-2 expression and results in prostanoid production by ASM cells (Van Ly et al., 
2013). Stimulation of TLRs can also augment COX-2 expression; in this way infectious stimuli 
can greatly enhance COX-2 upregulation induced by inflammatory mediators. Evidence suggests 
that prostanoids produced via COX-2 upregulation show diverse actions: these can be either 
beneficial or deleterious and their impact on respiratory disease can be dictated by local 
concentration and specific interaction with individual receptors. Understanding the regulation of 
COX-2 expression and associated receptor-mediated functional outcomes may reveal a number 
of critical steps amenable to pharmacological intervention. These may prove invaluable in our 
quest towards future development of novel anti-inflammatory pharmacotherapeutic strategies for 
the treatment of airway diseases. 
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Table 1.1 COX-2 inducers and their functional outcomes 
Inducer(s) Cell Type(s)/ 
Model(s) 
Secreted 
Prostanoid(s) 
Functional 
Outcome(s) 
Reference(s) 
TLR ligand human ASM 
HBEC 
PGE2 β2-AR desensitization (Alkhouri et al., 2014) 
(Van Ly et al., 2013) 
S1P humanASM 
 
HTSMCs 
PGE2 
 
β2-AR desensitization 
 
IL-6 secretion 
(Rumzhum et al., 
2015b) 
(Hsu et al., 2015) 
IL-1β human ASM 
 
 
 
NHTBE 
human ASM 
 
PGE2 β2-AR desensitization 
 
 
 
mucus secretion 
IL-6 secretion 
(Pang and Knox, 
1997; Laporte et al., 
1998; Pascual et al., 
2001) 
(Kim et al., 2002) 
(Lahiri et al., 2001) 
 
Bradykinin human ASM 
 
PGE2 β2-AR desensitization 
 
VEGF mediated 
angiogenesis 
(Pang and Knox, 
1998) 
(Knox et al., 2001) 
TNF, PAF, 
LPS 
NHTBE PGE2 mucus secretion (Gray et al., 2004) 
CSE HTSMCs 
human  sputum 
PGE2 
 
IL-6 secretion 
airway remodelling 
(Lin et al., 2010) 
(Chen et al., 2008) 
Capsaicin human BALF 
 
 
 
guinea pig 
BALF 
TXA2, PGE2, 
PGF2α,PGI2 
cough reflex 
sensitivity 
(Stone et al., 1992; 
Fujimura et al., 1995; 
Ishiura et al., 2009; 
Maher et al., 2009) 
(Kamei et al., 2004) 
Leptin, 
Cytomix 
human ASM PGE2 anti-proliferative 
effect 
(Nair et al., 2008) 
(Belvisi et al., 1998) 
Inhaled 
allergen 
mouse BALF PGI2 immunomodulatory 
function 
(Jaffar et al., 2002) 
Viral 
Infection 
mouse and rat 
BALF 
PGD2 eosinophilic 
inflammation and 
bronchial 
hyperresponsiveness 
(Shiraishi et al., 2008) 
Cytokine human ASM PGE2 reduce RANTES 
release 
(Lazzeri et al., 2001) 
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1.7 COX-2 regulation 
COX-2 expression can be regulated at different levels including transcriptional, post-
transcriptional or post-translational. In order to better understand the role and function of COX-2 
upregulation in respiratory disease, it is necessary to first explore the regulatory mechanisms and 
molecules that control COX-2 expression more generally. In the following text further details on 
COX-2 regulation are described. Table 1.2 includes reference to inducers signalling pathways 
that have been reported. 
 
1.7.1 Transcriptional regulation 
The human COX-2 gene is located on chromosome 1, which contains 10 exons and 9 introns and 
is approximately 8.3 kb long. Structural analysis of human COX-2 gene reveals the presence of a 
5'-flanking region, a 10 exon encoding site, the exon-intron boundaries and the 3'-untranslated 
region (UTR) in both strands of DNA (Appleby et al., 1994). The 5'-flanking region consists of 
approximately 800 bp of nucleotides and this 5'-UTR region contains distinct combinations of 
cis-regulatory elements including, peroxisome proliferator response element (PPRE), two cyclic 
AMP response elements (CRE), a sterol response element (SRE), two NF-κB sites, a specificity 
protein-1 (SP1) site, a CAAT enhancer binding protein (C/EBP), or nuclear factor for 
interleukin-6 (NF-IL6) expression motif, two activator protein-1 (AP-1) sites, an E-box, and a 
TATA box (Appleby et al., 1994; Harper and Tyson-Capper, 2008); all are the binding sites for a 
number of  trans-regulatory transcription factors. The 10 exon region encodes the entire open 
reading frame of the COX-2 gene which is unusually large as it includes not only the final 410 bp 
of the coding region but also 2550 bp of 3'-UTR (Appleby et al., 1994). The three potential poly-
adenylation sequences of 3'-UTR are approximately 280 bp apart from each other. The 23 copies 
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of the ATTTA RNA instability element of the 3'-UTR of the human COX-2 gene are responsible 
for the post-transcriptional regulation of COX-2 expression (Sawaoka et al., 2003). This 3'-UTR 
is characteristic of many other important genes that need to be rapidly “turned on” and then 
“turned off”. Thus, in a manner similar to expression mechanisms shared by proto-oncogene and 
cytokines (Caput et al., 1986; Xu et al., 1997), transcriptional activation of COX-2 gene 
expression occurs very promptly, but transiently, due to instability determinants in the 3'-UTRs. 
Specific binding of RNA-binding proteins to the COX-2 ARE regulates the stability of COX-2 
mRNA. Thereby the levels of COX-2 mRNA expression are determined by post-transcriptional 
regulation along with transcriptional mechanisms (Dixon et al., 2000). Further information on 
post-transcriptional control of COX-2 gene expression will be given in the following sections.  
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Table 1.2 Key molecules that induce COX-2 and their impact on signalling cascades 
Inducer(s) Cell Type(s) Involved Pathway(s) Reference(s) 
IL-β human epithelial 
cell line (A549) 
 
 
 
human ASM 
 
 
NF-B and post-transcriptional 
regulation  
 
 
 
ERK and p38 MAPK pathways 
different regulatory elements, 
transcription factors, and histone 
H4 acetylation 
(Newton et al., 
1997a; Newton et al., 
1997b; Newton et al., 
1997c) 
 
(Laporte et al., 1999; 
Laporte et al., 2000) 
(Nie et al., 2003) 
Bradykinin ASM 
 
 
pulmonary artery 
smooth muscle 
cells 
CREB-1 binding to the CRE in 
the COX-2 promoter  
 
activation of phospholipase A2 to 
promote release of the COX-2 
substrate - arachidonic acid  
(Nie et al., 2003) 
 
(Bradbury et al., 
2004) 
Oxidative 
stress 
human lung 
fibroblasts 
 
ASM 
 
 
 
human epithelial 
cell line (A549) 
 
ERK and NF-B  
 
TLR4/MyD88/TRAF6/c-
Src/NADPH oxidase signalling 
that leads to the activation of 
MAPKs and NF-κB  
 
P2 purinoceptors/PKCs/NADPH 
oxidase-mediated activation of 
Jak2 and STAT3 pathway 
 
cyclic GMP-mediated pathways 
(Martey et al., 2004) 
 
(Lin et al., 2010) 
 
(Cheng et al., 2013a) 
 
(Watkins et al., 1997) 
 
S1P 
rat vascular 
smooth muscle 
 
 
 
 
ASM 
 
Ca
2+
-dependent PKC and Src 
activation via S1P3 receptor 
coupled to pertussis toxin-
sensitive and -insensitive G 
proteins 
 
S1PR1/3/c-Src/PYK2/p42/p44 
MAPK- or JNK1/2- and 
S1PR1/3/c-Src/p38 MAPK-
dependent AP-1 activation 
(Nodai et al., 2007) 
 
 
 
(Hsu et al., 2015) 
trypsin  
 
ASM PAR-2-independent mechanism (Chambers et al., 
2003) 
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1.7.2 Post-transcriptional regulation 
COX-2 is known to be regulated at the post-transcriptional level by RNA-binding proteins and 
microRNAs (miRNAs). The 3'-UTR of COX-2 mRNA contains multiple copies of adenylate and 
uridylate rich (AU-rich) elements (AREs), and much has been learned over the past decade or so 
in regards to the cis-acting motifs within this region and the RNA-binding proteins that interact 
with AREs to dictate mRNA stability. Mukhopadhyay et al. identified a novel RNA binding 
protein, CUGBP2 (CUG triplet repeat, RNA-binding protein 2), which stabilizes COX-2 mRNA 
but inhibits its translation (Mukhopadhyay et al., 2003). Augmented binding of the stabilizing 
Human Antigen R (HuR) to the ARE of the COX-2 3'-UTR is responsible for COX-2 mRNA 
stability (Erkinheimo et al., 2003; Subbaramaiah et al., 2003; Doller et al., 2009) in different 
cells. Studies by Hall-Pogar et al. suggest that alternative polyadenylation of the COX-2 gene is 
an important post-transcriptional regulatory event and some RNA-binding proteins, U1A, PTB 
(polypyrimidine tract-binding protein), p54
nrb
 and PSF (PTB-associated splicing factor) can 
regulate the polyadenylation signal upon binding with upstream sequence elements (Hall-Pogar 
et al., 2005; Hall-Pogar et al., 2007). Time-dependent modulation of transcriptional and post-
transcriptional phases of the COX-2 biosynthetic pathway can be achieved by anti-inflammatory 
corticosteroids and confirmed by actinomycin D analysis (Raz et al., 1989). Tristetraprolin 
(TTP), a mRNA-binding protein that promotes message instability, has been shown to bind with 
COX-2 mRNA in the region of the 3′-UTR, and thus participate in post-transcriptional regulation 
of COX-2 in cancer cell lines (Sawaoka et al., 2003). Other cytoplasmic proteins with RNA-
binding properties can also regulate COX-2 gene expression including: T-cell intracellular 
antigen-1 (TIA-1) (Dixon et al., 2003; Phillips et al., 2004), RNA-binding motif protein 3  
(RBM3) (Cok and Morrison, 2001; Sureban et al., 2008) and Apobec-1 (Anant et al., 2004). The 
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stress-inducible 70-kDa heat shock protein (Hsp70) has also been recently identified as a novel 
post-transcriptional regulator of COX-2 gene that binds and stabilizes COX-2 mRNA (Kishor et 
al., 2013). Notably, the p38 MAPK pathway activated by various inflammatory mediators plays 
an important role in post-transcriptional regulation of COX-2 by influencing mRNA message 
stability as well as its abundance (Ridley et al., 1998; Dean et al., 1999; Jang et al., 2000; Zhang 
et al., 2000; Lasa et al., 2001).  
In addition to regulation by RNA-binding proteins, COX-2 has more recently been found to be a 
target of various microRNAs. Small non-coding RNAs called microRNAs (miRNAs), 
composing approximately 21–24 nucleotides, are considered to be vital post-transcriptional gene 
regulators through their ability to control mRNA stability and translation by imperfect base-
pairing to the 3′-UTR of their target mRNAs. Binding of two miRNAs, mmu-miR-199a and 
mmu-miR-101, results in post-transcriptional regulation of the COX-2 gene by affecting mRNA 
stability and translation (Chakrabarty et al., 2007). Another microRNA, miR-16, is known to 
silence COX-2 gene expression by two mechanisms: directly, by binding to the microRNA 
response element motif in the COX-2 3'-UTR and indirectly, by reducing the levels of HuR 
(Agra Andrieu et al., 2012). MicroRNA-320a is found to be regulating COX-2 expression 
through extracellular signal-regulated kinases (ERK)/NF-κB pathways, hence, effecting pro-
inflammatory cytokine production (Cheng et al., 2013b). 
 
1.7.3 Post-translational regulation 
Although most of the research on COX-2 regulation has been focused at the transcriptional and 
post-transcriptional levels, post-translational control is increasingly recognized as an important 
contributor to overall COX-2 protein production. The COX-2 protein that is immediately 
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translated from stable mRNA undergoes several post-translational regulatory modifications to 
control the abundance of active protein. COX-2 protein is found localized in the endoplasmic 
reticulum (ER) and the nuclear envelope (Reiger et al., 1993). This spatial regulation of COX-2 
protein is regulated by N-glycosylation. Among five potential N-glycosylation sites of COX-2 
protein sequences, three are always glycosylated, one (Asn
580
 in human and mouse) is 
glycosylated more than 50% of the time, and one is never glycosylated (Otto et al., 1993). The 
variability of glycosylation at Asn
580
 results in the formation of two distinct glycoforms, 
unmodified and modified, with molecular weights 72 and 74 kDa, respectively. Characterization 
by mass spectrometry reveals that the carbohydrate moieties at each site are composed of high-
mannose oligosaccharide (Percival et al., 1997; Nemeth et al., 2001). Glycosylation at Asn
580
 
plays a significant role in the COX-2 protein turnover (Sevigny et al., 2006). The mature 
monomer of COX-2 consists of three folding domains including an epidermal growth factor-like 
domain, a membrane binding domain, and a catalytic domain in sequence (Yuan and Smith, 
2015). A number of reports have identified the mechanistic cascades required for the maturation 
of COX-2 in the ER lumen including cleavage of the N-terminal signal sequence, N-
glycosylation at multiple sites, disulfide bond formation, membrane insertion, and dimer 
formation (Otto et al., 1993; Xiao et al., 1998; Spencer et al., 1999; Yuan et al., 2006). 
Protein degradation is also an important factor in post-translational regulatory control and 
properly folded COX-2 has been reported to be degraded via two independent pathways 
(Mbonye et al., 2008; Wada et al., 2009). The first degradative pathway is called substrate-
induced COX-2 degradation and it is considered to be proteasome independent (Mbonye et al., 
2008; Mbonye and Song, 2009). Arachidonic acid is the endogenous fatty acid substrate of 
COX-2 which is subject to oxygenation as a consequence of suicide inactivation of COX-2 
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catalytic activity (Mevkh et al., 1993; Song et al., 2001). Substrate-dependent degradation of 
COX-2 occurs as a result of structural damage to the enzyme that occurs by fatty acid substrate 
oxygenation.  
The second pathway involves ER-associated degradation (ERAD), a process by which ER-
associated N-glycoproteins are selectively removed for degradation and subsequently undergo 
proteolysis by 26 S proteasome. Because COX-2 is a luminal integral membrane protein, it needs 
to be transported out of the ER for degradation; this characteristic feature makes COX-2 an 
exclusive ERAD substrate (Mbonye and Song, 2009). Several studies have described the ERAD 
process for COX-2 protein in different cells (Mbonye et al., 2006; Mbonye and Song, 2009; 
Yuan and Smith, 2015). This process occurs at a relatively constant rate and it is believed that 
glycosylation of Asn
594
 of COX-2 is critical for initiating the entry of the enzyme into the ERAD 
system and, most importantly, any mutation of this site will prevent glycosylation as well as 
make COX-2 more stable (Mbonye et al., 2006; Mbonye et al., 2008). COX-2 protein 
ubiquitination and degradation through the 26 S proteasome in the cytoplasm is also shown in 
several other reports (Rockwell et al., 2000; Figueiredo-Pereira et al., 2002; Neuss et al., 2007; 
Chen et al., 2013) and Sing et al. revealed the importance of the ER-mannosidase I enzyme in 
facilitating the ERAD-mediated ubiquitin-proteasomal degradation of COX-2 in human uterine 
stromal cells (Singh et al., 2012). The membrane protein caveolin-1 has been implicated in the 
post-translational regulation of COX-2 via ERAD-mediated ubiquitination and proteasome 
degradation pathways (Chen et al., 2010; Chen et al., 2013). Further investigations are warranted 
to fully understand this contribution. 
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1.8 Inflammatory mediators 
Numerous mediators are capable of eliciting an inflammatory response from airway cells 
[reviewed in (Barnes et al., 1998)]. The cross-talk between cells and the mediators is the 
principle driving-force for the inflammatory response observed in respiratory diseases like 
asthma. In this project we have chosen TNFα, Pam3CSK4, S1P and IL-17A for their potential 
role in airway inflammation in the context of TLR2 activation and COX-2 upregulation. In the 
following sections we have given brief discussion about them. 
 
1.8.1 TNFα 
TNFα is a multifunctional pro-inflammatory cytokine that belongs to the TNF superfamily. It is 
a crucial cytokine mainly secreted by activated macrophages but also by other immune cells like 
mast cells, lymphocytes, endothelial cells and, importantly for this study, also by structural cells 
such as fibroblasts, epithelial cells and smooth muscle cells (Wajant et al., 2003; Brightling et 
al., 2008). Though TNFα is detectable in healthy individuals, elevated serum and tissue levels 
are found in inflammatory and infectious conditions. Literature suggests that large amounts of 
TNFα are released in response to LPS and other bacterial products (Wajant et al., 2003). Two 
forms of TNFα with distinct biological activities have been identified, membrane-associated and 
soluble TNFs. TNFα exert their action by binding with one of two distinct receptors, TNFR1 and 
TNFR2, which are differentially regulated on various cell types in normal and diseased tissue 
(Al-Lamki et al., 2001). This cytokine is involved in the regulation of a wide spectrum of 
biological processes including, cell growth promotion & inhibition, angiogenesis, 
immunomodulation and inflammation. Thereby, it plays an important role in modulating a wide 
range of inflammatory conditions such as rheumatoid arthritis (Sarzi-Puttini et al., 2005), 
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cardiovascular diseases (Sack, 2002), psoriasis (Kleyn and Griffiths, 2006) and cancer (Li et al., 
2015). The role of TNFα has been implicated in many aspects of the airway pathology in 
respiratory diseases (Berry et al., 2007; Brightling et al., 2008; Matera et al., 2010) and this 
project also highlighted the inflammatory role of TNFα in asthmatic condition. By stimulating a 
number of inflammatory pathways and releasing associated pro-inflammatory modulators, TNFα 
plays an important role in increasing airway hyperresponsiveness of ASM cells and airway 
remodelling (Amrani et al., 2001; Ammit et al., 2002). Our earlier studies also demonstrated 
TNFα as a model inflammatory mediator that secretes a significant amount of pro-inflammatory 
cytokines in ASM cells and confirmed its role in the pathology of inflammatory lung diseases 
like asthma. 
 
1.8.2 Pam3CSK4 
It is well described that the cells of the innate immune system identify molecules synthesized 
exclusively by microbes and coordinate the inflammatory response to pathogens via TLRs signal 
transduction pathways. Most common microbial products include LPS, peptidoglycans, 
lipotechoic acids and bacterial pathogens produced lipoproteins (BLPs) (Henderson et al., 1996; 
Aliprantis et al., 1999). BLPs are bacterial cell wall components found both in gram-negative 
and gram-positive bacteria that possess pro-inflammatory cytokine-inducing ability (Kostyal et 
al., 1994). The immunomodulatory effects of BLP are mediated through their amino acid 
terminus and N-palmitoyl-S-[2,3-bis-(palmitoyloxy)-(2R,S)-propyl]-(R)-cysteinyl-seryl-(lysyl)3-
lysine (Pam3CSK4) is a well-established synthetic tripalmitoylated lipopeptide that mimics the 
acetylated amino terminus of bacterial lipoproteins (Manukyan et al., 2005). Aliprantis et al. first 
described Pam3CSK4 as a potent TLR2 activator that induces the signalling cascade leading to 
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the activation of NF-κB (Aliprantis et al., 1999). It is believed that synthetic lipopeptides provide 
an important tool for studying innate immune recognition mechanisms as they are not only more 
easily obtained than the lipopeptides directly obtained from organisms but also are free of other 
contaminating bacterial components (Manukyan et al., 2005). Several reports demonstrate that 
TLR engagement with synthetic ligands or bacterial products enhance TLR2 function and induce 
proinflammatory cytokine secretion from human ASM cells, including eotaxin and IL-6, IL-8 
(Sukkar et al., 2006; Manetsch et al., 2012b). Manetsch et al. suggests that Pam3CSK4 robustly 
amplifies TNFα-induced IL-6 and IL-8 expression in ASM cells and enhances neutrophil 
chemotaxis and also demonstrates that the effect of Pam3CSK4 occurs via phosphorylation of 
CREB protein at Ser
133
 and CRE-mediated transcription, rather than via enhanced NF-κB- or 
MAPK-mediated signalling (Manetsch et al., 2012b). In our studies, we have used Pam3CSK4 as 
a potent TLR2 agonist (Pam3CSK4 also targets TLR1, however, in this thesis we focused only 
TLR2) and suggested that ligation of TLR2 with Pam3CSK4 may enhance the ASM 
inflammatory response during infectious exacerbation. 
 
1.8.3 S1P 
S1P is a bioactive end product of sphingolipid metabolism and has been identified as a unique 
molecule capable of mediating diverse biological responses. S1P level is found to be increased in 
multiple cell types in response to numerous stimuli, including antigen, cytokines and both 
receptor tyrosine kinase and G protein-coupled receptor (GPCR) agonists (Pyne and Pyne, 2000). 
It has been anticipated that S1P can act both as an extracellular mediator via a family of plasma 
membrane GPCRs, and as an intracellular second messenger for growth factors, by altering the 
activity of specific intracellular target proteins (Pyne and Pyne, 2000). It has been shown to 
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regulate cell growth, proliferation, differentiation and chemotaxis of various cell types, and the 
well-recognized role for S1P has been  proposed in disease states such as atherosclerosis (Wang 
et al., 1999b) and certain cancers (Hong et al., 1999; Wang et al., 1999a) . Ammit et al. first 
showed that S1P levels were elevated in the airways of asthmatic subjects following antigen 
challenge and explored the association of S1P with airway inflammation (Ammit et al., 2001). In 
addition, S1P was identified as an effective regulator of ASM growth, contraction and synthetic 
functions. Several further studies indicate S1P mediates the activation of a number of signalling 
pathways leading to physiological and also pathophysiological effects via COX-2 protein 
upregulation (Nodai et al., 2007; Fuerst et al., 2014; Hsu et al., 2015). Therefore, we believe that 
a better understanding of signalling mechanisms underlying S1P-induced COX-2 gene regulation 
will create opportunities for the development of anti-inflammatory therapeutic strategies for 
asthma. 
 
1.8.4 IL-17A 
In our study we have also used cytokine IL-17A as an inflammatory mediator in asthmatic 
conditions, confirming that, over the last decade, this cytokine has become of increasing interest 
in airway disease. Among six members in the interleukin 17 cytokine family (IL-17A-F), the 
biological function and regulation of IL-17A and IL-17F are best understood (Jin and Dong, 
2013). IL-17A is an approximately 15 kDa glycoprotein, originally identified as the human 
homologue, mostly secreted by activated T lymphocytes cells and also by several other innate 
immune cell types, such as lymphoid tissue inducer cells, natural killer and natural killer T cells 
and macrophages. It thereby plays key regulatory roles in host defence and inflammatory 
diseases (Henness et al., 2004; Jin and Dong, 2013). IL-17 family cytokines exert their biological 
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functions by binding with surface receptors on target cells. Five IL-17 receptor families have 
been identified including IL-17RA, IL-17RB, IL-17RC, IL-17RD and IL-17RE (Moseley et al., 
2003). Upon receptor-ligand interaction IL-17A promotes the secretion of various pro-
inflammatory cytokines and chemokines via stimulating a number of downstream signalling 
pathways including NF-κB and MAPK activation, tumor-necrosis factor receptor-associated 
factor (TRAF6),  IκB kinase I (IKKi),  ubiquitin-specific processing protease 25 (USP25) signal 
transduction pathways (Jin and Dong, 2013). Several reports suggest the  association  of high 
concentrations of IL-17A with autoimmunity and inflammatory diseases such as rheumatoid 
arthritis, psoriasis, multiple sclerosis , inflammatory bowel disease (IBD) and cancer (Zhang et 
al., 2013; Kirkham et al., 2014; Huang et al., 2015; Omrane et al., 2015). Moreover, an increased 
level of IL-17A protein is found in human airways during severe inflammatory conditions (Molet 
et al., 2001; Laan et al., 2002; Chesne et al., 2014). Previous studies in ASM cells also confirm 
the involvement of IL-17A in the production of a large spectrum of inflammatory cytokines (IL-
6, IL-1β, and IL-11), chemokines (Eotaxin/CCL-11 and CXCL8) and augmentation of ASM cell 
proliferation and migration, thus enhancing the inflammatory response (Dragon et al., 2007; 
Chang et al., 2012). Hence, the functional role of IL-17A in developing airway diseases led to 
further exploration mechanisms at the cellular level to develop a better understanding of the 
involvement of IL-17A in severe asthma. 
 
1.9 COX-2 upregulation and β2-AR desensitization 
β2-agonists are the first line therapy to relieve acute bronchoconstriction in people with asthma or 
COPD. β2-agonists exert their effects by binding with the β2-AR, a seven transmembrane GPCR. 
Binding of β2-agonists with β2-AR results in activation of adenylyl cyclase (AC) through a 
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stimulated Gs protein coupled mechanism that leads to the formation of second messenger cyclic 
adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA) (Figure 1.5). 
PKA phosphorylates a number of target proteins resulting in smooth muscle relaxation or 
bronchodialation. However, heterologous and homologous β2-AR desensitization can occur in a 
diverse range of clinically-relevant contexts, including β2-agonist overuse, inflammation and 
bacterial and viral infectious exacerbation [ reviewed in (Shore and Moore, 2003)]. Homologous 
desensitization occurred when the receptor lost its responsiveness upon binding with its agonist 
itself (Hall et al., 1993), whilst heterologous desensitization is attributed to receptor 
downregulation by other mediators present in the microenvironment around asthmatic airway 
smooth muscle (Pang and Knox, 1997; Laporte et al., 1998; Pang et al., 1998b). 
 
Figure 1.5 Mechanisms of action of β2-agonists and underlying molecular pathways of β2-
AR desensitization. 
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COX-2 immunoreactivity is found to be increased in asthmatic airways (Nasser et al., 1996; 
Demoly et al., 1997) and levels of PGE2 are increased in the lungs of people with COPD 
(Montuschi et al., 2003) in a manner correlated with airflow obstruction severity (Montuschi et 
al., 2003; Chen et al., 2008). PGE2 exerts multiple physiological and pathophysiological effects 
in airways. It is well-recognized that the β2-AR on human ASM cells is subject to homologous 
desensitization induced by PGE2. This was first demonstrated in 1993 when Hall et al. showed 
that pretreatment of cells with PGE2 induced a dose-dependent reduction in cAMP release in 
response to isoprenaline (Hall et al., 1993). Further mechanistic insights into the underlying 
mechanisms and direct links to COX-2-mediated prostanoid production followed (Laporte et al., 
1998; Pang et al., 1998b; Penn et al., 1998; Pascual et al., 2001; Shore and Moore, 2003); with 
many of these studies demonstrating that PGE2 directly induces β2-AR desensitization and thus 
tachyphylaxis to the first line bronchodilators in respiratory diseases - β2-agonists (Shore and 
Moore, 2003; Billington et al., 2013). Rhinoviral infection has also been shown to desensitize the 
β2-AR and reduces cAMP generation in response to β2-agonists (Trian et al., 2010) in a 
prostanoid-dependent manner (Van Ly et al., 2013). Thus, the clinical consequence of COX-2-
mediated upregulation of PGE2 secretion in the context of β2-AR desensitization on ASM cells 
may prove detrimental and perhaps particularly so in infectious exacerbation. 
 
1.10 Targeting COX-2 in airway inflammation: PGE2 receptor signalling 
Increased levels of COX-2 protein and prostanoid metabolites serve as key contributors to 
pathobiology in respiratory diseases typified by dysregulated inflammation. However, COX-2 
products may not be all bad: prostanoids can exert anti-inflammatory/bronchoprotective 
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functions in airways in addition to their pro-inflammatory actions. There are multiple ways to 
target COX-2, including: inhibiting enzymatic activity with non-selective (e.g. NSAIDs) or 
selective inhibitors (such as coxibs), repressing COX-2 mRNA expression by targeting 
transcriptional or post-transcriptional mechanisms (RNA-binding proteins or miRNAs) and 
enhancing COX-2 protein stability by affecting N-glycosylation or ERAD-mediated proteasomal 
degradation. These molecular mechanisms represent feasible options for targeting COX-2 as they 
are amenable to manipulation and some are controlled by spatiotemporal regulation so that 
beneficial effects within the context of respiratory disease remain a distinct possibility.  
Traditional NSAIDs, such as aspirin, can inhibit both COX-1 and COX-2. However, their regular 
use is associated with side effects, such as gastric bleeding due to their inhibitory effects on 
COX-1. Most importantly, in asthmatic patients the use of aspirin may lead to aspirin-sensitive 
respiratory disease (ASRD), or aspirin exacerbated respiratory disease (AERD), or aspirin-
induced asthma (AIA), or aspirin sensitive asthma (ASA) where the expression of COX-2 is 
critically low. A number of reports suggest that downregulation of PGE2 production associated 
with EP2 receptor defects is identified in AERD pathogenesis (Szczeklik et al., 1975; Szczeklik, 
1990; Sestini et al., 1996; Celik et al., 2001; Szczeklik and Stevenson, 2003; Jinnai et al., 2004; 
Ying et al., 2006; Corrigan et al., 2012; Liu et al., 2013; Steinke and Borish, 2015).  Moreover, 
modern NSAIDs that inhibit COX-2 selectively are associated with a lower incidence of upper 
gastro-intestinal disease (Chang and Howden, 2004). Hence, at this stage the greatest potential is 
offered by our advancing knowledge of the prostanoid receptor family to control the direct 
effects of prostanoids leaving the in general effects of COX-2. Prostanoids exert their diverse 
functions by binding with several receptor subtypes, including: the PGD receptor (DP1 and DP2), 
four subtypes of the PGE receptor (EP1, EP2, EP3, and EP4), the PGF receptor (FP), the PGI 
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receptor (IP) and the TxA receptor (TP) (Narumiya and FitzGerald, 2001) (Figure 1.6). 
Development of selective agonists and antagonists are valuable pharmacological tools and 
exciting lead compounds for future drug discovery in respiratory conditions (Buckley et al., 
2011; Birrell et al., 2013; Maher et al., 2015). Whether further studies will reveal that receptor 
redundancy exists, and that being more specific by targeting individual prostanoid receptors do 
not offer any added benefit over global approaches will emerge. However, coupled with mouse 
models where individual prostanoid receptors are knocked-out, these approaches offer an elegant 
means to address unanswered questions regarding the impact of COX-2 products in clinically 
relevant in vivo models of respiratory disease. This was recently shown by Birrell et al. where 
the EP4 receptor was shown to be responsible for anti-inflammatory effects of PGE2 in the lung 
(Birrell et al., 2015). 
 
 
Figure 1.6 COX-2 pathways - multiple ways to target COX-2 expression/activity or 
prostanoid receptors. 
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1.11 Hypothesis and aim of the study 
In this thesis, we largely aim to explore the underlying molecular mechanisms of TLR2 receptor 
activation, COX-2 protein upregulation and β2-AR desensitization in ASM cells. We have 
addressed two basic hypotheses : 
1.  Activation of TLR2 receptor in ASM cells may upregulate some key inflammatory 
regulators including NLRP3 inflammasome and COX-2.  
2. In ASM cells, COX-2, induced by not only TLR2 activation but also by some other 
inflammatory mediators (S1P & IL-17A), may be responsible for β2-AR desensitization 
via producing PGE2.  
The aims of this thesis are as follows:  
I. Role of TLR2 in the activation NLRP3 inflammasome in ASM cells 
A growing body of evidence suggests that the NLRP3 inflammasome is important in chronic 
airway diseases such as asthma and COPD [reviewed in (Im and Ammit, 2014)]. Therefore, in 
this study the aim was to determine the possible involvement of the NLRP3 inflammasome and 
IL-1β activation in ASM cells in response to Pam3CSK4-induced TLR2 activation.  
 
II. TLR2 activation induced desensitization of β2-AR via COX-2 production 
Research has revealed that β2-AR agonists lose bronchodilatory efficacy because the receptor-
mediated molecular pathways responsible for their beneficial actions are desensitized by 
infection (Trian et al., 2010). To date, most studies have focused on viral infection, leaving the 
impact of bacterial infection on β2-AR desensitization relatively under-investigated. We address 
this in this study. 
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III. COX-2 expression and PGE2 secretion by S1P: effects on β2-AR desensitization 
Cellular studies in ASM have shown that inflammatory mediators and infectious stimuli reduce 
β2-adrenergic responsiveness in a COX-2-mediated, PGE2-dependant manner (Van Ly et al., 
2013). In this study, we show that S1P, which plays an important role in the pathophysiology of 
asthma, also induces β2-AR desensitization in bronchial ASM cells and exerts 
hyporesponsiveness to β2-agonists. 
 
IV. TNF-induced COX-2 protein stability and PGE2 secretion by IL17A 
Recent evidence has implicated IL-17A as a key driver of disease exacerbation in severe asthma 
(Brandt et al., 2013) and in vivo models of infectious exacerbation (Essilfie et al., 2011; Lunding 
et al., 2015; Roos et al., 2015). We address this herein and examine the impact of IL-17A on 
COX-2 mRNA expression, protein upregulation and subsequent PGE2 secretion from ASM cells. 
In this study we also examined the impact of IL-17A on β2-AR desensitization on ASM cells. 
 
V. Identify the role of specific PGE2 receptors 
Understanding the effect of PGE2 is very complicated, as their biological activities are mediated 
via four distinct EP receptor subtypes, EP1-4, that are coupled to different intracellular signal 
transduction pathways (Chung, 2005). In this study, we attempt to find the role of specific PGE2 
receptors, in particular, EP2 and EP4 receptors, in the context of airway inflammation. 
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Chapter 2 
General Materials and Methods 
 
2.1 Materials 
Unless otherwise specified, all chemicals and reagents used in this study were purchased from 
Sigma-Aldrich (St.Louis, MO). 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Solutions 
Cell culture/feeding media for the culture of ASM cells is composed of Dulbecco‟s Modified 
Eagle‟s Medium (DMEM) with phenol red, enriched with 200 mM L-glutamine, 1 M HEPES (4-
(2-hydroxyethyl)-1- piperazineethanesulfonic acid), antibiotic-antimycotic liquid (containing 
10,000 units/mL pencillin, 10,000 µg/mL streptomycin and 25 µg/mL amphotericin B) 
(Invitrogen, Carlsbad, CA) and 10% heat-inactivated (56 °C for 30 min) foetal bovine serum 
(FBS) (Interpath Services, Heidelberg West, VIC, Australia). Starving media used in cell culture 
consists of 0.1% (v/v) BSA (30% w/v solution, sterile) in DMEM (no other supplements are 
added). 
 
2.2.1.2 Culture of primary human ASM cells 
Human bronchi from the large bronchial airways were obtained from patients undergoing 
surgical resection for carcinoma or lung transplant donors in accordance with procedures 
approved by the Central Sydney Area Health Service and the Human Ethics Committee of the 
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University of Sydney. Primary ASM cells were dissected, purified and cultured as previously 
described by Johnson et al. (Johnson et al., 1995b). Specific to our settings, after dissection of 
the bronchi from the surrounding tissue and removing of the epithelium layer individual ASM 
tissue bundles were plucked out and placed into 25cm
2 
tissue culture flask (Sarstedt, 
Nümbrecht Germany) with DMEM containing phenol red and supplemented with 2 mM L-
Glutamine, 20 mM HEPES, 10% heat inactivated FBS and 2% Antibiotic-Antimycotic mix 
(200 U/L Penicillin G, 0.5 µg/mL Amphotericin B and 200 µg/mL Streptomycin sulphate). The 
flasks were then placed in a 5% CO2 humidified incubator at 37°C. Cells grew to confluence 
over 14-21 days and were passaged when confluent. 
 
2.2.1.3 Passaging ASM cells 
Before trypsinizing the cells (2 min at 37°C) the media was aspirated and the cells were washed 
two times with sterile PBS (Ca
2+
/Mg
2+
-free) to remove all traces of FBS. Cell passaging was 
completed using a trypsin solution (0.5 g/l porcine trypsin and 0.2 g/l EDTA in Hank's balanced 
salt solution with phenol red).  The cell attachment was checked microscopically (Olympus 
CKX31, Olympus, Center Valley, PA) and if necessary the detachment was facilitated by 
agitation.  After detachment, feeding media was added to inhibit further tryptic activity.  Cell 
numbers were assessed on a haemocytometer using trypan blue solution. Cells were plated 
at a density of 1x10
6  
cells/T175 flask (Sarstedt, Nümbrecht, Germany) placed at 5% CO2 in 
air at 37°C, media change every week and passage into further T175 flasks (split 1:3) every 2 
weeks, depending on cell need. For all experiments in this thesis, smooth muscle cells were used 
between passage 4 and 8. Primary ASM cells typically use maximum passage number 8 to 10. 
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2.2.1.4 Plating and starvation 
Cells were plated at a density of 1.0 x 10
4 
cells/cm
2 
according to the guidelines in Table 2.1 
and commonly grown for one week (unless otherwise specified). Feeding media was changed 
approximately 72 h after plating. Before performing the experiments, the cells were growth 
arrested generally to synchronise all the cells into a particular growth cycle phase (Davis et al., 
2001). The feeding media was aspirated, the cells were washed twice with sterile PBS, and 
then starving media was added for 48 h. In most of our experiments we used 6-well plates 
(unless otherwise specified). 
Table 2.1 Guidelines for plating of ASM cells for experiments 
TYPE OF PLATE PLATING DENSITY MEDIA PER WELL 
96-well 3,200 cells/well 0.1 mL 
6-well 96,000 cells/well 2 mL 
24-well 18,000 cells/well 1 mL 
100 mm 785,000 cells/well 10 mL 
 
2.2.1.5 ASM cell characterization 
To characterize primary ASM cells, after the first passage, the Respiratory Research Group 
performs an immunoassay for the expression of the muscle cell markers for α-smooth muscle 
actin and calponin as previously described by Johnson et al. (Johnson et al., 1995a). In 
following passages the cells were visually examined and kept showing the, for primary ASM 
cells, typical hill-and-valley morphology, were elongated, thin, spindle-shaped and showed 
concentric, oval nuclei. The following table details the patient demographics for the cells used in 
this thesis. 
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Table 2.2: Patient demographics for the cells used in this thesis 
Patient 
# 
Age Gender Diagnosis FEV1 (L) 
and/or % 
predicted 
FVC (L) 
and/or % 
predicted 
FEV1: 
FVC 
(%) 
Smoking 
History 
Height 
(cm) 
2821 66 M NSCCa      
2839 
 
65 M Malignant 
metastatic 
melanoma 
2.86 3.58   175 
3476 80 F NSCCa      
3706 
 
66 M NSCCa 3.44    
102% 
4.79    
106% 
72 smoker, 62.5 
pack years 
180 
3717 
 
70 M Carcinoma (Ca) 2.14 3.84  ex-smoker 100 
pack years 
stopped 1 year 
prior 
173 
3729 
 
59 M Lesion 
(incidental 
finding) +COPD 
2.6    69% 3.5   71%  ex-smoker 
25/day X 30 
years stopped 
1 week prior 
178 
3731 
 
64 M Ca 2.4 4.15  ex-smoker 
50/day x 50 
years stopped 
6 weeks prior 
167 
3737 
 
71 M NSCCa 2.77   93% 3.49   
89% 
 no 175 
3764 67 M Ca/COPD 1.4 3.7  ex-smoker 180 
3777 60 F NSCCa 2.42   92% 2.9   94% 83 ex-smoker, 
quit 
1/8/2010(oper
ation 
31/08/2010) 
 
3817 66 M Squamous cell 
Ca 
1.74 2.9  ex-smoker 
25/day x 40 
years stopped 
11 years prior 
174 
3832 59 F Ca (adeno)  111 106  no 151 
3839 62 F Squamous cell 
Ca 
0.78    
38% 
1.47   
55% 
 ex-smoker 
20/day x 30 
years, stopped 
4 weeks prior 
150 
3879 68 F Ca 1.31   48% 2.56  ex-smoker 
(25/day x 45 
years, quit 6 
years prior) 
173 
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3891 73 M NSCCa 1.21   38% 2.42   
58% 
50 ex-smoker, 
quit 1999 
180 
3892 58 F NSCCa 2.22  96% 2.51   
91% 
88 non-smoker 160 
3897 67 F squamous cell 
carcinoma, 
carcinoid tumour 
1.81   93% 2.24   
86% 
80 non-smoker  
3902 51 M IPF 0.95 1.3  non-smoker 176 
3903 64 M IPF 1.06 1.42  ex-smoker, 10 
pack years 
177 
3907 63 M NSCLCa 2.32   71% 2.73   
63% 
85 ex-smoker 
125pk yrs, 
6/12 prior 
(quit 6 months 
prior) 
173 
3910 68 F Ca 2.21   94% 3.01   
104% 
73 heavy smoker 
currently 10-
15/day, approx 
30-40 pack 
years, stopped 
2/52 prior 
171 
3912 67 M NSCLCa 2.22 3.1  ex-smoker, 25 
packs/day x 40 
years, quit 2 
weeks prior 
(2/52) 
168 
3920 71 M NSCCa 1.3   51% 1.76   
53% 
74 ex-smoker, 
60/day, quit 16 
yrs prior 
165 
3923 66 M NSCCa 2.38   71% 3.15  70%  ex-smoker, 
quit 2001 
180 
3926 62 F Emphysema 0.41 1.96  ex-smoker, 60 
pack years 
153 
3932 73 F NSCCa 2.4  100% 3.26113%  ex-smoker, 28 
pack yrs, quit 
30 yrs prior 
173 
3935 57 F COPD 0.55 1.64  ex-smoker, 30 
pack yrs 
153 
3938 56 F Adenocarcinoma
, malignant 
neoplasm 
2.2  66% 2.96  71%  ex-smoker 
10/day, 20/day 
for 20 years, 
ceased 
1/1/1997 
168 
3944 78 F Secondary 
malignant 
carcinoma 
1.82  88% 2.38  95%  ex-smoker 158 
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3946 51 F Emphysema 0.47 1.84  ex-smoker, 35 
pack/years 
159 
3948 59 F COPD      
3953 75 M squamous cell 
carcinoma, 
mucinous 
adenocarcinoma 
2.15   85% 2.66   
79% 
81 ex-smoker,  
20-30/day, 
quit 2002 
 
3971 60 F Alpha1 
anti-trypsin 
deficiency 
0.46  21% 1.91  73%  10 pack/yrs 159 
3994 58 M COPD 0.56  18% 3.11  78%  ex-smoker, 60 
pack yrs 
174 
4005 72 F Adenocarcinoma
, NSCCa 
1.49  64% 1.24  76%  ex-smoker quit 
1990, 35/day 
174 
4036 71 M NSCCa 2.02  79% 2.87  86%  ex-smoker quit 
1997 
165 
4037 61 M       
4039 47 M Acute interstitial 
pneumonia 
     
4042 68 M NSCCa 2.97  82% 3.6  78%  ex-smoker quit 
1972 
187 
4073 46 M Emphysema      
4077 61 F NSCCa 2.08  84% 2.72  85%  ex-smoker quit 
1998 15 pack 
yrs 
161 
4083 25 F Cystic fibrosis      
4085 54 M Pulmonary 
fibrosis 
     
4098 41 F Adenocarcinoma 
NOS, 
paraneoplastic 
neuropathy 
2.25  62% 2.48  55%  smoker, quit 
3wks ago, 60 
pack yrs 
179 
4100 64 F NSCLC, 
metastatic 
adenorarcnoma 
1.22  50% 1.44  47%  heavy smoker, 
quit 2 weeks 
ago 
163 
4159 38 F LUL tumour 
inflammatory 
histopathology, 
no malignancy. 
Chondrodermatit
isnodularishelicis
, CT spiculated 
1.5cm subpleural 
mass LUL, no 
malignant cells 
3.13   93% 4.01  98%  15 cigs day for 
20 years 
170 
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4171 70 M NSCLC stage I, 
secondary 
malignancy 
1.80  57% 3.09  72%  smoker, 50 
pack years 
176 
 
2.2.2 Western blotting 
2.2.2.1 Solutions 
5x Cell lysis/sample buffer is composed of TrisHCl 250 mM, DTT 500 mM, SDS 10% 
(w/v), bromophenol blue 0.5% (w/v), glycerol 50%, pH 6.8 and was used to collect cell lysates. 
The separating gel (8% or 12%) consisted of a 30% acrylamide- 0.8% bisacrylamide- solution, 
TRIS (pH 8.8). 
1.5 M, SDS 10%, N,N,N‟,N‟ tetramethylethylenediamine (TEMED) and a 30% (w/v) 
ammonium persulfate (APS) solution. The stacking gel (5%) consisted of a 30% acrylamide- 
0.8% bisacrylamide- solution TrisHCl (pH 6.8) 1 M, SDS 10%, TEMED and a 30% APS 
solution. The electrophoresis buffer (pH 8.3) contained TRIS 25 mM, glycine 250 mM, and SDS 
0.5 %. The transfer buffer (pH 8.5) used for electro transfer consisted of TRIS 25 mM, glycine 
192 mM and 20% (v/v) methanol. The transfer buffer used for diffusion transfer is composed of 
NaCl 50mM, EDTA 2mM, Tris-HCl pH 7.5 10 mM and DTT.  Tris- buffered saline solution 
with tween (TBS-T) pH 7.6 is composed of Tris 20 mM, NaCl 137 mM, and 0.1% (v/v) Tween 
20. Blocking buffer contained 5% (w/v) skim milk powder in TBS-T (pH 7.6). 
 
2.2.2.2 Sample preparation and immunoblotting 
According to cell needs and experimental plans, ASM cells were plated in petri dishes, 6-well 
plates (BD Bioscience, Franklin Lakes, NJ) and cultured until they reached confluence. After 
growth arresting for 48 hours, cells were treated according to the experimental plans as indicated 
in the respective Chapters. Cells were then washed two times with ice-cold PBS, 1x sample 
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buffer was added and after scraping, the lysates were collected in eppendorf tubes and boiled 
for 5 min. To fractionize the samples by size and to detect specific proteins of interest, a 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed. The 
SDS-PAGE was run at 200 V constant using the Power Pac 200 (Bio-Rad, Hercules, CA) until 
the bromophenol blue in the sample buffer completely reached the end of the gel. Proteins were 
then transferred onto a nitrocellulose membrane (Pall Corporation, Port Washington, NY) by 
electrotransfer (100 V constant on the Power Pac 200, 1 h). To check the uniformity and the 
overall effectiveness of the protein the membranes were stained with Ponceau. After blocking 
the membranes for 1 h at room temperature with blocking buffer on the rocking platform mixer 
(Ratek Instruments, Boronia, VIC, Australia) and subsequent washing with TBS-T the 
membranes were incubated with the primary antibody specific to the target protein (see Table 
2.2). After 3 other wash steps, primary antibodies were detected with goat anti-mouse 
horseradish peroxidase-conjugated secondary antibodies (see Table 2.2) and visualized by 
enhanced chemiluminescence (PerkinElmer, Wellesley, MA). The blots were exposed to a 
medical film (Fujifilm, Tokyo, Japan) and then developed with an x-ray processor (SRX-101A, 
Konica, Tokyo, Japan). Densitometry analysis was performed using ImageJ. 
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Table 2.3 Primary and secondary antibodies used for immunoblotting 
 Buffer Incubation Company 
 
C/N Dilution 
Primary antibody 
Mouse 
monoclonal 
COX-2  
Blocking buffer Overnight, 4°C Santa Cruz 
Biotechnology 
SC-
19999 
1:500 
Rabbit 
polyclonal IκB-α 
Blocking buffer Overnight, 4°C Santa Cruz 
Biotechnology 
SC-371 1:500 
Mouse 
monoclonal  
α-Tubulin 
Blocking buffer 30 min, RT Santa Cruz 
Biotechnology 
SC-
32293 
1:10000 
Secondary antibody  
Anti-mouse IgG Blocking buffer 1 h, RT Cell signaling 7076 1:10000 
Anti-rabbit IgG Blocking buffer 1 h, RT Cell signaling 7074 1:10000 
 
2.2.3 RT-PCR 
2.2.3.1 RNA sample collection and RNA extraction 
ASM cells were plated in 6-well plates at a density of 10
4 
cells/cm
2
, cultured for one week and 
growth-arrested for 48 h prior to the experiment. On the day of  the  experiment  the  cells  were  
treated  according  to  the  experimental protocol. For the extraction of total RNA an adapted 
protocol from Qiagen protocol: RNeasy® Mini Handbook (Qiagen, Valencia, CA) was used. 
After completely aspirating the cell-culture medium and washing the wells 2 times with PBS, 
RLT lysis buffer, containing guanidine thiocyanate and ß- mercaptoethanol was added to the 
wells, to lyse the cells and to immediately inactivate RNases to ensure purification of intact 
RNA. The lysates were collected with a rubber scraper (Sarstedt, Nümbrecht, Germany) and 
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pipetted into a 1.5 mL microcentrifuge tube. A syringe and a needle were used to fully lyse and 
homogenize the cells. To shear the DNA the lysates were passed through a 23-gauge needle 
attached to a sterile plastic syringe (needle and syringe both from: Livingstone  International,  
Rosebery,  NSW, Australia)  at least 5-10 times. To provide appropriate binding conditions for 
the RNA to the RNeasy membrane, 70% ethanol was added to the homogenized lysates and 
mixed well by pipetting up and down. After transferring the samples to a provided RNeasy spin 
column placed in a 2 mL collection tube, the samples were centrifuge for 15 sec >10,000 rpm in 
a microcentrifuge (Centrifuge 5415R, Eppendorf AG, Hamburg Germany). In this step the total 
RNA binds to the membrane and any contaminants are efficiently washed away. After 3 
more wash steps the total RNA was eluted by placing the RNeasy spin column in a new  1.5  mL  
collection  tube,  adding  RNase-free  water  directly  to the  spin column membrane and after 
centrifugation for 1 min at >10,000 rpm the high- quality RNA was collected. To check the 
integrity of the RNA 5µl of each sample (5 µL of extracted RNA + 1 µL of RNA loading 
buffer) were run on a 1% agarose/TAE gel in 1x TAE (Tris-acetate-EDTA) at 100 V for about 
30 min. The RNA integrity was assessed using the denaturing agarose gel electrophoresis 
method followed by ethidium bromide staining. Assessing the gels on the transilluminator, 
both 18S and 28S rRNA appeared as sharp, distinct bands after electrophoresis of total 
eukaryotic RNA and therefore the RNA was considered to be intact. 
 
2.2.3.2 Reverse transcription and polymerase chain reaction 
After this control step reverse transcription was performed to prepare single- stranded DNA 
from the RNA samples using the Fermentas RevertAid™ First Strand cDNA Synthesis Kit 
(Fermentas, Thermo Scientific, Burlington, Canada). To avoid any contamination and to ensure 
  Chapter 2 
47 
 
the preparation of a high- quality complementary DNA (cDNA) all tubes used were autoclaved 
and only filter tips were used for the preparation of the samples. All the following reactions were 
prepared on ice. The water/primer master mix, containing Random Hexamer Primer and bottled 
water (Livingstone International, Rosebery, NSW, Australia), was prepared and aliquoted to the 
appropriate number of autoclaved, thin-walled 200 µL PCR tubes. Then the extracted RNA 
samples were added to each PCR tube. The tubes were placed into the PCR machine (MJ 
Research, PTC-200 Thermal Cycler, GMI inc, Ramsey, Mn) and heated at 70°C for 5 min for 
denaturation and to provide the right annealing conditions for the primers. After that step the 
tubes were placed on ice and reaction buffer, RNase inhibitor and dNTPs were added to the 
samples and the tubes were heated at 25°C for 5 min in the PCR machine. After adding the 
reverse transcriptase (RevertAid™ M-MuLV Reverse Transcriptase, Fermentas, Thermo 
Scientific, Burlington, Canada) to each tube the rest of the program was run to obtain the cDNA. 
The conditions were the following:  25°C for 10 min then 42°C for 60 min, 70°C for 10 min, 
and then the samples were cooled to 4°C and the cDNA was collected. Subsequent mRNA 
expression of the target genes was quantified by real-time RT-PCR using an ABI Prism 7500 
real-time PCR machine (Applied Biosystems, Foster City, CA) and the appropriate primer set 
(Assays on Demand; Applied Biosystems, Foster City, CA). The samples were multiplexed with 
a eukaryotic 18S rRNA endogenous control probe (Applied Biosystems, Foster City, CA) and 
subjected to the following cycle parameters: in TaqMan method- 50°C for 2 min, 1 cycle; 
95°C for 10 min, 1 cycle; 95°C for 15 sec, 60°C for 1 min, 40 cycles and in SYBER green 
method- 95°C for 10 min, 1 cycle; 95°C for 15 sec, 60°C for 1 min, 40 cycles. Fold increase of 
mRNA expression was quantified by delta delta Ct calculations. 
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Table 2.4 List of primers and their UniGene ID used in this thesis 
Gene Name UniGene ID Assay ID Assay Type 
IL-1β Hs.126256 Hs01555410_m1 TaqMan 
IL-6 Hs.654458 Hs00174131_m1 TaqMan 
IL-8 Hs.624 Hs00174103_m1 TaqMan 
NLRP3 Hs.159483 Hs00918082_m1 TaqMan 
Caspase-1 Hs.2490 PPH00105B SYBER Green 
18S Not known PPH0566E SYBER Green 
COX-2 Hs.196384 Hs0015133_m1 TaqMan 
MKP-1 Hs.171695 Hs00610256_g1 TaqMan 
18S HSRRN18S Hs03003631_g1  TaqMan 
 
2.2.4 Enzyme-linked immunosorbent assay (ELISA) 
For all ELISAs conducted during this study a protocol adapted from BD Biosciences protocol: 
Human IL-6/ IL-8 ELISA was used and capture antibody, detection antibody, protein standards 
and streptavidin-HRP were all provided by BD Bioscience Systems Human IL-6/ IL-8 ELISA 
Set (BD Bioscience, Franklin Lakes, NJ). 
To perform an ELISA a 96-well ELISA plate (NUNC Maxisorp Immuno Plate F96; Noble 
Park North, VIC, Australia) was coated with a capture antibody diluted in coating buffer 
(0.1 M sodium carbonate, pH 9.5) specific for the target protein. For all recommended 
antibody dilutions, the manufacturer‟s lot-specific I n s t r u c t i o n /Analysis C e r t i f i c a t e  w a s  
c o n s u l t e d .  The p l a t e  w a s  sealed and incubated overnight at 4°C. The wells were washed 
3 times with wash buffer (PBS with 0.05% Tween-20) to wash off possible unbound capture 
antibody. Subsequently the plate was blocked with assay diluent (PBS with 10% FBS, pH 
7.0) and incubated for 1 h at RT to block all unbound sites and therefore to prevent false 
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positive results. After 3 other wash steps the standards and cell supernatant dilutions 
(prepared in 0.1% BSA in DMEM) were added as set out in the experimental protocol, the 
plate was sealed and incubated for 2 h at RT. During this incubation the protein of interest binds 
to the capture antibody. Following 5 other wash steps a biotinylated detection antibody together 
with a streptavidin-horseradish peroxidase conjugates (SAv- HRP) in assay diluent was added, in 
one-step incubation, to the wells. The plate was again sealed and incubated for 1 h at RT. 
Subsequent 7 wash steps were performed to wash off unbound Biotin/Streptavidin reagent and 
the plate was incubated with the substrate solution (TMB 2-Component Microwell peroxidase 
substrate system; KPL, Inc., Gaithersburg, MD) for 30 min at room temperature in the dark. 
During this incubation the enzyme streptavidin-horse radish peroxydase (HRP), bound to the 
detection antibody, converts the added substrate in to a coloured product and the colour is 
proportional to the amount of bound protein. To stop this process an acidic stop solution was 
added to the wells and the colour was measured using a spectrometer at 450 nm wave length 
(Microplate Reader, Model 680, Bio-rad, Hercules, CA). 
 
2.2.5 cAMP assay 
Cell lysates preparation and measurement of intracellular cAMP concentration were performed 
using a specific enzyme immunoassay (EIA) kit according to the manufacturer‟s instruction 
(Cayman Chemical Co. Ann Arbor, Michigan, USA). In brief, reactions were terminated and 
cells were lysed by the addition of 0.1 M HCL. The contents were then cleared of debris by 
centrifugation at 1000 x g for 10 min. The aliquots were diluted in EIA buffer and incubated with 
reconstituted cAMP monoclonal antibody and cAMP AChE tracer in 96-well plates for 18 h at 4
0 
C. After washing with wash buffer the plates were incubated with reconstituted Ellman‟s reagent 
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for 1 h with gentle shaking in dark. The absorbance was measured at 415 nm and quantities of 
cAMP were determined using manufacturer‟s analysis tools (excel workbooks) comparing with 
cAMP standards concentrations ranging from 750 – 0.3 pmol/mL. The results were represented 
as pmol cAMP/mL. 
 
2.2.6 PGE2 assay 
The levels of PGE2 in culture supernatants were measured using enzyme immunoassay (EIA) 
kits according to the manufacturer‟s instruction (Cayman Chemical Company, Ann Arbor, 
Michigan, USA). Briefly, different dilutions (straight, 1/5, 1/10, 1/50, 1/100) of each sample and 
standards, concentration range 7.8-1000 pg/mL were incubated with reconstituted PGE2 
monoclonal antibody and PGE2 AChE tracer for 18 h at 4
0
C. After 5 times washing with wash 
buffer the plate (96-well plate supplied with EIA kits) was incubated with immediate 
reconstituted Ellman‟s reagent (200 μL/well) for 1 h with gentle shaking in dark. Absorbance 
was taken at 415 nm and results were calculated using manufacturer‟s analysis tools (excel 
workbooks). The results were represented as pg PGE2/mL supernatant. 
 
2.2.7 Statistical analysis 
Statistical analysis was performed using either the Student's unpaired t test, one-way ANOVA or 
two-way ANOVA followed by Bonferroni‟s post-test. P values <0.05 were sufficient to reject 
the null hypothesis for all analyses. 
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Chapter 3 
NLRP3 inflammasome is not activated in ASM 
upon TLR2 ligation 
 
3.1 Introduction 
Inflammasomes represent a multiprotein high molecular weight complex that control innate 
immunity and inflammation.  Several evidences support the key role of inflammasome activation 
in lung diseases such as asthma and COPD by regulating the processing and release of 
proinflammatory cytokines (predominantly IL-1β) (Birrell and Eltom, 2011; dos Santos et al., 
2012). The NLRP3 inflammasome has been best characterized, and both in vivo and in vitro 
models of allergic asthma and asthmatic inflammation have demonstrated an important role for 
the NLRP3 inflammasome in the amplification and potentiation of inflammation during airway 
diseases (Ather et al., 2011; Besnard et al., 2011; Bauer et al., 2012; Im and Ammit, 2014). 
Elevated IL-1β protein secretion that is stimulated via active inflammasome components was 
suggested to play a role in asthma exacerbation (Bochkov et al., 2010; Bauer et al., 2012), we 
were interested in exploring whether the NLRP3 inflammasome is activated under in vitro 
conditions in ASM cells that mimic infectious exacerbations in asthma. 
 The NLRP3 inflammasome is a multimeric intracellular protein complex consisting of three 
domains: NLRP3, the apoptosis associated speck-like protein containing the caspase activation 
and recruitment domain, and caspase-1 (Cassel et al., 2009). NLRP3 expression is inducible, and 
mRNA regulation can take place at the transcriptional and posttranscriptional levels 
(Bauernfeind et al., 2009; Qiao et al., 2012). Recognition of invading pathogens by the NLRP3 
domain results in the assembly of three components to form a stable inflammasome, which in 
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turn activates pro–caspase-1 into active caspase-1 autocatalytically (Birrell and Eltom, 2011). 
Caspase-1 is a cysteine protease that cleaves inactive precursors of IL-1β into bioactive cytokine, 
which is then competent to be secreted out of the cell.  
During the past decade, the ability of ASM cells to produce and secrete proinflammatory 
mediators, including cytokines and chemokines, has been established by many studies, as 
reviewed elsewhere (Damera et al., 2009; Ozier et al., 2011). Furthermore, accumulating 
evidence has shown that the treatment of ASM cells with IL-1β in vitro augments the production 
of numerous proinflammatory mediators, including IL-6, IL-8 (Hedges et al., 2000), IL-17A 
(Henness et al., 2004), PGE2 (Laporte et al., 1998), and matrix metalloproteinase–9 (Liang et al., 
2007), thus serving to amplify airway inflammation. The enhanced synthetic function of ASM 
may play a pivotal role, leading to acute exacerbations of asthma, by provoking and amplifying 
airway inflammatory responses (Damera and Panettieri, 2011; Manetsch et al., 2012b). The 
possible involvement of the NLRP3 inflammasome and IL-1β activation in the enhanced 
synthetic function of ASM cells in response to invading pathogens remains largely unexplored. 
When human body is infected by bacteria or virus, cells of the innate immune system recognize 
PAMPs and the activation of TLR2 become crucial for the induction of immune response against 
the pathogen or for an effective presentation of antigens to the adaptive system. TLR2 receptors 
are mainly responsible for the recognition of various bacterial cell wall components (Chaudhuri 
et al., 2005). In this study, we aim to show the engagement of TLR2 with the TLR2 agonist 
Pam3CSK4 exerted any effect on NLRP3 expression in ASM cells in vitro. Pam3CSK4 is a 
well-recognised synthetic lipopeptide (LP) that mimics bacterial lipoproteins and therefore 
activates TLR2 (Aliprantis et al., 1999). We explored the role of the inflammasome and the 
secretion of IL-1β from ASM cells in response to Pam3CSK4 activation and also measured the 
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downstream IL-6 and IL-8 cytokines secretion. We found that the cytokines are upregulated 
upon TLR2 ligation though this upregulation of cytokines is IL-1β-independent. Further we 
found that the engagement of TLR2 with the TLR2 agonist Pam3CSK4 exerted no effect on 
NLRP3 and caspase-1 expression. These results suggest that because of the absence of key 
components, NLRP3 inflammasome activation will not be possible, and consequently IL-1β will 
not be processed for secretion. Our data support this assertion, because we show that although 
TLR2 ligation increased TNFα-induced IL-1β mRNA expression, IL-1β protein is not secreted 
from ASM cells. Thus, the NLRP3 inflammasome is not activated in ASM upon TLR2 ligation. 
 
3.2 Meterials and methods 
3.2.1 Cell culture 
For detailed description, see Chapter 2.2.1. 
Unless otherwise specified, all chemicals used in this study were purchased from Sigma-Aldrich 
(St.Louis, MO). 
 
3.2.2 Real-Time RT-PCR 
Total RNA was extracted using the RNeasyMini Kit (Qiagen, Doncaster, Victoria, Australia), 
and reverse-transcribed using the RevertAid First Strand cDNA Synthesis Kit (Fermentas Life 
Sciences, Hanover, MD). Real-time RT-PCR was performed on an ABI Prism 7500 (Applied 
Biosystems, Foster City, CA) with IL-1β (TaqMan ID: Hs01555410_m1), IL-6 
(Hs00174131_m1), IL-8 (Hs00174103_m1), NLRP3 (Hs00918082_m1), and 18S ribosomal 
RNA measured with TaqMan probes (Applied Biosystems) or caspase-1 (PPH00105B) and 18S 
(PPH0566E) measured by SYBR Green RT
2
 qPCR Primer Assays (Qiagen), thermal cycle- 95°C 
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for 10 min, 1 cycle; 95°C for 15 sec, 60°C for 1 min, 40 cycles. For detailed description, see 
Chapter 2.2.3. 
 
3.2.3 ELISAs 
IL-1β (DuoSet DY201; R&D Systems, Minneapolis, MN), IL-6 (BD OptEIA 555220; BD 
Biosciences, San Diego, CA), and IL-8 (BD OptEIA 555244; BD Biosciences) ELISAs were 
performed according to the manufacturers‟ instructions. For detailed description, see Chapter 
2.2.4. 
 
3.2.4 IL-1β neutralization 
To neutralize IL-1β, conditioned media from treated ASM cells or IL-1β recombinant protein 
(R&D Systems) were incubated for 1 h at 37
0
C with 2 mg/mL of either vehicle, normal mouse 
IgG1 (Santa Cruz Biotechnology, Santa Cruz, CA) as an isotype control, or a monoclonal mouse 
IgG1 antibody to human recombinant IL-1β (clone 8516; R&D Systems). 
 
3.2.5 Statistical analysis 
Statistical analysis was performed using either the Student‟s unpaired t test or two-way ANOVA, 
followed by the Bonferroni post hoc test. P<0.05 was considered sufficient to reject the null 
hypothesis for all analyses. Data represent means ± SEMs. 
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3.3 Results 
3.3.1 Time course of TNFα-induced IL-1β mRNA expression and augmentation by 
Pam3CSK4 
We measured the temporal kinetics of TNFα-induced IL-1β mRNA expression in ASM cells, 
and examined whether the TLR2 agonist, Pam3CSK4, up-regulated IL-1β concentrations. As 
shown in Figure 3.1A, TNFα significantly enhanced IL-1β mRNA expression over time, with 
significant expression observed as early as 1 h, and a peak of 90.4- ± 18.4-fold at 2 h, before 
subsiding to concentrations that were not significantly different from those of vehicle controls by 
8 h (P<0.05). Pam3CSK4 alone also significantly enhanced IL-1β mRNA expression, with a 
significant 14.8- ± 8.4-fold increase observed at 4 h (P<0.05). Importantly, TNFα-induced IL-1β 
upregulation was significantly potentiated by Pam3CSK4 (P<0.05). As shown in Figure 3.1A, 
the effect of Pam3CSK4 on TNFα-induced IL-1β mRNA was first observed at 2 h (although not 
significantly), and this effect increased to significant levels at 4 h, and by 24 h was measured at 
337.0- ± 48.0-fold, compared with 23.0- ± 14.9-fold using TNFα alone (P<0.05). Interestingly, 
when we compared the temporal kinetics of IL-1β mRNA expression with those of IL-6 (Figure 
3.1B) and IL-8 (Figure 3.1C), we also observed a later significant upregulation of TNFα-induced 
cytokine secretion at 24 h (P<0.05). This raises the intriguing possibility that the early phase of 
IL-1β mRNA may undergo translation, to result in IL-1β protein secretion that can then act back 
on ASM cells in an autocrine manner to stimulate the cytokine mRNA expression observed at 24 
h. Thus, we hypothesize that the TLR2 agonist, Pam3CSK4, activates the inflammasome to 
result in IL-1β secretion from ASM cells and the potentiation of cytokine secretion from ASM 
cells. 
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Figure 3.1 Time course of TNFα-induced IL-1β mRNA expression and augmentation by 
Pam3CSK4 (in comparison to IL-6 and IL-8 mRNA temporal kinetics).Growth-arrested 
ASM cells were pretreated with vehicle or Pam3CSK4 (1 μg/mL) for 1 h, followed by treatment 
with vehicle or TNFα (10 ng/mL) for 0, 1, 2, 4, 8, and 24 h. (A) IL-1β, (B) IL-6 and (C) IL-8 
mRNA expression was quantified by real-time RT-PCR and results expressed as fold increase 
compared to vehicle-treated cells at 0 h (mean±SEM values from n=7 primary ASM cell 
cultures). Statistical analysis was performed using two-way ANOVA then Bonferroni's post hoc 
test (where * denotes a significant effect of treatment on mRNA expression, compared to 
vehicle-treated cells, and § indicates a significant effect of Pam3CSK4 on TNFα-induced mRNA 
expression at the same time point (P<0.05)). 
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3.3.2 Pam3CSK4 potentiates TNFα-induced IL-6 and IL-8 protein secretion, but IL-1β is 
not secreted from ASM cells 
To address this hypothesis, we measured concentrations of IL-1β, IL-6, and IL-8, as secreted 
from ASM cells over 0 to 24 h. As shown in Figures 3.2B and 3.2C, respectively, Pam3CSK4 
pretreatment significantly enhanced TNFα-induced IL-6 and IL-8 at 24 h (Figures 3.2A and 
3.2B; P<0.05), in confirmation of our earlier report (Manetsch et al., 2012b) . We then attempted 
to measure IL-1β in the same supernatants, using an ELISA that had been confirmed able to 
measure secreted IL-1β that resulted from inflammasome activation (Rajan et al., 2010). 
Importantly, IL-1β was not detected (Figure 3.2A), suggesting that even though IL-1β mRNA 
was up-regulated, the inflammasome was not activated and IL-1β was not secreted from ASM 
cells.  
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Figure 3.2 Pam3CSK4 potentiates TNFα-induced IL-6 and IL-8 protein secretion, but IL-
1β is not secreted from ASM cells. Growth-arrested ASM cells were pretreated with vehicle or 
Pam3CSK4 (1 μg/mL) for 1 h, followed by treatment with vehicle or TNFα (10 ng/ml) for 0, 1, 
2, 4, 8, and 24 h. ELISA were used to measure (A) IL-1βand (B) IL-8 and (C) IL-6 protein 
secretion. Please note that IL-1β secretion from ASM cells (A) was not detected. Statistical 
analysis was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of treatment on protein secretion, compared to vehicle-treated cells, and § 
indicates a significant effect of Pam3CSK4 on TNFα-induced protein secretion at the same time 
point (P<0.05)). Data represent mean±SEM values from n=4 primary ASM cell cultures. 
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3.3.3 Effect of IL-1β neutralizing antibody on IL-6 and IL-8 protein secretion induced by 
IL-1β recombinant protein 
To confirm that IL-1β was not secreted from ASM cells, we used an IL-1β–neutralizing 
antibody. We initially validated IL-1β neutralization by incubating a range of concentrations of 
IL- 1β recombinant protein (1–500 pg/mL) with IL-1β–neutralizing antibody, and measured its 
inhibitory effect on IL-1β–induced IL-6 and IL-8 protein secretion. As shown in Figure 3.3, IL-
1β induced a concentration-dependent augmentation of IL-6 and IL-8 protein secretion in 
vehicle-treated or isotype control–treated ASM cells, with no significant difference between cells 
treated with vehicle or the isotype control. Importantly, the neutralization of IL-1β reduced IL-6 
protein secretion from ASM cells in response to a range of IL-1β concentrations (1–500 pg/mL; 
Figure 3.3A), with only 79.5 ± 39.8 pg/mL IL-6 secreted in response to 500 ng/mL IL-1β 
preincubated with the IL-1β neutralizing antibody, as opposed to approximately 150-fold greater 
amounts of IL-6 secretion after preincubation with the isotype control (P<0.05). Similarly, this 
down-regulation by IL-1β neutralization was also observed in IL-8 protein secretion, as depicted 
in Figure 3.3B. 
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Figure 3.3 Effect of IL-1β neutralizing antibody on IL-6 and IL-8 protein secretion induced 
by IL-1β recombinant protein. To validate the effect of neutralization antibody on IL-6 (A) and 
IL-8 (B) protein secretion, vehicle or increasing concentrations of IL-1β recombinant protein (1-
500 pg/mL) were incubated for 1 h at 37˚C with 2 μg/mL of either vehicle, isotype control or IL-
1β neutralizing antibody, and then added to growth-arrested ASM cells for 24 h. IL-6 and IL-8 
protein secretion was measured by ELISA. Statistical analysis was performed using two-way 
ANOVA then Bonferroni's post-test (where * denotes a significant effect of IL-1β neutralizing 
antibody on protein secretion, compared with isotype control (P<0.05)). Data represent 
mean±SEM values from n=3 primary ASM cell cultures. 
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3.3.4 Neutralization of IL-1β in conditioned media exerts no effect on cytokine secretion 
We next examined whether the neutralization of IL-1β in conditioned media exerted any effect 
on IL-6 and IL-8 protein secretion by ASM cells. As shown in Figure 3.4A, the removal of IL-1β 
by the neutralizing antibody exerted no effect on the amount of IL-6 secreted in response to 
conditioned media from cells stimulated with TNFα alone or Pam3CSK4 + TNFα. Similarly, IL-
8 secretion in response to conditioned media preincubated with IL-1β neutralizing antibody was 
not significantly different from that preincubated with the isotype control (Figure 3.4B). As a 
positive control, we confirmed IL-1β neutralization with ASM cells treated with 100 ng/mL IL-
1β recombinant proteins in parallel experiments. As shown in Figures 3.4C and 3.4D, IL- 1β 
neutralization significantly inhibited IL-6 and IL-8 secretion from ASM cells, compared with the 
isotype control (P<0.05). 
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Figure 3.4 Neutralization of IL-1β in conditioned media has no effect on cytokine secretion. 
Conditioned media was prepared by removing supernatants from ASM cells treated with TNFα 
or Pam3CSK4 + TNFα for 1, 2, 4, 8, and 24 h. Conditioned media was incubated at 37˚C for 1 h 
with 2 μg/mL of either IL-1β neutralizing antibody or isotype control then incubated with ASM 
cells for 24 h and the resultant (A) IL-6 and (B) IL-8 protein in the supernatants measured by 
ELISA. Results were expressed as a percentage of TNFα – isotype control at 1 h. To confirm IL-
1β neutralization, parallel studies were conducted with vehicle or IL-1β recombinant protein 
(100 pg/mL) treated under identical conditions and (C) IL-6 and (D) IL-8 measured by ELISA. 
Statistical analysis was performed using the Student's unpaired t test (where * denotes a 
significant effect of IL-1β neutralizing antibody on protein secretion, compared with isotype 
control). Data represent mean±SEM values from n=3 primary ASM cell cultures. 
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3.3.5 Pam3CSK4 does not affect TNFα-induced NLRP3 and caspase-1 mRNA expression in 
ASM cells 
NLRP3 is an important component of the inflammasome and has been shown to be upregulated 
under inflammatory conditions. Caspase-1 also plays an important role in inflammasome 
function to cleave precursor pro-IL-1β into mature IL-1β. Collectively, our data thus far 
demonstrates that Pam3CSK4-mediated augmentation of TNFα-induced IL-6 and IL-8 mRNA 
and protein level is not mediated by IL-1β secretion, thus, these results indicate that components 
of the NLRP3 inflammasome may not be upregulated in ASM cells upon TLR2 activation. To 
address this we measured NLRP3 and caspase-1 mRNA expression in response to Pam3CSK4 
and TNFα, alone and in combination, over time (0-24 h). As shown in Figure 3.5A, neither 
Pam3CSK4, nor TNFα had a significant effect on NLRP3 mRNA expression over 24 h. 
Moreover, the temporal kinetics of NLRP3 mRNA expression is not affected in response to 
Pam3CSK4 + TNFα in combination. We also measured the temporal kinetics of caspase-1 
mRNA expression in response to Pam3CSK4 + TNFα, alone and in combination (Figure 3.5B) 
and found TNFα induced a small (~3-fold) but significant effect on caspase-1 mRNA expression 
at 8 h (P<0.05) but Pam3CSK4 did not upregulate TNFα-induced caspase-1 mRNA expression. 
Taken together, these results suggest that because NLRP3 and caspase-1 are not present in ASM 
cells, the NLRP3 inflammasome is not activated upon TLR2 ligation; thus IL-1β is not secreted 
from ASM cells. 
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Figure 3.5 Pam3CSK4 does not affect TNFα-induced NLRP3 and caspase-1 mRNA 
expression in ASM cells.(A-B) Growth-arrested ASM cells were pretreated with vehicle or 
Pam3CSK4 (1 μg/ml) for 1 h, followed by treatment with vehicle or TNFα (10 ng/mL) for 0, 1, 
2, 4, 8, and 24 h. (A) NLRP3 and (B) caspase-1 mRNA expression was quantified by real-time 
RT-PCR and results expressed as fold increase compared to vehicle-treated cells at 0 h 
(mean±SEM values from (A) n=6 or (B) n=4 primary ASM cell cultures). Statistical analysis 
was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of treatment on caspase-1 mRNA expression, compared to vehicle-treated cells 
(P<0.05)). 
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3.4 Discussion 
The inflammasomes are a group of protein complexes thought to be responsible for inflammation 
associated respiratory diseases including asthma. Inflammasome-mediated activation of caspase-
1 is crucial for maturation and secretion of IL-1β, which plays the pivotal role in inflammation 
associated asthma. However, the underlying molecular mechanism is yet to be revealed. In our 
present study, we address this issue. In this study, we uncover the molecular pathway/s 
underlying TLR2-induced activation of the inflammasome and investigate if, and how, the 
inflammasome induces cytokine secretion in airway smooth muscle cells in vitro. Our data 
demonstrate that the Pam3CSK4 mediated augmentation of TNFα-induced IL-6 and IL-8 mRNA 
and protein concentrations are not mediated by IL-1β secretion via NLRP3 inflammasome 
activation in ASM cells. NLRP3 and caspase-1are not expressed in ASM cells in vitro. Thus, the 
NLRP3 inflammasome is not activated in ASM upon TLR2 ligation.  
TLRs are receptors that are known to bind PAMPs found in bacteria, viruses, fungi and other 
microbes and play an important role in the innate immune response. Respiratory infections are 
key factors underlying asthma exacerbations, moreover it has been shown that ASM cells 
express TLR2, 3 and 4,  activated by bacterial cell wall components and viruses (Sukkar et al., 
2006). By propagating and amplifying inflammation in response to bacterial and viral pathogens, 
airway structural cells play an important immunomodulatory role in asthma. Although 
Pam3CSK4 is primarily known as a TLR2 agonist, its ability to activate the NLRP3 
inflammasome to release IL-1β has been demonstrated in macrophages (Kanneganti et al., 2006). 
This led us to examine the effects of IL-1β neutralization on Pam3CSK4 and TNFα-induced 
cytokine upregulation in ASM cells. 
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Recent in vivo and in vitro studies have implicated the NLRP3 inflammasome as a potential 
therapeutic target in asthma (Ather et al., 2011; Besnard et al., 2011; Birrell and Eltom, 2011; 
dos Santos et al., 2012), although debate continues (Kool et al., 2011; Allen et al., 2012). To 
date, several reports demonstrated the presence of the functional NLRP3 inflammasome in 
asthmatic airway epithelia (Allen et al., 2009; Hirota et al., 2012; Tran et al., 2012). The NLRP3 
inflammasome mediated production of IL-1β in airway epithelial cells leads to airway 
neutrophilic inflammation (Hirota et al., 2012), which is the predominant phenotype of airway 
inflammation in acute exacerbations (ten Brinke et al., 2004; Cowan et al., 2010). Allen et al. 
demonstrated that the NLRP3 inflammasome expressed in airway epithelial cells and 
macrophages is required for inflammation after influenza infection (Allen et al., 2009). Thus, a 
growing body of research suggests that the NLRP3 inflammasome may be activated in the 
airways to promote increased cytokine expression and a proinflammatory milieu during 
infections. 
Increasing evidence demonstrates that ASM cells play a role in the amplification of 
inflammatory responses during infectious exacerbations in asthma via augmented cytokine 
production (Elias et al., 1997; Morris et al., 2006; Oliver et al., 2006; Sukkar et al., 2006; 
Manetsch et al., 2012b). Our study is the first to examine the involvement of the NLRP3 
inflammasome and possible IL-1β secretion in Pam3CSK4 and TNFα-induced cytokine up-
regulation in ASM cells. We first demonstrated that IL-1β induces a significant increase in IL-6 
and IL-8 protein secretion by ASM cells in a concentration dependent manner. We also 
demonstrated that the IL-1β-induced upregulation of IL-6 and IL-8 secretion is completely 
inhibited by IL-1β neutralizing antibody. These results show that the IL-1β neutralizing antibody 
can successfully neutralize the effects of IL-1β on cytokine upregulation in ASM cells. However, 
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the Pam3CSK4-induced upregulation of IL-6 and IL-8 protein secretion was not inhibited by the 
neutralization of IL-1β. This finding suggests that IL-1β secretion is not involved in TLR2 
ligand-induced cytokine upregulation in ASM cells. 
In support of this, we also demonstrated that ASM cells treated with Pam3CSK4 and TNFα do 
not secrete detectable concentrations of IL-1β protein over 24 h, although gene expression is 
significantly augmented. For the NLRP3 inflammasome in ASM cells to be active in a classic 
manner, the production and secretion of mature IL-1β should be observed in response to 
Pam3CSK4 (Martinon et al., 2009), because IL-1β secretion is widely accepted as a surrogate 
marker for NLRP3 inflammasome activation. However, TLR2 ligation by Pam3CSK4 appears 
unable to induce assembly of the NLRP3 inflammasome and the processing of IL-1β secretion. 
Together, our results provide evidence that the NLRP3 inflammasome is not activated to 
promote IL-1β maturation and secretion in response to Pam3CSK4 and TNFα in ASM cells. This 
rules out the possibility that IL-1β secreted as a result of Pam3CSK4 enhanced, TNFα-induced 
IL-1β mRNA expression observed at an early time point (4 h) acts in an autocrine manner to 
boost the further augmentation of IL-6, IL-8, and IL- 1β gene expression at later time points (24 
h) via a positive feedback loop. 
The results presented here indicate important cell-type specificity in airway inflammation, 
because we demonstrate that the robust up-regulation of proinflammatory cytokines by invading 
pathogens may not be mediated by activation of the NLRP3 inflammasome and IL-1β secretion 
in ASM. Using primary cultures of human ASM cells, we demonstrated that Pam3CSK4 
robustly up-regulates TNFα-induced IL-1β mRNA expression, but does not significantly change 
the expression of NLRP3 and caspase-1 mRNA. Importantly, IL-1β is not secreted from ASM 
cells. Thus IL-1β is unable to act in an autocrine manner to induce an inflammatory milieu that 
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mimics exacerbation in ASM cells by promoting IL-6 secretion and upregulation of the 
neutrophil chemoattractant chemokine, IL-8. 
We explored the role of the NLRP3 inflammasome and the secretion of IL-1β from ASM cells in 
response to Pam3CSK4 activation, and although TLR2 ligation robustly enhanced cytokine 
expression, this upregulation was IL-1β independent. Exacerbated asthmatic symptoms are not 
effectively attenuated by current pharmacological management. By addressing molecular 
mechanisms of exacerbation, our experiments have revealed a potentially important cell type 
difference, that is, whereas the NLRP3 inflammasome is activated in human airway epithelium 
(Hirota et al., 2012), the TLR2-mediated enhancement of proinflammatory cytokine secretion in 
the underlying ASM layer is NLRP3 inflammasome independent.  
In our published paper, there are some more supporting data (not shown here as those are done 
by our collaborator in other lab) generated by using in situ model of human tracheas, which are 
align with our in vitro data and further strengthen our hypothesis (Hirota et al., 2013). Therefore, 
we believe that our findings in both in vitro and in situ models have clinical significance and 
reinforce future investigations using contemporary experimental models.  Although the 
functional relevance of the restricted localization of the NLRP3 inflammasome in the airways is 
unclear at present, crosstalk between airway structural cells (and inflammatory cells) remains a 
possibility.  Moreover, in our study we have used only one stimulus that may be not sufficient to 
stimulate active IL-1β, as such in many cells a secondary stimulus is needed to stimulate the 
activation step. And also, we cannot rule out that other inflammasomes may be playing a role 
given that caspase-1 mRNA was increased in our setting. Thus, further studies are warranted to 
develop new therapeutic strategies to combat asthma exacerbations in the future.
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Chapter 4 
TLR2 activation causes desensitization 
of β2-adrenoreceptor via COX-2 
production 
 
This work has been published as a part of the article entitled “TLR2 activation causes 
tachyphylaxis to β2-agonists in vitro and ex vivo: modeling bacterial exacerbation. Hatem 
Alkhouri, Nowshin N. Rumzhum, Md. Mostafizur Rahman, Meghan FitzPatrick, Monique de 
Pedro, Brian G. Oliver, Jane E. Bourkeand Alaina J. Ammit. Allergy 2014; 69: 1215–
1222(Alkhouri et al., 2014). 
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Chapter 4 
TLR2 activation causes desensitization of β2-
adrenoreceptor via COX-2 production 
 
4.1 Introduction 
Both viruses and bacteria are considered as the most important factors contributing asthma 
exacerbation. Viruses are identified in 80% of asthma exacerbations in children and 45–80% in 
adults (Hayden, 2004). Rhinovirus, which causes the majority of common colds, is responsible 
for at least half of all asthma exacerbations (Corne et al., 2002). Bacterial infections are 
increasingly recognized as playing an important role in asthma exacerbations [reviewed in 
(Edwards et al., 2012)], although they have been less well investigated to date. Moreover the 
expression of TLR2 receptor in ASM cells that is activated by bacterial cell wall components 
such as LPS and lipopeptides strongly suggests their involvement in the amplification of airway 
inflammatory responses during infectious exacerbation. 
When a person with asthma suffers from a viral or bacterial infection, the molecular pathways by 
which asthma medicines act are changed making them less sensitive. As bronchodilators, β2-
agonists are considered the first line therapy of asthma that relax the muscles surrounding the 
airways and opens the airways that become tighten during asthma exacerbation. There are two 
types of β2-agonists available, short-acting β2-agonists are often referred to as rescue inhalers and 
are used to quickly relieve of asthma symptoms and long acting β2-agonists taken regularly to 
control chronic symptoms and prevent asthma attacks. In well-controlled asthma, β2-agonists 
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relax the airways by interacting with β2-AR. β2-AR are one of the most well characterized seven 
transmembrane receptor belongs to GPCRs family, consist of three extracellular loops, with one 
amino-terminus, and three intracellular loops, with a carboxy-terminus [reviewed in (Shore and 
Moore, 2003)]. Binding of a β2-agonist to the β2-AR ultimately relax the airways by rapidly 
increasing cAMP levels in ASM cells.  
However, these molecular pathways are changed by infection and mounting evidences suggest 
that β2-adrenergic relaxant mechanisms may be dysfunctional in airways (Pang et al., 1998b; 
Shore and Moore, 2003). Recent studies have revealed that viral infection desensitizes the β2-AR 
and reduces cAMP generation in response to β2-agonists (Trian et al., 2010). These changes are 
due to interaction of viral products with specific TLRs, resulting in COX-2-mediated 
prostaglandin production (including PGE2) and repression of β2-AR activity (Van Ly et al., 
2013). To date, however, whether bacterial infection directly affects β2-AR function in a similar, 
TLR/COX-2-dependent manner has not been investigated. This is the aim of the current study. 
Previous reports support that in human ASM cells β2-AR receptor desensitization can be either 
homologous or heterologous [reviewed in (Shore and Moore, 2003)]. In our present study we 
attempt to determine whether TLR2 agonist Pam3CSK4, mimic bacterial infection, affects β2-
AR function in a similar manner as viral infection heterologously via COX-2 production. In 
parallel study we also showed the homologous desensitization of β2-AR by short acting and long 
acting β2-agonists, salbutamol and formoterol respectively. 
In addition to bronchodilatory actions in the airways, β2-agonists also have anti-inflammatory 
effects via cAMP-dependent upregulation of immunomodulatory molecules. One such molecule 
is the MAPK-deactivating protein MKP-1 (Manetsch et al., 2012a; Manetsch et al., 2013). MKP-
1 expression is mediated via β2-AR/cAMP-dependent mechanisms (Manetsch et al., 2012a); 
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thus, we propose that upregulation of this critical anti-inflammatory molecule by β2-agonists 
would be severely curtailed in bacterial infection. Therefore in this study we demonstrated the 
impact of TLR2 ligand associated β2-AR desensitization by impaired cAMP production as well 
as reduced gene expression of the critical anti-inflammatory molecule MKP-1 in response to β2-
agonists. 
 
4.2 Meterials and methods 
4.2.1 Cell culture 
For detailed description, see Chapter 2.2.1. 
 
4.2.2 Chemicals 
Pam3CSK4 was purchased from InVivoGen (San Diego, CA, USA), tumour necrosis factor a 
(TNFα) from R&D Systems (Minneapolis, MN, USA) and celecoxib and PGE2 from Cayman 
Chemical Company (Ann Arbor, MI, USA). Unless otherwise specified, all chemicals used in 
this study were purchased from Sigma-Aldrich (St.Louis, MO). 
 
4.2.3 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and reverse transcribed using the 
RevertAid First strand cDNA Synthesis Kit (Fermentas Life Sciences). Real-time RT-PCR was 
performed on an ABI Prism 7500 with COX-2 (Hs0015133_m1) and MKP-1 (DUSP1: 
Hs00610256_g1) TaqMan® Gene Expression Assays and the eukaryotic 18S rRNA endogenous 
control probe (Applied Biosystems) subjected to the following cycle parameters: 50°C for 2 min, 
1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 60°C for 1 min, 40 cycles and mRNA 
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expression (fold increase) quantified by delta delta Ct calculations. For detailed description, see 
Chapter 2.2.3. 
 
4.2.4  cAMP and PGE2 assay 
Measured by enzyme immunoassay according to the manufacturers‟ instructions (Prostaglandin 
E2 EIA 514010 and cAMP EIA 58100: Cayman). For detailed description, see Chapter 2.2.5 and 
2.2.6. 
 
4.2.5 Statistical analysis 
Statistical analysis was performed using either the Student‟s unpaired t test or one or two-way 
ANOVA, followed by the Bonferroni post hoc test. P<0.05 was considered sufficient to reject 
the null hypothesis for all analyses. Data represent means ± SEMs. 
 
4.3 Results 
4.3.1 TLR2 ligand engagement upregulates TNFα-induced COX-2 mRNA expression and 
increases PGE2 secretion 
Our previous studies have modelled rhinovirus-induced asthma exacerbation in vitro in ASM 
cells to reveal the molecular events responsible for β2-AR desensitization (Trian et al., 2010; 
Trian et al., 2011; Van Ly et al., 2013). To date however, whether bacterial infection directly 
affects β2-AR function had not been explored. We addressed this by modelling bacterial 
exacerbation in vitro. ASM cells were treated with the synthetic bacterial lipoprotein Pam3CSK4 
to mimic bacterial infection via TLR2 activation and with TNFα to simulate inflammation. We 
then measured the temporal kinetics of COX-2 mRNA expression and PGE2 secretion. 
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Upregulation of COX-2 mRNA expression by TNF was sustained in the presence of 
Pam3CSK4, with TLR2 activation significantly increasing TNF-induced COX-2 expression at 
24 h (Figure 4.1A: P<0.05). Secretion of the COX-2 product PGE2 increased in a similar manner 
(Figure 4.1B); TLR2 ligand engagement by Pam3CSK4 significantly upregulated TNFα-induced 
PGE2 secretion at 24 h (P<0.05).  
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Figure 4.1 TLR2 ligand engagement upregulates TNFα-induced COX-2 mRNA expression 
and increases PGE2 secretion. Growth-arrested ASM cells were pretreated with vehicle or 
Pam3CSK4 (1 μg/mL) for 1 h, followed by treatment with vehicle or TNFα (10 ng/mL) for 0, 1, 
2, 4, 8, and 24 h. (A) COX-2 mRNA expression was quantified by real-time RT-PCR (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (B) PGE2 secretion was 
measured by EIA. Statistical analysis was performed using two-way ANOVA then Bonferroni's 
post-test (where * denotes a significant effect of Pam3CSK4 on TNFα-induced COX-2 mRNA 
expression and PGE2 secretion (P<0.05)). Data are mean±SEM values from (A) n=7 and (B) n=4 
primary ASM cell cultures. 
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4.3.2 PGE2 induces heterologous β2-AR desensitization as measured by inhibition of β2-
agonist-induced cAMP production 
Because COX-2 products, such as PGE2, are responsible for rhinovirus-induced β2-AR 
desensitization (Van Ly et al., 2013), our results suggest that bacteria and viruses may induce a 
common molecular mechanism to downregulate β2-AR on ASM cells in a heterologous manner. 
To confirm this, we pretreated ASM cells for 24 h with a range of concentrations of PGE2 (0.1–
100 nM) and measured cAMP production in response to two β2-agonists: short-acting β2-agonist 
salbutamol (Figure 4.2A) and long-acting β2-agonist formoterol (Figure. 4.2B). These 
experiments were performed in parallel with control experiments to demonstrate homologous β2-
AR desensitization by β2-agonists. In confirmation of earlier reports (Shore and Moore, 2003), 
salbutamol induced a 5-fold increase in cAMP production that was sensitive to homologous β2-
AR desensitization (Figure 4.2A: P<0.05). Notably, pretreatment with PGE2 induced 
heterologous β2-AR desensitization in a concentration-dependent manner (P<0.05) (5, 12). 
Similarly, formoterol or PGE2 also significantly repressed cAMP generation in response to 
formoterol (Figure. 4.2B: P<0.05). 
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Figure 4.2 PGE2 induces heterologous β2-AR desensitization as measured by inhibition of 
β2-agonist-induced cAMP production. Growth-arrested ASM cells were pretreated for 24 h 
with vehicle, salbutamol (10 µM), formoterol (0.01 µM), or a range of PGE2 concentrations (0.1-
100 nM).Desensitization of the β2-AR was assessed by measuring production of cAMP in 
response to stimulation with (A) 10 µM salbutamol or (B) 0.01 µM formoterol for 15 min, 
compared to vehicle, in the presence of the pan-phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX: 30 min pretreatment at 10 µM). Results are expressed as a percentage of 
β2-agonist-induced cAMP. Statistical analysis was performed using one-way ANOVA then 
Bonferroni's post-test (where § or * denotes a significant effect of β2-agonists or PGE2 on cAMP 
production, respectively (P<0.05)). Data are mean±SEM values from n=5 primary ASM cell 
cultures. 
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4.3.3 Celecoxib inhibits PGE2 secretion but not COX-2 mRNA expression 
We are first to show that TLR2 activation also leads to β2-AR desensitization in ASM cells. As 
this occurs in a COX-2-dependent, PGE2-mediated manner we now wished to test the 
effectiveness of the specific COX-2 inhibitor celecoxib. Celecoxib inhibits COX-2 enzymatic 
activity, not expression; therefore we confirmed that celecoxib had no effect on COX-2 mRNA 
expression (Figure 4.3A). In contrast, celecoxib did have the expected inhibitory effect on PGE2 
secretion. This is shown in Figure 4.3B, where celecoxib pretreatment completely represses 
PGE2 secretion induced by Pam3CSK4 + TNF (Figure 4.3B: P<0.05).  
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Figure 4.3 Celecoxib inhibits PGE2 secretion but not COX-2 mRNA expression. Growth-
arrested ASM cells were pretreated with vehicle or 10 µM celecoxib for 1 h. Cells were then 
treated with vehicle or Pam3CSK4 (1 μg/mL) for 1 h, followed by vehicle or TNFα (10 ng/mL) 
for 24 h. (A) COX-2 mRNA expression was quantified by real-time RT-PCR (results expressed 
as fold increase compared to vehicle-treated cells) and (B) PGE2 secretion was measured by EIA. 
Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test (where * 
denotes a significant effect of celecoxib on PGE2 secretion (P<0.05)). Data are mean±SEM 
values from n=4 primary ASM cell cultures. 
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4.3.4 Pam3CSK4 + TNF cause tachyphylaxis of β2-AR agonists mediating MKP-1 gene 
expression and this can be reversed by celecoxib 
We next examined the effects of TLR2 activation on MKP-1 responses. Notably, pretreating 
cells with Pam3CSK4 + TNF resulted in a significant reduction in β2-AR agonist-induced 
MKP-1 gene expression (Figure 4.4A: P<0.05). Figure 4.4B represents control experiments 
confirming PGE2-mediated β2-AR desensitization. These data demonstrate that Pam3CSK4 + 
TNF causes tachyphylaxis of β2-AR agonist-induced MKP-1 gene expression in a PGE2-
dependent manner. This could be reversed by celecoxib, selective COX-2 inhibitor, to allow β2-
agonist-induced MKP-1 gene expression to be reinstated (Figure 4.4C). 
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Figure 4.4 Pam3CSK4 + TNFα cause tachyphylaxis of β2-AR agonists mediating MKP-1 
gene expression and this can be reversed by celecoxib. Growth-arrested ASM cells were 
pretreated for 24 h with vehicle, Pam3CSK4 (1 μg/mL) + TNFα (10 ng/mL), or PGE2 (100 nM). 
(A) The impact of TLR2-mediated β2-AR desensitization on anti-inflammatory actions of β2-
agonists was assessed by measuring MKP-1 mRNA expression by RT-PCR in response to 
stimulation with 10 µM salbutamol or formoterol (0.01 µM) for 1 h, in comparison to vehicle 
(results expressed as fold increase compared to vehicle- or Pam3CSK4 + TNFα-treated cells). 
(B) Control experiments confirm PGE2-mediated β2-AR desensitization results in reduced β2-
agonist-mediated MKP-1 expression, in comparison to vehicle-treated cells. (C) In parallel 
experiments, cells were pretreated with vehicle or 10 µM celecoxib for 1 h, and treated under 
identical conditions as above (A) to demonstrate that tachyphylaxis of β2-AR agonists was 
reversed by celecoxib allowing β2-agonist-induced MKP-1 gene expression to be reinstated. 
Statistical analysis was performed using one-way ANOVA then Bonferroni's post-test (where * 
denotes a significant repression of β2-agonist-induced MKP-1 mRNA expression and § denotes a 
significant effect of celecoxib (P<0.05)). Data are mean±SEM values from n=3 primary ASM 
cell cultures. 
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4.4 Discussion 
β2-AR agonist hyporesponsiveness is a hallmark feature in human asthma. The affinity of β2-
agonists to bind with β2-AR is found to be much less sensitive in virus-induced asthma 
exacerbations (Reddel et al., 1999; Reddel et al., 2011; Rueter et al., 2012) and can be 
compromised by bacterial infection (Edwards et al., 2012). To date, the underlying mechanisms 
are not completely understood, and to ultimately improve asthma therapy, we require a greater 
understanding of the molecular events that occur at the cellular level that manifest clinically with 
reduced β2-agonist response during infection. Utilizing an in vitro model of bacterial 
exacerbation, we show that TLR2 activation in the presence of an inflammatory stimulus, TNFα, 
leads to β2-AR desensitization in ASM cells. TLR2 activation induced a significant time-
dependent increase in expression of COX-2 mRNA and secretion of COX-2 product, PGE2. 
PGE2 induces heterologous desensitization of the β2-AR on ASM cells thereby limiting the 
bronchodilatory actions of β2-agonists by repressing the amount of cAMP and also curtailing the 
anti-inflammatory effects of β2-agonists by reducing the amount of anti-inflammatory protein, 
MKP-1. Consistent with our previous findings that COX-2 product, such as PGE2, is responsible 
for rhinovirus-induced β2-AR desensitization (Trian et al., 2010; Van Ly et al., 2013), these 
results show that bacteria also induce same prostanoid-dependent molecular mechanism to 
downregulate the β2-AR on ASM cells.  
To demonstrate the impact of β2-AR desensitization, we measured the effect on two important 
ways in which β2-agonists induce their beneficial effects in asthma: (i) bronchorelaxation and (ii) 
anti-inflammatory actions. Firstly, as β2-agonists exert their bronchodialatory action by 
increasing the level of cAMP, we show that β2-agonist-induced cAMP level is significantly 
repressed when the β2-AR is heterologously desensitized by PGE2. Although Pam3CSK4 + 
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TNFα induced the expected increased secretion of PGE2 in this setting, the measured levels 
released from a very small amount of lung tissue and diluted within the surrounding media were 
markedly lower than the concentration of exogenous PGE2 shown to induce desensitization of 
salbutamol- mediated relaxation. Nevertheless, we propose that the local concentrations of PGE2 
generated within the whole lung in vivo following infection would be sufficient to contribute to 
the loss of dilator responsiveness. This is supported by a previous in vivo study in an infection 
model where influenza A infection-induced sustained increases in BAL levels of PGE2, and 
COX2 _/_mice had reduced BAL inflammatory cells and cytokines compared with wild-type 
mice (Carey et al., 2005). Thus, we have begun to achieve a better understanding of the 
molecular mechanisms of infection-induced asthma exacerbations that will ultimately allow the 
development of new therapeutics to specifically treat infection-induced asthma exacerbations. 
Because COX-2 products, including PGE2, are also responsible for rhinovirus-induced β2-AR 
desensitization (Van Ly et al., 2013), our results suggest that bacteria and virus induce a common 
molecular mechanism responsible for β2-agonist tachyphylaxis.  
Secondly, our recent studies have demonstrated that one of the key ways in which β2-agonists 
have an anti-inflammatory effect in airways is via upregulation of anti-inflammatory protein, 
MKP-1 (Manetsch et al., 2012a; Manetsch et al., 2013). As this upregulation is mediated via β2-
AR/cAMP-dependent mechanisms (Manetsch et al., 2012a), we now show that β2-agonist-
induced MKP-1 mRNA expression is significantly repressed when the β2-AR is heterologously 
desensitized by PGE2. The extent of repression of the response to salbutamol and formoterol by 
PGE2 was also consistent with their relative capacity induce cAMP-dependent MKP-1 
expression. Being a full agonist, formoterol appeared to be relatively less sensitive to β2-AR 
desensitization than the partial agonist salbutamol. As salbutamol lacks receptor reserve, PGE2-
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mediated desensitization had a greater impact on its capacity to increase expression of MKP-1 
and potentially to limit airway inflammation. Importantly, we also demonstrated that TLR2 
activation has a direct effect on β2-agonist-induced MKP-1 response. Pam3CSK4 + TNFα 
caused tachyphylaxis of β2- AR agonist-induced MKP-1 gene expression, and this could be 
reversed by celecoxib. These results suggest that celecoxib could be therapeutic in infectious 
exacerbation as treatment reverses the tachyphylaxis of salbutamol and formoterol on MKP-1 
gene expression. 
Utilizing a model of rhinovirus-induced asthma exacerbation in vitro in ASM cells (Trian et al., 
2010; Trian et al., 2011; Van Ly et al., 2013), we previously learned how key molecular steps 
responsible for the action of β2-agonists are severely curtailed by viral infectious stimuli. 
Whether bacterial infection directly affects β2-AR function had not been explored. To address 
this, we modelled bacterial exacerbation in vitro with the synthetic bacterial lipoprotein 
Pam3CSK4 (a TLR2 agonist) to mimic bacterial infection and TNFα to simulate inflammation. 
TLR2 is a pattern-recognition receptor important for mediating the response to bacterial 
products, and Pam3CSK4 has been widely used to mimic bacterial infections (gram + bacteria) 
(Beckett et al., 2012; Manetsch et al., 2012b). Using this model, we now show that TLR2 
activation results in a time-dependent increase in TNFα-induced COX-2 mRNA expression. 
COX-2 converts arachidonic acid to prostanoids (including prostaglandins), and in confirmation 
of earlier reports (Pang et al., 1998b), COX-2 upregulation in ASM cells consequently results in 
secretion of PGE2. Secreted PGE2 then acts back on the ASM in an autocrine manner to cause 
heterologous β2-AR desensitization (Pang et al., 1998b; Shore and Moore, 2003; Van Ly et al., 
2013). Homologous desensitization was confirmed in parallel experiments (Hall et al., 1993); 
ASM cells were pretreated with β2-agonists, and the resultant cAMP formed in response to 
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salbutamol and formoterol was significantly attenuated. Moreover, it was interesting to note that 
the sensitivity to heterologous β2-AR desensitization induced by PGE2 differed between the two 
β2-agonists tested. Inhibition of salbutamol-induced cAMP generation was evident after 
pretreatment with a 10-fold lower concentration of PGE2 than was required to inhibit the 
formoterol response, perhaps reflecting the lack of receptor reserve for salbutamol, which is a 
partial agonist at β2-ARs. 
These findings suggest that in ASM cells the increased effect of TLR2 agonist, Pam3CSK4 on 
COX-2 mediated PGE2 secretion further contribute in heterologous desensitization of β2-AR.  
In our published paper, there are some more supporting data (not shown here as those are done 
by our collaborator in other lab) showing similar events in mouse lung slices ex vivo model, 
which further strengthen our hypothesis (Alkhouri et al., 2014). Collectively, our findings in both 
in vitro and ex vivo models successfully demonstrate the role of TLR2 agonist in β2-AR 
desensitization in asthma. Therefore, we believe the data presented in this chapter will provide 
greater understanding in the context of β2-AR desensitisation and reinforce further investigation 
using contemporary experimental models to ascertain its clinical significance. Understanding 
these events may prove to be an important step in improving the efficacy of β2-agonists for the 
treatment of asthma and will help to develop efficacious pharmacotherapeutic strategies to treat 
respiratory disease without unwanted side effects in the near future. 
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Chapter 5 
Sphingosine 1-phosphate increases 
COX-2 expression and PGE2 secretion: 
effects on β2-adrenergic receptor 
desensitization 
 
This work has been published as “Sphingosine 1-phosphate Increases COX-2 Expression and 
PGE2 Secretion: Effects on β2-adrenergic Receptor Desensitization. Nowshin N Rumzhum, Md. 
Mostafizur Rahman, Brian G Oliver, and Alaina J Ammit. Am J Respir Cell Mol Biol.”Jun 2015 
as DOI: 10.1165/rcmb.2014-0443OC(Rumzhum et al., 2015b). 
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Chapter 5 
Sphingosine 1-phosphate increases COX-2 
expression and PGE2 secretion: effects on β2-
adrenergic receptor desensitization 
 
5.1 Introduction 
In Chapter 4, we successfully demonstrate that TLR2 agonist, Pam3CSK4 induces COX-2 
expression in ASM cells and contributes in heterologous desensitization of β2-AR via PGE2 
secretion. Here, in this chapter, we aim to explore the effect of another inflammatory mediator, 
S1P, on COX-2 upregulation and its impact on β2-AR desensitization. Increased COX-2 protein 
level has potential in regulating several aspects of inflammatory diseases including airway 
inflammation such as asthma and COPD. As “inflammation-associated” enzyme, induction of 
COX-2 is triggered by a number of cytokines and inflammatory mediators present in various 
inflammatory cells. In acute and chronic inflammatory states the induced COX-2 is primarily 
responsible for the synthesis of the prostanoids and along with COX-2 that prostanoids are 
associated in pathological process of several inflammatory conditions. 
S1P is a bioactive sphingolipid found elevated in BAL from individuals with allergic asthma and 
was associated with inflammatory cell influx into the airways (Ammit et al., 2001) . S1P exerts 
potent effects in in vitro and in vivo models of asthmatic inflammation and airway remodelling 
(Ammit et al., 2001; Roviezzo et al., 2007; Nishiuma et al., 2008; Che et al., 2014; Rahman et 
al., 2014). Moreover, Fuerst et al. reported that S1P potently regulated calcium mobilization and 
gene expression (including COX-2) in ASM grown from bronchial biopsies from healthy and 
asthma individuals (Fuerst et al., 2014). Notably, an S1P analog (FTY720; fingolimod) was 
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recently shown to be linked to exacerbation of asthma symptoms (van Rossum et al., 2014). 
Thus, although COX-2/PGE2 expression has been linked to S1P, its role in hyporesponsiveness 
of the β2-AR in ASM cells has not been examined. S1P has been shown to induce β2-AR 
desensitization in a guinea pig model of bronchoconstriction (Makino et al., 2012) and was 
recently shown to increase COX-2/PGE2 in tracheal ASM cells in vitro (Hsu et al., 2015) . 
Herein we investigate the effect of S1P on COX-2 upregulation alone and in combination with 
TNF in bronchial ASM cells and provide the first demonstration of β2-AR desensitization by 
S1P in vitro.  
Bronchodilatory β2-agonists are the most commonly used drugs to relieve acute 
bronchoconstriction in people with asthma or COPD. β2-agonists exert their effects by binding 
with the β2-AR, a seven transmembrane GPCR and ultimately relax the airways by rapidly 
increasing cAMP levels in ASM cells. However, heterologous and homologous β2-AR 
desensitization can occur in diverse range of clinically-relevant contexts, including β2-agonist 
overuse, inflammation, bacterial and viral infectious exacerbation (Corne et al., 2002; Shore and 
Moore, 2003; Edwards et al., 2012). As this can result in hyporesponsiveness to β2-agonists, β2-
AR desensitization is an important issue limiting effective treatment of chronic respiratory 
disease; thus further investigation into the causes and underlying molecular mechanisms are 
warranted.  
Accumulating evidence has demonstrated the key role played by the enzyme COX-2 and its 
prostanoid products (PGE2 in particular) in mediating β2-AR desensitization. A number of pro-
inflammatory cytokines elevated in BAL from people with asthma have been shown to induce 
COX-2 expression and result in PGE2 secretion from ASM cells in vitro. Cytokines investigated 
include TNF, interleukin 1β and interferon , added alone or in combination (cytomix) (Belvisi 
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et al., 1997; Pang and Knox, 1997; Pang et al., 1998b; Singer et al., 2003). PGE2 is known to 
exert homologous desensitization of β2-AR (Hall et al., 1993) and we have recently confirmed 
COX-2-dependent/PGE2-mediated hyporesponsiveness to β2-agonists in models of viral- and 
bacterial-induced exacerbation (Trian et al., 2010; Van Ly et al., 2013; Alkhouri et al., 2014).  
As a part of our ongoing research on unveiling the molecular events of COX-2 upregulation as 
well as its impact in β2-AR desensitization, in this study we investigate the effect of S1P alone 
and in combination with TNF  on COX-2 upregulation in bronchial ASM cells and provide the 
first demonstration of β2-AR desensitization by S1P in vitro. We show the bioactive sphingolipid 
S1P induces hyporesponsiveness to the β2-agonists salbutamol and formoterol, and demonstrate 
that S1P augments COX-2 expression and PGE2 secretion induced by TNF in an additive 
manner. Notably, S1P-induced effects are repressed by the COX-2 selective inhibitor, celecoxib 
and dexamethasone, thus, representing feasible pharmacotherapeutic strategies for restoring β2-
AR sensitivity. 
 
5.2 Materials and methods 
5.2.1 ASM cell culture 
For detailed description, see Chapter 2.2.1. 
 
5.2.2 Chemicals 
TNF was purchased from R&D Systems (Minneapolis, MN) and celecoxib from Cayman 
Chemical Company (Ann Arbor, MI). S1P (Biomol) was purchased from Enzo Life Sciences 
(Farmingdale, NY). Unless otherwise specified, all chemicals were from Sigma-Aldrich (St. 
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Louis, MO). Unless otherwise specified, all chemicals used in this study were purchased from 
Sigma-Aldrich (St.Louis, MO). 
 
5.2.3 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, 
Australia) and reverse transcribed using the RevertAid First strand cDNA Synthesis Kit 
(Fermentas Life Sciences, Hanover, MD). Real-time RT-PCR was performed on an ABI Prism 
7500 with COX-2 (Hs0015133_m1) TaqMan® Gene Expression Assays and the eukaryotic 18S 
rRNA endogenous control probe (Applied Biosystems, Foster City, CA) subjected to the 
following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 
60°C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta delta Ct 
calculations.  
 
5.2.4 PGE2 assay 
PGE2 was measured by enzyme immunoassay (Prostaglandin E2 EIA 514010: Cayman Chemical 
Company) according to the manufacturer‟s instructions. For detailed description, see Chapter 
2.2.6. 
 
5.2.5 Western blotting 
Western blotting was performed using mouse monoclonal antibodies against COX-2 (29: Santa 
Cruz Biotechnology, Santa Cruz, CA), compared to α-tubulin as the loading control (clone DM 
1A, Santa Cruz Biotechnology). Primary antibodies were detected with goat anti-mouse horse 
radish peroxidase–conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA) 
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and visualized by enhanced chemiluminescence (Perkin Elmer, Wellesley, MA). For detailed 
description, see Chapter 2.2.2. 
 
5.2.6 COX-2 siRNA 
ASM cells were transiently transfected using nucleofection with 1 μg COX-2-specific ON-Target 
SMART pool siRNA, consisting of a pool of four individual siRNA (Dharmacon: Thermo Fisher 
Scientific, Waltham, MA) or a scrambled siRNA control (ON-Target plus Control Non-targeting 
siRNA: Dharmacon), using methods established in our earlier publication (Quante et al., 2008). 
ASM cells were plated in 6-well plates for 16 h after transfection, before being growth-arrested 
with 2 mL DMEM media with 0.1% BSA for a further 24 h. Cells were then stimulated with S1P 
(1 µM) before COX-2 mRNA was measured by RT-PCR at 1 h, COX-2 protein detected by 
Western blotting at 24 h  and secreted PGE2 at 24 h measured by enzyme immunoassay.  
 
5.2.7 cAMP assay 
Growth-arrested ASM cells were pretreated for 24 h with vehicle, 100 nM PGE2, vehicle, S1P (1 
µM), S1P (1 µM) + TNF (10 ng/ml). Desensitization of the β2-AR was assessed by measuring 
production of cAMP in response to stimulation with 10 µM salbutamol or 10 nM formoterol for 
15 min, compared to vehicle, in the presence of IBMX (30 min pretreatment at 10 µM) 
(Alkhouri et al., 2014). Cell lysates were prepared and intracellular cAMP was measured by 
enzyme immunoassay (cAMP EIA 581001: Cayman Chemical Company) according to the 
manufacturer‟s instructions. For detailed description, see Chapter 2.2.5. 
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5.2.8 Statistical analysis 
Statistical analysis was performed using Student's unpaired t test, one-way ANOVA then 
Fisher‟s post-hoc multiple comparison test, or two-way ANOVA then Bonferroni's post-test. P 
values<0.05 were sufficient to reject the null hypothesis for all analyses.  
 
5.3 Results 
5.3.1 S1P upregulates COX-2 mRNA expression and protein upregulation to increase PGE2 
secretion from ASM cells 
To explore the role of S1P in β2-AR desensitization, we first treated ASM cells with S1P (1 µM) 
over 24 h and measured the temporal kinetics of COX-2 mRNA expression, protein upregulation 
and PGE2 secretion. Stimulation of ASM cells with S1P significantly upregulated COX-2 mRNA 
expression at 1 and 2 h (Figure 5.1A). COX-2 protein upregulation followed with a peak at 8 h 
(Figures 5.1B and 5.1C) and resulted in increased levels of PGE2 by 24 h (Figure 5.1D) 
(P<0.05). 
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Figure 5.1 S1P upregulates COX-2 mRNA expression and protein upregulation to increase 
PGE2 secretion from ASM cells. Growth-arrested ASM cells were treated with vehicle or S1P 
(1 µM) for 0, 1, 2, 4, 8, and 24 h.(A) COX-2 mRNA expression was quantified by real-time RT-
PCR (results expressed as fold increase compared to vehicle-treated cells at 0 h). (B, C) COX-2 
protein was detected by Western blotting (with α-tubulin as the loading control), where results 
are representative Western blots (72 kDa) (B), while (C) demonstrates densitometric analysis 
(results expressed as fold increase compared to vehicle-treated cells at 0 h). (D) PGE2 secretion 
was measured by EIA. Statistical analysis was performed using one-way or two-way ANOVA 
then Bonferroni's post-test (where * denotes a significant effect of S1P (P<0.05)). Data are 
mean±SEM values from n=3 primary ASM cell cultures. 
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5.3.2 Celecoxib has no effect on S1P-induced COX-2 mRNA, but significantly inhibited 
S1P-induced PGE2 secretion 
We then treated cells with the selective COX-2 inhibitor, celecoxib, and examined its effect on 
COX-2 mRNA expression and PGE2 secretion. As expected, celecoxib had no effect on S1P-
induced COX-2 mRNA expression (Figure 5.2A). In contrast, celecoxib pretreatment 
significantly repressed S1P-induced PGE2 secretion (Figure 5.2B: P<0.05). These results confirm 
that celecoxib inhibits COX-2 enzymatic activity, but not its mRNA expression, and demonstrate 
that S1P-induced PGE2 secretion occurs in a COX-2-dependent manner. 
 
 
Figure 5.2 Celecoxib has no effect on S1P-induced COX-2 mRNA, but significantly 
inhibited S1P-induced PGE2 secretion. Growth-arrested ASM cells were pretreated with 
vehicle or 10 µM celecoxib for 1 h before treatment with S1P (1 µM) for 0, 1, 2, 4, 8, and 24 h. 
(A) COX-2 mRNA expression was quantified by real-time RT-PCR (results expressed as fold 
increase compared to vehicle-treated cells at 0 h). (B) Repression of S1P-induced PGE2 secretion 
(results expressed as a percentage of S1P-induced PGE2 secretion at 24 h). Statistical analysis 
was performed using Student's unpaired t test (where § denotes significant repression by 
celecoxib). Data are mean±SEM values from n=3 primary ASM cell cultures. 
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5.3.3 Dexamethasone represses S1P-induced COX-2 mRNA expression and PGE2 secretion 
Corticosteroids are first line anti-inflammatory therapies in asthma and we have already shown 
that they have repressive effects on S1P-induced cytokine secretion (Che et al., 2014; Rahman et 
al., 2014). Earlier publications have shown that cytokine-induced COX-2 expression and PGE2 
secretion can be repressed by the corticosteroid dexamethasone (Belvisi et al., 1997; Pang and 
Knox, 1997). To assess whether corticosteroids repress S1P-induced effects, ASM cells were 
pretreated with 100 nM dexamethasone for 30 min before stimulation. As shown in Figure 5.3A, 
dexamethasone abolished S1P-induced COX-2 mRNA expression, with significant repression 
observed at the 1, 2 and 4 h time point (P<0.05). Moreover, we observed that pretreatment with 
dexamethasone significantly inhibited S1P-induced PGE2 secretion at 24 h (Figure 5.3B: 
P<0.05). 
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Figure 5.3 Dexamethasone represses S1P-induced COX-2 mRNA expression and PGE2 
secretion. Growth-arrested ASM cells were pretreated with vehicle or 100 nM dexamethasone 
for 30 min before treatment with S1P (1 µM) for 0, 1, 2, 4, 8, and 24 h. (A) COX-2 mRNA 
expression was quantified by real-time RT-PCR (results expressed as fold increase compared to 
vehicle-treated cells at 0 h). (B) Repression of S1P-induced PGE2 secretion (results expressed as 
a percentage of S1P-induced PGE2 secretion at 24 h). Statistical analysis was performed using 
one-way or two-way ANOVA then Bonferroni's post-test (where § denotes significant repression 
by dexamethasone). Data are mean±SEM values from n≥3 primary ASM cell cultures. 
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5.3.4 COX-2 knockdown by siRNA represses S1P-induced COX-2 mRNA expression, 
protein upregulation and PGE2 secretion 
To further support the role of S1P-induced COX-2 expression on PGE2 secretion, we examined 
the impact of specifically knocking down COX-2 with siRNA on S1P-induced COX-2 mRNA 
expression, protein upregulation and PGE2 secretion (Figure 5.4). ASM cells were transiently 
transfected using nucleofection with scrambled control or COX-2 siRNA, growth-arrested, then 
stimulated with S1P (1 µM). As shown in Figure 5.4A, the peak of COX-2 mRNA expression at 
1 h was significantly reduced by COX-2 siRNA (P<0.05). S1P-induced COX-2 protein 
expression was significantly reduced by siRNA knockdown (Figure 5.4B), with densitometric 
analysis revealing a significant 66.9±9.8% reduction of COX-2 protein expression at 24 h in cells 
transfected with siRNA against COX-2, compared to scrambled control (Figure 5.4C: P<0.05). 
This resulted in corresponding decrease in the amount of PGE2 secreted (Figure 5.4D: P<0.05). 
Collectively, these results confirm that S1P significantly enhances COX-2 expression and PGE2 
secretion, as this was repressed by the selective COX-2 inhibitor, celecoxib, the corticosteroid 
dexamethasone, or siRNA knockdown of COX-2 expression. 
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Figure 5.4 COX-2 knockdown by siRNA represses S1P-induced COX-2 mRNA expression, 
protein upregulation and PGE2 secretion. ASM cells were transiently transfected using 
nucleofection with scrambled control or COX-2 siRNA, growth-arrested, then stimulated with 
S1P (1 µM). (A) COX-2 mRNA was measured by RT-PCR at 1 h (results expressed as % of 
S1P-induced COX-2 mRNA expression, scrambled control). (B, C) COX-2 protein was detected 
by Western blotting (with α-tubulin as the loading control) at 24 h (results are representative 
Western blots (72 kDa) (B), while (C) demonstrates densitometric analysis). (D) Secreted PGE2 
at 24 h was measured by enzyme immunoassay (results expressed as % of S1P-induced PGE2 
secretion, scrambled control). Statistical analysis was performed using Student's unpaired t test 
(where § denotes a significant effect of siRNA against COX-2, compared to scrambled control). 
Data are mean±SEM values from n=3 primary ASM cell cultures. 
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5.3.5 TNF enhances S1P-induced COX-2 mRNA expression and protein upregulation and 
increases PGE2 secretion 
We (Alkhouri et al., 2014) and others (Belvisi et al., 1997; Pang and Knox, 1997) have shown 
that the pro-inflammatory cytokine TNF found elevated in BAL increases COX-2 mRNA 
expression and induces PGE2 secretion from ASM cells. Comparatively, TNF alone is a 
relatively modest inducer of COX-2 mRNA expression and PGE2 secretion (Pang and Knox, 
1997; Comer et al., 2014), but robust upregulation can be observed in combination with other 
cytokines, IL-1β in particular (Belvisi et al., 1997), or as cytomix (Belvisi et al., 1997; Singer et 
al., 2003) . We propose that the effects of S1P would be enhanced in the presence of TNF and 
in order to test this we treated growth-arrested ASM cells with S1P (1 µM) or TNF (10 ng/mL), 
alone or in combination. As shown in Figure 5.5A, the temporal kinetics of COX-2 mRNA 
expression induced by TNF is similar to that observed when ASM cells are stimulated with S1P 
alone. However, when cells are stimulated with both mediators together there is an additive 
effect, with TNF significantly enhancing S1P-induced COX-2 mRNA expression at 4 and 8 h 
(Figure 5.5A: P<0.05). COX-2 protein upregulation at 24 h (Figure 5.5B), aligned with the 
mRNA data, and densitometric analysis confirmed that TNF significantly enhanced S1P-
induced COX-2 protein upregulation (Figure 5.5C: P<0.05).These data concur with the temporal 
kinetics of PGE2 secretion. As shown in Figure 5.5D, when added in combination, we observed 
that TNF significantly increased S1P-induced PGE2 secretion at 4, 8 and 24 h (P<0.05).  
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Figure 5.5 TNFα enhances S1P-induced COX-2 mRNA expression and protein 
upregulation and increases PGE2 secretion. Growth-arrested ASM cells were treated with 
vehicle, S1P (1 µM), TNF (10 ng/ml), or S1P + TNF, for 0, 1, 2, 4, 8, and 24 h.(A) COX-2 
mRNA expression was quantified by real-time RT-PCR (results expressed as fold increase 
compared to vehicle-treated cells at 0 h); (B, C) COX-2 protein was detected by Western blotting 
at 24 h (compared to -tubulin as a loading control), where (B) is a representative blot (72 kDa)  
and (C) is densitometric analysis of COX-2 protein upregulation (results normalised with -
tubulin expressed as fold increase compared to vehicle-treated cells); (D) PGE2 secretion was 
measured by EIA. Statistical analysis was performed with two-way ANOVA then Bonferroni's 
post-test or Student's unpaired t test (where * denotes a significant effect of TNF on S1P-
induced effects (P<0.05)). Data are mean±SEM values from n=3 primary ASM cell cultures. 
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5.3.6 S1P induces heterologous β2-adrenergic desensitization as measured by inhibition of 
β2-agonist-induced cAMP production; in a manner independent of adenylate cyclase 
Taken together, our data thus far shows that S1P increases COX-2 upregulation and significantly 
enhances PGE2 secretion from ASM cells. Moreover, when added in combination with TNF, 
COX-2 expression and PGE2 secretion is substantially increased in an additive manner. PGE2 is 
a known inducer of β2-AR desensitization and so we now wished to demonstrate that S1P, alone 
and in combination with TNF, caused β2-AR desensitization and resulted in β2-AR 
hyporesponsiveness to two widely-used β2-agonists in asthma and COPD, short-acting 
salbutamol and long-acting formoterol. ASM cells were exposed to a concentration of PGE2 
known to induce heterologous desensitization, i.e. 100 nM (Alkhouri et al., 2014), in parallel 
with S1P, or S1P + TNF, compared to vehicle. We then stimulated cells for 15 min with either 
salbutamol (Figure 5.6A) or formoterol (Figure 5.6B) and measured the cAMP produced in 
response to β2-agonists as a measure of β2-AR desensitization. As shown in Figure 5.6A, 
salbutamol significantly increased cAMP production in ASM cells and this was significantly 
repressed by pretreatment with PGE2. These data concur with our previous study (Alkhouri et al., 
2014). Notably, pretreating cells with S1P, or S1P + TNF, also resulted in a significantly less 
cAMP, indicative of β2-AR desensitization (P<0.05). There was also evidence of 
hyporesponsiveness to the β2-agonist formoterol, as shown in Figure 5.6B; where formoterol 
induced 121.0±9.1 pmol cAMP/mL that was significantly repressed by PGE2, S1P, or S1P + 
TNF (P<0.05). This is independent of adenylate cyclase involvement, as shown in Figure 5.6C, 
where the adenylate cyclase activator, forskolin, significantly increases cAMP secretion from 
ASM cells and this was unaffected by PGE2 alone, S1P, or S1P in combination with TNF. 
These data support the assertion that S1P induces heterologous β2-AR desensitization via PGE2, 
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in a manner that may be upstream of adenylate cyclase. Collectively, these studies provide the 
first evidence that, like other inflammatory mediators found elevated in asthma, the bioactive 
sphingolipid S1P induces β2-adrenergic desensitization in ASM. 
  Chapter 5 
104 
 
 
Figure 5.6 S1P induces heterologous β2-adrenergic desensitization as measured by 
inhibition of β2-agonist-induced cAMP production; in a manner independent of adenylate 
cyclase. Growth-arrested ASM cells were pretreated for 24 h with vehicle, 100 nM PGE2, 
vehicle, S1P (1 µM), S1P (1 µM) + TNF (10 ng/mL). (A, B) Desensitization of the β2-
adrenergic receptor was assessed by measuring production of cAMP (pmol/mL) in response to 
stimulation with (A) 10 µM salbutamol or (B) 10 nM formoterol for 15 min, compared to 
vehicle, in the presence of the pan-phosphodiesterase inhibitor IBMX. (C) To exclude the 
involvement of adenylate cyclase, we measured production of cAMP (pmol/ml) in response to 
stimulation with the adenylate cyclase activator forskolin (10 µM) for 15 min, compared to 
vehicle, in the presence of IBMX. Statistical analysis was performed using one-way ANOVA 
then Bonferroni's post-test (where * denotes a significant effect on β2-agonist-induced cAMP 
production (P<0.05)). Data are mean±SEM values from n=3 (A, B) and n=4 (C) primary ASM 
cell cultures. 
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5.4 Discussion 
S1P is a bioactive sphingolipid found elevated in the BAL from people with allergic asthma. It 
has potent effects on airway inflammation and herein we show that S1P robustly upregulates 
COX-2 expression to result in PGE2 production in bronchial ASM cells. We also provide the first 
evidence to demonstrate that S1P induces β2-AR desensitization to result in reduced cAMP 
production to clinically-used β2-agonists, salbutamol and formoterol. Moreover, S1P acts in an 
additive manner to enhance the COX-2/PGE2-mediated upregulation in response to the pro-
inflammatory cytokine TNF. Thus, with this study we are the first to implicate this mediator in 
β2-AR desensitization. 
β2-AR desensitization is an important issue in respiratory medicine. Mechanisms have been 
elucidated in part, and are clearly linked to COX-2 upregulation in ASM and the subsequent 
autocrine effects of PGE2. A range of pro-inflammatory cytokines have been shown to increase 
COX-2/PGE2 [reviewed in(Shore and Moore, 2003)]. Collectively, these studies reinforce the 
notion that a key characteristic of a pro-inflammatory cytokine in airway inflammation, in 
addition to their established ability to initiate potentiate and amplify the pro-asthmatic cascade, is 
their capacity to dampen the ability of β2-agonists to exert their bronchodilatory effects. 
Moreover, cytokine responses can be robustly potentiated by activation of pattern-recognition 
receptors on ASM cells, with our recent studies showing that activation of TLRs for viral and 
bacterial products augments COX-2 expression/PGE2 secretion and amplifies β2-AR 
desensitization (Trian et al., 2010; Van Ly et al., 2013; Alkhouri et al., 2014). These studies may 
provide a mechanistic basis for clinically significant hyporesponsiveness to β2-agonists observed 
in infectious exacerbation (Reddel et al., 1999).  
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Our study is the first to examine the impact of S1P on β2-AR desensitization in ASM cells. S1P 
is a bioactive sphingolipid found in increased levels in the BAL of people with allergic asthma , 
with effects on asthmatic inflammation and bronchoconstriction in vitro (Ammit et al., 2001; 
Che et al., 2014; Rahman et al., 2014) and in vivo (Roviezzo et al., 2007; Nishiuma et al., 2008; 
Fuerst et al., 2014). It is a legitimate target in asthma and our current study reveals that in 
addition to its known pro-inflammatory and bronchoconstrictive functions, S1P can also induce 
β2-AR desensitization. In this way, S1P can accelerate the pro-asthmatic phenotype, while 
disabling the brake. 
COX-2 is an inducible gene and is known to be rapidly expressed in ASM cells in response to a 
diverse range of mediators; viz, cytokines (including TNF, interleukin 1β and interferon , 
added alone or in combination as cytomix) (Belvisi et al., 1997; Pang and Knox, 1997; Pang et 
al., 1998b), TLR activators (Trian et al., 2010; Van Ly et al., 2013; Alkhouri et al., 2014) and 
now S1P ( (Hsu et al., 2015)and this study). Thus, the COX-2/PGE2 pathway has emerged as a 
legitimate therapeutic target pathway in order to restore β2-AR responsiveness. Understanding 
the molecular mechanisms responsible will reveal future pharmacotherapeutic strategies. COX-2 
mRNA expression can repressed by corticosteroids, as we have shown for S1P, and in 
confirmation of studies with COX-2 induced by other stimuli (Belvisi et al., 1997; Pang and 
Knox, 1997; Singer et al., 2003). Targeting COX-2 more specifically offers great promise and a 
notable recent study, Comer et al. demonstrate that cytokine stimulation of ASM cells from 
people with asthma have enhanced COX-2 mRNA and protein and increased secretion of PGE2, 
compared to non-asthmatic controls, and this is due to epigenetic regulation involving miR-155, 
a microRNA found elevated in asthma (Comer et al., 2014). Prostanoid products of COX-2 
enzymatic action can also be blocked with the use of non-selective (Belvisi et al., 1997; Pang and 
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Knox, 1997) and selective COX-2 inhibitors, such as celecoxib (Van Ly et al., 2013; Alkhouri et 
al., 2014; Comer et al., 2014). We could also target the specific receptors for PGE2, and this may 
also relevant given that increased E-prostanoid receptor surface expression has been reported in 
ASM cells from people with asthma (Burgess et al., 2004). Further studies are warranted. 
With this study we have highlighted the potential impact of S1P on β2-AR receptor function. We 
have revealed that S1P can increase COX-2 mRNA and protein expression, which in turn leads 
to enhanced secretion of PGE2 from ASM cells in vitro and suggested that S1P may contribute to 
β2-AR desensitization in patients with asthma. This new knowledge may be exploited to discover 
novel targets for restoring the efficacy of bronchodilatory β2-agonists in the future.  
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Chapter 6 
IL-17A increases TNF-induced COX-
2 protein stability and augments PGE2 
secretion from airway smooth muscle 
cells 
 
This work has been published as the article entitled “IL-17A increases TNF-induced COX-2 
protein stability and augments PGE2 secretion from airway smooth muscle cells. Nowshin N. 
Rumzhum, Brijeshkumar S. Patel, Pavan Prabhala, Ingrid C. Gelissen, Brian G. Oliver, and 
Alaina J. Ammit”. Allergy, November 2015 doi: 10.1111/all.12810 (Rumzhum et al., 2015a). 
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Chapter 6 
IL-17A increases TNF-induced COX-2 protein 
stability and augments PGE2 secretion from 
airway smooth muscle cells 
 
6.1 Introduction 
In Chapter 4 and 5, we demonstrate that both TLR2 agonist and S1P induce COX-2 expression 
in ASM cells and contribute in heterologous desensitization of β2-AR via PGE2 secretion. We 
further aim to extend our study herein by exploring the effects of another important 
inflammatory mediator, IL-17A on COX-2 expression and PGE2 secretion and eventually on β2-
AR desensitization. COX-2 is an inducible enzyme that can be rapidly, but transiently, 
upregulated by a diverse range of stimuli, including pro-inflammatory mediators and infectious 
stimuli acting via TLRs (Trian et al., 2010; Van Ly et al., 2013; Alkhouri et al., 2014; Rumzhum 
et al., 2015b). Although IL-17A has been implicated in infectious exacerbation in respiratory 
disease, its impact on COX-2/PGE2 has not been explored to date. 
IL-17A orchestrates airway inflammation in asthma and COPD. This pivotal cytokine is found in 
elevated levels in respiratory diseases, including severe asthma (Chesne et al., 2014) and COPD 
(Caramori et al., 2014), and directs pulmonary immunity and inflammation (McAleer and Kolls, 
2014). Recent evidence has implicated IL-17A as a key driver of disease exacerbation in severe 
asthma (Brandt et al., 2013) and in vivo models of infectious exacerbation (Essilfie et al., 2011; 
Lunding et al., 2015; Roos et al., 2015).  
Herein  we examine the impact of IL-17A on COX-2 mRNA expression, protein upregulation 
and subsequent PGE2 secretion from ASM cells. Modelling inflammation with TNF we show 
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that although IL-17A has no effect when added alone, it substantially amplifies TNF-mediated 
responses in ASM cells. Interestingly, the molecular mechanism responsible for COX-2 
upregulation differs from those previously reported in ASM cells (Alkhouri et al., 2014; 
Rumzhum et al., 2015b). That is, IL-7A had no effect on COX-2 mRNA expression; rather it 
enhances TNF-induced COX-2 protein stability. We reveal that steady-state COX-2 protein 
production in response to TNFα stimulation is relatively transient (reaching a peak at 8 h, then 
subsiding: indicative of proteasomal degradation and confirmed by pretreatment with proteasome 
inhibitors). However, in the presence of IL-17A, TNFα-induced COX-2 protein levels are 
enhanced and sustained for to 24 h. This was confirmed by cycloheximide chase experiments 
where we show that TNFα-induced COX-2 protein stability is greatly enhanced in the presence 
of IL-17A. This is the first report to highlight the role that enhanced COX-2 protein stability may 
play in the context of respiratory disease driven by inflammation; because by increasing TNF-
induced COX-2 protein stability, IL-17A serves to substantially enhance secretion of PGE2 from 
ASM cells. PGE2 is a multifunctional prostanoid with both beneficial and adverse effects in 
airway pathogenesis (Sastre and del Pozo, 2012) and in this study we examined the impact of IL-
17A on β2-AR desensitization on ASM cells. 
 
6.2 Material and methods 
6.2.1 ASM cell culture 
For detailed description, see Chapter 2.2.1. 
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6.2.2 Chemicals 
TNF and IL-17A were purchased from R&D Systems (Minneapolis, MN) and celecoxib from 
Cayman Chemical Company (Ann Arbor, MI). Unless otherwise specified, all chemicals were 
from Sigma-Aldrich (St. Louis, MO).  
 
6.2.3 PGE2 assay 
PGE2 was measured by enzyme immunoassay (Prostaglandin E2 EIA 514010: Cayman Chemical 
Company) according to the manufacturer‟s instructions. For detailed description, see Chapter 
2.2.6. 
 
6.2.4 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, VIC, 
Australia) and reverse transcribed using the RevertAid First strand cDNA Synthesis Kit 
(Fermentas Life Sciences, Hanover, MD). Real-time RT-PCR was performed on an ABI Prism 
7500 with COX-2 (Hs0015133_m1) TaqMan® Gene Expression Assays and the eukaryotic 18S 
rRNA endogenous control probe (Applied Biosystems, Foster City, CA) subjected to the 
following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 s, 
60°C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta delta Ct 
calculations. 
 
6.2.5 Western blotting 
SDS-PAGE was performed with 8% (COX-2) or 12% (IB-α) separating gels and proteins were 
electrophoretically transferred to nitrocellulose membranes (Pall Corporation, Port Washington, 
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NY). Western blotting was performed using mouse monoclonal antibodies against COX-2 (sc-
19999) or rabbit polyclonal antibodies against IB-α (sc-371), compared to α-tubulin as the 
loading control (clone DM 1A: sc-32293). All primary antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA) and were detected with goat anti-mouse or goat anti-rabbit 
HRP–conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA) and 
visualized by enhanced chemiluminescence (Perkin Elmer, Wellesley, MA). For detailed 
description, see Chapter 2.2.2. 
 
6.2.6 cAMP assay 
Desensitization of the β2-AR was assessed by measuring production of cAMP in response to 
stimulation with the β2-agonists salbutamol (10 µM) and formoterol (10 nM) for 15 min, in the 
presence of IBMX (30 min pretreatment at 10 μM), in accordance with previously published 
methods (Alkhouri et al., 2014; Rumzhum et al., 2015b). cAMP was measured by enzyme 
immunoassay (cAMP EIA 581001: Cayman Chemical Company) according to the 
manufacturer‟s instructions. For detailed description, see Chapter 2.2.5. 
 
6.2.7 Statistical analysis 
Statistical analysis was performed using Student's unpaired t test, one-way ANOVA then 
Fisher‟s post-hoc multiple comparison test, or two-way ANOVA then Bonferroni's post-test.P 
values<0.05 were sufficient to reject the null hypothesis for all analyses.  
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6.3 Results 
6.3.1 IL-17A augments TNF-induced PGE2 secretion, but does not increase TNF-
induced COX-2 mRNA expression 
IL-17A is known to modulate airway inflammation in respiratory disease. Our recent studies in 
ASM cells have revealed the important role played by the prostanoid PGE2 in mediating β2-AR 
desensitization (Alkhouri et al., 2014; Rumzhum et al., 2015b). This occurs in a COX-2-
dependent manner and to date, whether IL-17A exerts an influence on COX-2 
upregulation/PGE2 secretion in ASM cells was unknown. To address this, we first treated cells 
with IL-17A (10 ng/mL) alone, or in combination with TNF (10 ng/mL), and measured the 
temporal kinetics of PGE2 secretion, compared to vehicle-treated cells. As shown in Figure 6.1A, 
IL-17A alone had no effect on PGE2 secretion, while stimulation with TNF, a known inducer of 
PGE2 (Pang and Knox, 1997; Alkhouri et al., 2014; Rumzhum et al., 2015b), resulted in 
significantly elevated levels of PGE2 by 24 h (P<0.05). Importantly, when cells were stimulated 
with TNF in the presence of IL-17A, PGE2 secretion was robustly enhanced with significant 
and sustained amounts of PGE2 secretion observed as early as 4 h (Figure 6.1A: P<0.05).  
We were intrigued to understand the underlying molecular mechanism. PGE2 is produced by the 
action of the enzyme COX-2. COX-2 can be upregulated by increased gene expression (via 
transcriptional or post-transcriptional means), and/or post-translationally via increased protein 
stability. To date, the effect of IL-17A on COX-2 gene expression in ASM cells was unknown. 
To understand the mechanism responsible for the upregulation of TNF-induced PGE2 secretion 
in ASM cells by IL-17A, we examined the impact of IL-17A on COX-2 mRNA expression and 
whether it played a role in potentiating the effects of TNF. In Figure 6.1B we demonstrate the 
temporal regulation of COX-2 mRNA expression; and, in corroboration of our earlier studies 
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(Alkhouri et al., 2014; Rumzhum et al., 2015b), TNF increases COX-2 mRNA expression with 
significant expression (P<0.05) observed as early as 1 h, sustained until 4 h, and then shown to 
decline by 8 h. As predicted by the lack of PGE2 secretion, IL-17A alone did not induce COX-2 
mRNA expression. More unexpectedly however, IL-17A added in combination with TNF did 
not enhance COX-2 mRNA expression. 
 
Figure 6.1IL-17A augments TNF-induced PGE2 secretion, but does not increase TNF-
induced COX-2 mRNA expression. Growth-arrested ASM cells were treated with vehicle, IL-
17A (10 ng/mL), TNF (10 ng/mL), or IL-17A + TNF (both at 10 ng/mL), for 0, 1, 2, 4, 8, and 
24 h. (A) PGE2 secretion was measured by EIA. (B) COX-2 mRNA expression was quantified 
by real-time RT-PCR (results expressed as fold increase compared to vehicle-treated cells at 0 
h). Statistical analysis was performed using two-way ANOVA then Bonferroni's post-test (where 
* denotes a significant effect of TNF onPGE2 secretion or COX-2 mRNA expression, and § 
denotes a significant effect of IL-17A on TNF-induced PGE2 secretion (P<0.05)). Data are 
mean±SEM values from n=5 primary ASM cell cultures. 
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6.3.2 IL-17A increases TNF-induced COX-2 protein upregulation 
Because these data indicate that the augmentation of TNF-induced PGE2 by IL-17A is not via 
potentiation of TNF-induced COX-2 mRNA expression, we then examined COX-2 protein 
upregulation after growth-arrested ASM cells were treated with vehicle, IL-17A, TNF, or IL-
17A + TNF (Figure 6.2A). In accordance with the lack of effect of IL-17A on COX-2 mRNA 
expression and PGE2 secretion, IL-17A alone did not induce COX-2 protein (data not shown). 
As shown by Western blotting (Figure 6.2A), there was a peak of TNF-induced protein 
upregulation observed at 8 h, that later declined at 24 h. This was confirmed by densitometric 
analysis (Figure 6.2B: P<0.05), where TNF induced a significant 10.6±5.5-fold increase in 
COX-2 protein upregulation at 8 h, that then declined by 24 h. Thus, the temporal kinetics of 
COX-2 protein upregulation after TNF stimulation (Figure 6.2) aligns well with COX-2 mRNA 
expression (Figure 6.1B): that is, COX-2 mRNA induced by TNF stimulation was 
consequently translated into COX-2 protein; albeit in a transient manner. In contrast, while IL-
17A had no effect on TNF-induced COX-2 mRNA (Figure 6.1B), IL-17A robustly upregulated 
TNF-induced COX-2 protein in a sustained manner (Figure 6.2). Western blotting revealed that 
IL-17A enhanced TNFα-induced COX-2 protein upregulation at 4 h, 8 h and 24 h (Figure 6.2A). 
This was confirmed by densitometric analysis (Figure 6.2B: P<0.05). Notably, at 24 h, IL-17A 
added in combination with TNF induced a 33.8±1.7-fold increase in COX-2 protein, in 
comparison to 3.9±1.7-fold with TNF alone at the same time point (Figure 6.2B: P<0.05). 
Taken together, our data shows that IL-17A increases TNF-induced COX-2 protein stability, 
but not TNF-induced COX-2 mRNA gene expression in ASM cells. 
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Figure 6.2 IL-17A increases TNF-induced COX-2 protein upregulation. Growth-arrested 
ASM cells were treated with vehicle, IL-17A (10 ng/mL), TNF (10 ng/mL), or IL-17A + TNF 
(both at 10 ng/mL), for 0, 1, 2, 4, 8, and 24 h. COX-2 protein was detected by Western blotting 
(compared to -tubulin as a loading control), where (A) is a representative blot (72 kDa) (vehicle 
and IL-17A did not induce COX-2 protein – data not shown) and (B) is densitometric analysis of 
COX-2 protein upregulation (results normalised with -tubulin then expressed as fold increase 
compared to vehicle-treated cells at 0 h). Statistical analysis was performed by two-way 
ANOVA then Bonferroni's post-test (where * denotes a significant effect of TNF on COX-2 
protein upregulation, and § denotes a significant effect of IL-17A onTNF-induced COX-2 
protein upregulation (P<0.05)). Data are mean±SEM values from n=4 primary ASM cell 
cultures. 
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6.3.3 Proteasome inhibitors increase TNFα-induced COX-2 protein and PGE2 secretion 
COX-2 is an inducible gene known to be expressed by a wide variety of inflammatory stimuli, 
but COX-2 protein upregulation in cells is typically transient [reviewed in (Kang et al., 2007)]. 
Post-translational regulatory mechanisms have begun to emerge (Haddad et al., 2012), and in cell 
types apart from ASM, degradation by the 26S proteasome has been shown to play a role 
(Rockwell et al., 2000; Haddad et al., 2012; Brender and Barki-Harrington, 2014).  Our data 
suggests that IL-17A increases the stability of COX-2 protein induced by TNFα. But to date, 
whether protein stability contributes to steady-state levels of COX-2 protein in ASM cells was 
unknown. Thus, in order to show that TNFα-induced COX-2 protein is subject to proteasomal 
degradation in ASM, we pretreated cells with two inhibitors of the proteasome - bortezomib and 
MG-132 – and examined whether TNFα-induced COX-2 protein levels are increased. Growth-
arrested ASM cells were pretreated for 30 min with bortezomib (10 nM) or MG-132 (10 µM), 
before stimulation with TNF for up to 24 h. In the representative Western blots shown in Figure 
6.3A, blocking the proteasome with bortezomib or MG-132 enhances COX-2 protein 
upregulation induced by TNF. This is confirmed by densitometric analysis in Figure 6.3B, 
where the level of TNF-induced COX-2 protein at 24 h (3.3±0.9-fold) was significantly 
increased by bortezomib to 8.9±1.8-fold and MG-132 to 19.5±2.5-fold (P<0.05). These data 
support our assertion that TNF-induced COX-2 is degraded by the proteasome. Thus, it follows 
that if COX-2 protein stability is enhanced, production of COX-2-mediated prostanoid products, 
including PGE2, will be increased. In support, Figure 6.3C shows that the TNF-induced PGE2 
secretion at 24 h is significantly enhanced after bortezomib or MG-132 pretreatment (P<0.05). 
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Figure 6.3 Proteasome inhibitors increase TNFα-induced COX-2 protein and PGE2 
secretion. Growth-arrested ASM cells were pretreated for 30 min with vehicle, bortezomib (10 
nM), or MG-132 (10 µM) before stimulation with TNF (10 ng/mL) for 0, 1, 2, 4, 8, and 24 h. 
(A, B) COX-2 protein was detected by Western blotting at 24 h (compared to -tubulin as a 
loading control), where (A) is a representative blot (72 kDa) and (B) is densitometric analysis of 
COX-2 protein upregulation (results normalised with -tubulin then expressed as fold increase 
compared to TNF-treated cells at 0 h). Statistical analysis was performed with two-way 
ANOVA then Bonferroni's post-test (where § denotes a significant effect of proteasome 
inhibition onTNF-induced COX-2 protein upregulation (P<0.05)). (C) PGE2 secretion at 24 h 
was measured by EIA (results expressed as fold increase compared to vehicle-treated cells at 0 
h). Statistical analysis was performed one-way ANOVA then Fisher‟s post-hoc multiple 
comparison test (where § denotes a significant effect of proteasome inhibition onTNF-induced 
PGE2 secretion (P<0.05)). Data are mean±SEM values from n=6 primary ASM cell cultures. 
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6.3.4 IL-17A enhances TNFα-induced COX-2 protein stability 
To confirm that IL-17A enhances TNFα-induced COX-2 protein stability, we performed 
cycloheximide chase experiments. We treated growth-arrested ASM cells for 8 h with TNFα ± 
IL-17A (to achieve peak levels of COX-2 steady-state protein production; as demonstrated 
earlier in Figure 6.2A). Cells were then washed and treated with cycloheximide (20 µg/mL) to 
block further protein translation; in accordance with previous published methods (Bradshaw et 
al., 2011). Cell lysates were prepared at 1, 2, 4, 6, and 16 h after the addition of cycloheximide 
(designated as 0 h). COX-2 was then quantified by Western blotting (normalized to α-tubulin), 
analysed by densitometry and expressed as a percentage of COX-2 at 0 h. As shown in Figure 
6.4, the percentage of COX-2 remaining 2, 4, 6 and 16 h after protein translation had been halted 
by cycloheximide treatment was significantly greater in cells treated with IL-17A + TNFα, 
compared to TNFα alone (P<0.05). Thus, IL-17A enhances TNFα-induced protein stability. 
Future studies examining the molecular mechanisms responsible for enhanced COX-2 protein 
stability exerted by IL-17A are warranted, but herein we were intrigued to examine whether IL-
17A stabilizes other proteins relevant to airway inflammatory diseases. To address this, we 
focussed on IB-α, the inhibitory protein regulated by the 26S proteasome that complexes with 
pro-inflammatory NF-B to hold it in check. When ASM cells are stimulated by TNFα, IB-α 
protein was degraded (as shown in Figure 6.5, and in confirmation of our previous reports 
(Moutzouris et al., 2010; Manetsch et al., 2012b)). NF-B is then released from the inhibitory 
complex and is now competent to activate transcriptional pathways and promote ASM synthetic 
function (Moutzouris et al., 2010; Manetsch et al., 2012b).  Interestingly, we show that TNFα-
induced degradation of inhibitory IB-α was unaffected by IL-17A (Figure 6.5). These results 
address, in part, the specificity of the IL-17A-mediated COX-2 response by showing that under 
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identical conditions, other proteins shown to be regulated proteasomally (utilizing IB- as an 
example) are unaffected by IL-17A.  
 
 
Figure 6.4 IL-17A increases TNF-induced COX-2 protein stability. Growth-arrested ASM 
cells were treated with TNF (10 ng/mL) or IL-17A + TNF (both at 10 ng/mL) for 8 h. Cells 
were then washed and treated with 20 µg/ml cycloheximide to inhibit further protein translation. 
Cell lysates were then prepared at 0, 1, 2, 4, 6 and 16 h and COX-2 protein quantified by 
Western blotting (compared to -tubulin as a loading control). COX-2 protein levels at each time 
point was measured by densitometry and expressed as a percentage of COX-2 at 0 h (i.e. time of 
treatment with cycloheximide). Statistical analysis was performed by two-way ANOVA then 
Bonferroni's post-test (where § denotes a significant effect of IL-17A onTNF-induced COX-2 
protein stability (P<0.05)). Data are mean±SEM values with non-linear regression curve fit from 
n=6 primary ASM cell cultures. 
 
  Chapter 6 
121 
 
 
Figure 6.5 TNFα-induced IκB-α degradation was unaffected by IL-17A. Growth-arrested 
ASM cells were treated with vehicle, IL-17A (10 ng/mL), TNF (10 ng/mL), or IL-17A + TNF 
(both at 10 ng/mL), for 0, 15, 30, 45 and 60 min. IκB-α was analysed by Western blotting 
compared to -tubulin as a loading control (35-41 kDa). Results are representative of n=3 
primary ASM cell cultures. 
 
6.3.5 Heterologous β2-adrenergic desensitization as measured by inhibition of β2-agonist-
induced cAMP production in ASM cells: effects of IL-17A ± TNF 
PGE2 is known to induce heterologous β2-AR desensitization on ASM cells. Because we have 
shown that IL-17A robustly increased COX-2 protein/PGE2 induced by TNF, we sought to 
examine the impact of IL-17A ± TNF on β2-AR desensitization, as measured by inhibition of 
β2-agonist-induced cAMP production. As shown in Figures 6.6A and 6.6B, ASM treated with the 
β2-agonists, salbutamol or formoterol, respectively, significantly increased cAMP release from 
ASM cells. This could be significantly repressed by pretreatment with 100 nM PGE2, in 
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confirmation of our previous publications (Alkhouri et al., 2014; Rumzhum et al., 2015b). These 
results demonstrate the known ability of PGE2 to heterologously desensitize the β2-AR. As IL-
17A did not increase PGE2, it was unsurprising that there was no significant repression of cAMP 
produced induced by salbutamol (Figure 6.6A) or formoterol (Figure 6.6B). What was surprising 
however was that IL-17A in combination with TNF, treatment conditions known to robustly 
increase PGE2, had no effect on β2-agonist-induced cAMP (Figures 6.6A and 6.6B). If anything, 
cAMP production appeared to increase. In parallel studies we confirmed that indeed this is the 
case, and as shown in Figure 6.6C, pretreatment of ASM cells with IL-17A + TNF resulted in 
significantly increased cAMP production (P<0.05). PGE2 is a multifunctional prostanoid and can 
increase cAMP in ASM cells via receptor-mediated pathways. Our study shows that treating 
ASM cells with IL-17A + TNF results in a robust and sustained production of PGE2. Thus we 
propose that the resultant PGE2 acts to increase cAMP, confounding interpretation of 
hyporesponsiveness to β2-agonists. This was confirmed by utilization of a COX-2 selective 
inhibitor where pretreatment with celecoxib significantly reduced cAMP produced by IL-17A in 
combination with TNF (Figure 6.6D: P<0.05). 
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Figure 6.6 Heterologous β2-adrenergic desensitization as measured by inhibition of β2-
agonist-induced cAMP production in ASM cells: effects of IL-17A ± TNF. (A, B) Growth-
arrested ASM cells were pretreated for 24 h with vehicle, 100 nM PGE2, IL-17A (10 ng/mL), or 
IL-17A + TNF (both at 10 ng/mL). Desensitization of the β2-AR was assessed by measuring 
production of cAMP (pmol/mL) in response to stimulation with (A) 10 µM salbutamol or (B) 10 
nM formoterol for 15 min, compared to vehicle, in the presence of the pan-phosphodiesterase 
inhibitor IBMX. In parallel studies using conditions outlined above: (C) cells were pretreated for 
24 h with vehicle, IL-17A, or IL-17A + TNF, and cAMP production (pmol/mL) measured; (D) 
cells were pretreated for 1 h with vehicle or celecoxib (10 µM) and the effect on % IL-17A + 
TNF-induced cAMP assessed. Statistical analysis was performed using Student's unpaired t test 
(where * denotes a significant effect on cAMP production and § denotes significant repression 
(P<0.05)). Data are mean±SEM values from n=6 primary ASM cell cultures. 
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6.4 Discussion 
In this study we show that TNF upregulates COX-2 by inducing mRNA expression in ASM 
cells. We reveal that the transient upregulation of COX-2 protein induced by TNF in ASM cells 
is due to degradation by the proteasome. We show that two inhibitors of the 26S proteasome - 
bortezomib (Velcade) and MG-132 - can block degradation of TNF-induced COX-2 and 
enhance PGE2 production. We have shown that IL-17A acts to increase TNF-induced PGE2 by 
enhancing COX-2 protein stability, but not COX-2 gene expression. This is a novel finding in 
ASM cells and this new knowledge improves our understanding of how IL-17A impacts on the 
COX-2/PGE2 regulatory network. 
Given the impact of the COX-2 enzyme in health and disease, it unsurprisingly that there are 
multiple molecular mechanisms that allow COX-2, and its resultant prostanoids, to be controlled 
in precise spatiotemporal regulatory networks. COX-2 gene expression is known to be regulated 
transcriptionally (Appleby et al., 1994) and/or post-transcriptionally via increased mRNA 
stability (Lasa et al., 2000). Somewhat more recently, mechanisms responsible for the post-
translational regulation of COX-2 protein stability have begun to emerge (Mbonye et al., 2008; 
Haddad et al., 2012; Brender and Barki-Harrington, 2014). Although IL-17A is known to 
increase gene expression by enhancing mRNA stability (Hartupee et al., 2007), and we have 
previously shown that IL-17A significantly enhanced TNF-induced IL-6 and IL-8 mRNA 
expression via post-transcriptional means in ASM cells (Henness et al., 2004; Henness et al., 
2006), in this study we show that IL-17A has no effect on COX-2 mRNA gene expression, 
instead IL-17A acts to enhance the stability of COX-2 protein induced by TNF.  
Diverse stimuli are known to induce COX-2 (Kang et al., 2007) and the half-life (t1/2) of the 
protein is known to be relatively short-lived. This allows the protein to be rapidly upregulated 
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and labile prostanoids produced, and then rapidly switched off to limit the amount of prostanoids 
produced. In cell types apart from ASM, the t1/2 for COX-2 varies from 2-7 h [reviewed in (Kang 
et al., 2007)] where Kang et al. comments that “COX-2 protein degradation is specifically 
programmed to limit the COX-2”. Herein we perform cycloheximide chase experiments and 
demonstrate, for the first time in ASM cells, that the t1/2 of TNFα-induced COX-2 (defined here 
as time (h) taken to reach 50% of COX-2 protein levels observed before cycloheximide 
treatment) is between 1-2 h (as shown in Figure 6.4). In contrast, COX-2 protein produced after 
stimulation with IL-17A + TNFα is comparatively stable and does not degrade to levels below 
50% over the evaluation period examined (up to 16 h post-cycloheximide treatment). In the 
presence of IL-17A, TNFα-induced COX-2 protein is sustained and remains at plateau of ~ 70%, 
compared to ~ 30% in the absence of IL-17A. The mechanisms responsible for enhanced protein 
stability may involve post-translational modifications and endoplasmic reticulum-associated 
degradation systems (Mbonye et al., 2006; Mbonye et al., 2008), and in cell types apart from 
ASM, degradation by the 26S proteasome has been shown to play a role (Rockwell et al., 2000; 
Haddad et al., 2012; Brender and Barki-Harrington, 2014). Further studies are warranted as these 
molecular mechanisms may be amenable to pharmacological intervention as members of the 
proteasomal machinery may prove to be important drug targets to combat inflammatory disease 
in the future (Skaar et al., 2014). 
We show that IL-17A has a substantial impact on PGE2 secretion from ASM cells by increasing 
TNF-induced COX-2 protein upregulation in a sustained manner. PGE2 is a multifunctional 
prostanoid with both beneficial and adverse effects in respiratory disease. Early studies revealed 
that PGE2 has bronchodilatory and anti-inflammatory effects in human airways (Kawakami et 
al., 1973; Pavord and Tattersfield, 1995). This is consistent with the ability of PGE2 to act via 
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receptor-mediated pathways to enhance cAMP (Billington et al., 2013). However, PGE2 can also 
cause desensitization of the β2-AR on ASM cells [reviewed in (Shore and Moore, 2003; 
Billington et al., 2013)], and we have shown that pro-inflammatory mediators and infectious 
stimuli (acting via TLRs) (Trian et al., 2010; Van Ly et al., 2013; Alkhouri et al., 2014; 
Rumzhum et al., 2015b) cause PGE2-dependent heterologous desensitization of the β2-ARin 
vitro. In this way, PGE2 may curtail the beneficial bronchodilatory actions of β2-agonists. Given 
that hyporesponsiveness to bronchodilators is a hallmark feature of exacerbation in respiratory 
disease (Reddel et al., 1999), and IL-17A has been shown to drive infectious exacerbation 
(Essilfie et al., 2011; Brandt et al., 2013; Lunding et al., 2015; Roos et al., 2015), we sought to 
examine the impact of IL-17A on β2-AR desensitization. Utilizing our established method 
(Alkhouri et al., 2014; Rumzhum et al., 2015b) for assessing β2-AR desensitization in ASM cells 
by measuring β2-agonist-induced cAMP production, we confirmed that PGE2 caused 
desensitization, and as expected due to its inability to induce PGE2, IL-17A did not. Consistent 
with the aforementioned ability of PGE2 to induce cAMP, it was not possible to demonstrate an 
effect of IL-17A + TNF on β2-AR desensitization, as IL-17A + TNF significantly induced 
cAMP in a COX-2/PGE2-dependent manner.  
In summary, our study extends the role and function of IL-17A as a multifaceted fine-tuning 
cytokine in respiratory disease. We show that IL-17A potentiates COX-2 upregulation in 
inflammation modelled in vitro and can enhance PGE2 secretion. PGE2 is experiencing a 
somewhat of a renaissance in the respiratory field, driven by the development of selective 
receptor antagonists and transgenic mouse-models (Birrell et al., 2015; Maher et al., 2015). 
These research tools may allow precise delineation of the “good” and “bad” effects of PGE2 in 
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this context of infectious exacerbation and may pave the way for novel pharmacotherapeutic 
strategies to treat severe asthma and COPD in the future. 
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Chapter 7 
Role of specific PGE2 receptors 
 
7.1 Introduction 
In Chapter 4 - Chapter 6, we successfully demonstrate the role of COX-2-induced PGE2 on β2-
AR desensitization in in vitro ASM cell model. In this chapter, we aim to identify the role of 
specific PGE2 receptors in the context of β2-AR desensitization. COX-2 has multiple prostanoid 
products, among which studies have shown that PGE2 predominates in some inflammatory 
contexts (Belvisi et al., 1997; Pang et al., 1998a; Van Ly et al., 2013). Rather than stored, PGE2 
is de novo synthesized. Immediately after synthesis it is inactivated by the actions of the enzyme, 
15-hydroxyprostaglandin dehydrogenase (PGDH) (Tai et al., 2006). PGE2 shows pleiotropic 
autocrine, paracrine and endocrine functions (Reid et al., 2003). The actions of PGE2 are 
mediated via four distinct E prostanoid (EP) receptor subtypes, EP1, EP2, EP3 and EP4, belonging 
to the homologous GPCR superfamily (Narumiya et al., 1999; Vancheri et al., 2004). PGE2 is a 
multifunctional protein and the diverse effects of PGE2 are presumably associated with the 
presence of several EP receptors that mediate different and sometimes opposing downstream 
effects. PGE2 signalling through EP2 and EP4 receptors promotes the accumulation of cAMP. 
This leads to smooth muscle relaxation. PGE2 signalling through EP1 and EP3 receptors 
activation increase intracellular calcium or decrease cAMP generation which could be associated 
with smooth muscle contraction (An et al., 1993; Coleman et al., 1994; Qian et al., 1994; Breyer 
et al., 2001; Vancheri et al., 2004; Kay et al., 2006; Foudi et al., 2008; Machado-Carvalho et al., 
2014; Claar et al., 2015). Hence, controlling the balance between the contractile and relaxant 
response to PGE2 in favour of protective relaxation is very crucial. 
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Previous report suggests that further research on EP receptors, specifically EP2 and EP4, may 
lead to novel therapeutic strategies for the treatment of asthma and COPD (Billington et al., 
2013). Previous reports have revealed the expression of EP2 and EP4 receptors in ASM cells 
(Clarke et al., 2005b; Billington et al., 2013). Considering the potential role of EP2 and EP4 
receptors in inflammatory lung diseases, in this study, we target EP2 and EP4 receptors and aim 
to provide a stronger molecular framework behind the observed functional responses in ASM 
cells generated by PGE2. EP2 receptor was first cloned in human by Regan et al. in 1994 (Regan 
et al., 1994). Its cDNA encodes a 358-amino-acidpolypeptide and signals through increased 
cAMP. EP2 receptor is widely distributed in lung tissue and possesses a relaxant role in 
bronchioles, suggesting that EP2 agonists could be used to treat pulmonary diseases (Pavord et 
al., 1991; Coleman et al., 1994; Narumiya et al., 1999). The human EP4 receptor cDNA encodes 
a 488-amino-acid polypeptide and is widely distributed in  thymus, ileum, lung, spleen, adrenal, 
and kidney tissues (Breyer et al., 2001). Similar to EP2 receptor, activation of the EP4 receptor 
leads to an increase in cAMP levels. Thereby, research also suggests that EP4 receptors are most 
similar to EP2 prostanoid receptors not only in pharmacological terms, but also in many 
physiological settings. EP2 and EP4 receptors are co-located, making identification of individual 
roles difficult (Wilson et al., 2006). Several reports examine EP receptor subtype functions in 
ASM and highlight the potential therapeutically beneficial effects of EP2 and EP4 agonists on 
airway remodelling (Guo et al., 2005; Kong et al., 2008; Buckley et al., 2011; Yan et al., 2011; 
Benyahia et al., 2012). In elucidating their specific roles, we used PF-04418948 and 
GW627368X as selective EP2 and EP4 receptor antagonists respectively (Wilson et al., 2006; af 
Forselles et al., 2011). 
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7.2 Material and methods 
7.2.1 ASM cell culture 
For detailed description, see Chapter 2.2.1. 
 
7.2.2 Chemicals 
PGE2, PF-04418948 and GW-627368X were purchased from Cayman Chemical Company (Ann 
Arbor, MI, USA). Unless otherwise specified, all chemicals used in this study were purchased 
from Sigma-Aldrich (St.Louis, MO). 
 
7.2.3 Real-time RT-PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and reverse transcribed using the 
RevertAid First strand cDNA Synthesis Kit (Fermentas Life Sciences). Real-time RT-PCR was 
performed on an ABI Prism 7500 with MKP-1 (DUSP1: Hs00610256_g1) TaqMan® Gene 
Expression Assays and the eukaryotic 18S rRNA endogenous control probe (Applied 
Biosystems) subjected to the following cycle parameters: 50°C for 2 min, 1 cycle; 95°C for 10 
min, 1 cycle; 95°C for 15 s, 60°C for 1 min, 40 cycles and mRNA expression (fold increase) 
quantified by delta delta Ct calculations. For detailed description, see Chapter 2.2.3. 
 
7.2.4 cAMP assay 
Desensitization of the β2-AR was assessed by measuring production of cAMP in response with a 
range of concentrations of PGE2 (0.1–100 nM) for 24 h, in the presence of IBMX (30 min 
pretreatment at 10 μM), in accordance with previously published methods (Alkhouri et al., 2014; 
Rumzhum et al., 2015b). cAMP was measured by enzyme immunoassay (cAMP EIA 581001: 
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Cayman Chemical Company) according to the manufacturer‟s instructions. For detailed 
description, see Chapter 2.2.5. 
 
7.2.5 Statistical analysis 
Statistical analysis was performed using Student's unpaired t test, one-way ANOVA then 
Fisher‟s post-hoc multiple comparison test, or two-way ANOVA then Bonferroni's post-test. P 
values<0.05 were sufficient to reject the null hypothesis for all analyses.  
 
7.3 Results 
7.3.1 PGE2 induces MKP-1 expression in ASM cells 
Previous study described that PGE2 induces cAMP production (Ammit et al., 2002), and as 
cAMP upregulation induces MKP-1 expression in ASM cells (Patel et al., 2015a) it makes sense 
to show PGE2-induced MKP-1 mRNA expression in ASM and, more importantly, to show 
whether it is mediated via EP2 and/or EP4 receptors. As mentioned before, we used selective 
antagonists, PF-04418948 to block the EP2 receptor, and GW 627368X to block the EP4 
receptor. We found that PGE2 (0.1-1000 nM) dose-dependently increases MKP-1 mRNA 
expression (Figure 7.1). Notably, pretreatment of cells with PF-04418948 or GW 627368X (both 
at 1 µM) for 30 min, prior to 1 h treatment with a range of concentrations of PGE2 (0.1-1000 
nM), didn‟t show any differences in MKP-1 mRNA expression (Figure 7.1). This suggests that 
neither EP2 nor EP4 receptors are solely responsible for PGE2-induced MKP-1 expression, or 
perhaps other receptors or mechanisms are involved. 
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Figure 7.1 PGE2 induces MKP-1 expression and the role of EP2 and EP4 receptors. Growth-
arrested ASM cells were pretreated for 30 min with vehicle or PF-04418948, EP2 antagonist, 
(1μM)  or GW 627368X, EP4 antagonist (1μM) followed by a range of PGE2 concentrations 
(0.1-100 nM). After 1 h MKP-1 mRNA expression was measured by RT-PCR. Statistical 
analysis was performed using one-way ANOVA and Fisher‟s PLSD (where * denotes a 
significant upregulation of MKP-1 mRNA compared to vehicle control (P<0.05)). Data are 
mean±SEM values from n=4 primary ASM cell cultures. 
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7.3.2 Role of EP receptor antagonists on PGE2-induced β2-AR desensitization (short 
protocol) 
In chapter 4, we measured PGE2-induced cAMP levels to describe β2-AR receptor 
desensitization where cells were allowed to grow for 48 h before serum starvation (short 
protocol). Following the same condition herein, we aim to explore the pathways for PGE2-
induced β2-AR desensitization, in particular, the role of EP2 or EP4 receptor is identified. To 
confirm this, ASM cells were pretreated for 24 h with a range of concentrations of PGE2 (0.1–
100 nM) and cAMP production was measured in response to two β2-agonists: long-acting β2-
agonist formoterol (Figure. 7.2A) and short-acting β2-agonist salbutamol (Figure. 7.2B). In 
accordance with previous findings (Chapter 4-6), this result also showed that pretreatment with 
PGE2 induced heterologous β2-AR desensitization in a concentration-dependent manner (P<0.05) 
in response to both the β2-agonists. Interestingly, we found that antagonism of the EP2 receptor, 
but not the EP4 receptor, significantly blocks PGE2-induced heterologous β2-AR desensitization 
and restores cAMP production. This finding suggests that EP2 receptor may be involved in β2-
AR receptor desensitization. 
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Figure 7.2 Role of EP receptor antagonists on PGE2-induced β2-AR desensitization (short 
protocol). Growth-arrested ASM cells were pretreated for 24 h with vehicle, or a range of PGE2 
concentrations (0.1-100 nM). Desensitization of the β2-AR was assessed by measuring 
production of cAMP in response to stimulation with (A) 0.01 µM formoterol or (B) 10 µM 
salbutamol for 15 min compared to vehicle, in the presence of the pan-phosphodiesterase 
inhibitor IBMX (30 min pretreatment at 10 µM). Cells were pretreated for 30 min with PF-
04418948, EP2 antagonist, (1μM) or GW 627368X, EP4 antagonist (1μM) before PGE2 
treatment. Results are expressed as a percentage of β2-agonist-induced cAMP. Statistical analysis 
was performed using two-way ANOVA then Bonferroni's post-test (where * denotes a 
significant effect of β2-agonists or PGE2 on cAMP production, respectively (P<0.05)). Data are 
mean±SEM values from n=4 primary ASM cell cultures. 
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7.3.3 Role of EP receptor antagonists on PGE2-induced β2-AR desensitization (standard 
protocol) 
We mostly followed the standard protocol (ASM cells are allowed one week to grow before 
serum starvation) in this thesis. Data in Figure 7.2 demonstrated that EP2 antagonist reverse 
PGE2-induced β2-AR desensitization by restoring cAMP production. As such the data in Figure 
7.2 generated using short protocol; hence we aim here to explore the effect of both antagonists 
(EP2 and EP4) in PGE2-induced β2-AR desensitization following the standard protocol. ASM 
cells were pretreated with PGE2 (0.1–100 nM) for 24 h and cAMP production was measured in 
response to two β2-agonists: long-acting β2-agonist formoterol (Figure. 7.3A) and short-acting 
β2-agonist salbutamol (Figure. 7.3B). In parallel, the cells were treated with specific EP2 or EP4 
receptor antagonists, 30 min before PGE2 treatments. Although, both protocols (short and 
standard) produced similar results in terms of PGE2-induced β2-AR desensitization, variable 
results obtained in terms of antagonism. Unlike short protocol, in standard protocol none of the 
EP2 or EP4 receptor sems to be involved in β2-AR desensitization.  
  Chapter 7 
137 
 
 
 
Figure 7.3 Role of EP receptor antagonists on PGE2-induced β2-AR desensitization 
(standard protocol). Growth-arrested ASM cells were pretreated for 24 h with vehicle, or a 
range of PGE2 concentrations (0.1-100 nM).Desensitization of the β2-AR was assessed by 
measuring production of cAMP in response to stimulation with (A) 0.01 µM formoterol or (B) 
10 µM salbutamol for 15 min, compared to vehicle, in the presence of the pan-phosphodiesterase 
inhibitor IBMX (30 min pretreatment at 10 µM). Cells were pretreated for 30 min with PF-
04418948, EP2 antagonist, (1μM) or GW 627368X, EP4 antagonist (1μM) before PGE2 
treatment. Results are expressed as a percentage of β2-agonist-induced cAMP. Statistical analysis 
was performed using two-way ANOVA then Bonferroni's post-test (P<0.05)). Data are 
mean±SEM values from n=4 primary ASM cell cultures. 
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7.4 Discussion 
The human lung is a rich source of prostaglandins, particularly PGE2 (Karim et al., 1967). 
Despite intense research for several decades focusing on the functional effects of PGE2 in the 
lung and other tissues, this interesting molecule still offers a vast scope of study to uncover the 
complex biology associated with it. PGE2 is a multifunctional protein and its actions are 
mediated via complex crosstalk between EP1-4 receptors (Figure 7.4) (Chell et al., 2006). 
Previous reports have revealed the expression of EP2 and EP4 receptors in ASM cells that upon 
ligand binding lead to the secretion of cAMP (Clarke et al., 2004; Clarke et al., 2005a; Clarke et 
al., 2005b). Anti-inflammatory protein, MKP-1 is a promising target to attenuate the 
inflammatory responses mediated by MAPK activation (Franklin and Kraft, 1997; Abraham and 
Clark, 2006). MKP-1 serves a crucial negative feedback role in regulating pro-remodelling signal 
transduction. The anti-inflammatory action of MKP-1 is shown to be mediated in a cAMP 
dependent manner in ASM cells (Manetsch et al., 2012a; Manetsch et al., 2013; Patel et al., 
2015a). Moreover, MKP-1 expression is found to be CREB responsive (Cho et al., 2009).  This 
study is the first to explore the direct effect of PGE2 on MKP-1 expression. As a cAMP elevating 
agent PGE2 dose dependently upregulates MKP-1 mRNA expression. Moreover, this effect 
found unaffected using EP2 or EP4 antagonists, indicating that these receptors are not involved in 
PGE2-induced MKP-1 secretion. Further experiments to reveal the molecular pathways 
associated with PGE2-induced MKP-1 protein level and identify the cAMP mediated 
downstream signalling pathways are warranted. 
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Figure 7.4 PGE2 signalling pathways through EP1-4 receptors (Chell et al., 2006). 
 
We have also attempted to explore the underlying molecular pathways of PGE2-induced β2-AR 
using two different established protocols for cAMP experiments; short (cells are allowed to grow 
for 48 h) and standard (cells are allowed to grow for one week). Although using the short 
protocol it appears EP2 may be involved in β2-AR receptor desensitization as EP2 antagonist 
restores the cAMP level which was repressed by PGE2, but, the standard protocol did not 
reproduce the same result. However, in both protocols it was found that stimulation with PGE2 
induces heterologus desensitization of β2-AR in ASM cells. It is not clear what causes the 
apparent disparity between these studies in terms of receptor antagonism, but due to the 
difference in cell plating time among these two protocols, a number of possibilities can be 
considered including, differential production of cAMP and difference in cell cycle progression.  
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Previous reports also suggest that identifying the particular receptor(s) involved in prostanoid-
mediated events is complicated due to the complex association of the ligands with the receptor 
subtypes and similarity in second messenger pathways (Tsuboi et al., 2002). In this study, we 
only focused on EP2 and EP4 receptors, which didn‟t appear to play a major role in mediating the 
PGE2 responses in the context of β2-AR desensitization in our in vitro ASM cell model. 
However, our findings don‟t rule out the role of other two EP receptors, EP1 & EP3, in the same 
experimental settings.  Further, great advances in last few years have identified selective, well 
characterized compounds to study independent receptor functions and knock-out mice generation 
for all prostanoid receptors and subtypes. This will help to elucidate the physiological and 
potential pathological roles of this receptor family (Kobayashi and Narumiya, 2002; Naganawa 
et al., 2006; Murase et al., 2008; Maubach et al., 2009; Singh et al., 2009; af Forselles et al., 
2011). Future experiments to understand the further levels of EP receptor regulation are 
warranted. 
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Chapter 8 
General Discussion and Conclusion 
 
8.1 Overview 
Millions of people worldwide are affected by asthma and its prevalence is increasing day by day. 
It is the most common chronic disease both in children and adults and a major cause of disability 
and poor quality of life: physically, emotionally, socially and professionally, for those who are 
affected. Asthma prevalence is high (> 10%) in developed countries and rates are increasing in 
developing regions as they become more westernized. It is, therefore, regarded as a global 
burden (Braman, 2006). Along with loss of health and work productivity, its global prevalence 
also causes economic hardship due to increasing health resource utilization and consumption of 
considerable health care costs. Despite considerable efforts having been taken over the past 
decades into understanding the many aspects of asthma, the basic causes of the disease 
mechanism and the reasons for its increased prevalence remain largely unknown. 
Asthma is a chronic pulmonary inflammatory diseases characterized by airway inflammation, 
airway hyperresponsiveness and airway remodelling. It is a long term disease that has no cure 
although good therapeutic management can control its severity by maintaining good lung 
function. Currently, corticosteroids and β2-agonists are the most commonly used therapy against 
the inflammatory condition caused by asthma. However, glucocorticoid insensitivity is a 
considerable problem in respiratory disease, as is β2-AR desensitization. Acute exacerbations of 
asthma are of particular importance in these cases, where the drugs become much less effective 
or the receptors become irresponsive. Viruses and bacteria are considered the most common 
cause of asthma exacerbation. It is therefore very important to understand the molecular 
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mechanisms underlying receptor hyporesponsiveness in the infectious asthmatic condition to 
improve the efficacy of drug treatment. A better insight into the pathways and mechanisms 
associated with infectious asthmatic conditions would allow us to use this knowledge for the 
future development of anti-inflammatory therapy with the most targeted but least side effects. In 
this project, we therefore aimed to explore the underlying molecular mechanisms involving 
TLR2 receptor activation, COX-2 protein upregulation and β2-AR desensitization in ASM cells 
during infectious asthma exacerbation. 
 
8.2 Our approaches 
In this thesis we have focussed on the role of the ASM in asthma and asthma exacerbation. The 
primary ASM cell lines were established from human bronchi obtained from patients undergoing 
surgical resection for carcinoma or lung transplant donors in accordance with procedures 
approved by the Sydney South West Area Health Service and the Human Research Ethics 
Committee of the University of Sydney. 
Apart from mucus plugging and swelling of airway tubes, ASM cells are believed to be the main 
effector cells that amplify airway narrowing and airway remodelling by changing their (ASM 
cells‟) proliferative, contractile and synthetic functions via a number of inflammatory signalling 
pathways. Moreover, ASM cells play a role in the amplification of inflammatory responses 
during infectious exacerbations in asthma via augmented cytokine production. Further, recent 
detection of functional TLRs expression in ASM cells has great potential in utilizing ASM cells 
as a model of infectious asthma exacerbation. The main aim of this thesis, therefore, was to 
investigate the bacterial infections (TLR2 engagement by Pam3CSK4) generated outcomes in 
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ASM cells. The role of ASM cells in inflammasome activation and COX-2 secretion upon TLR2 
ligation was identified.  
Further studies investigated the molecular mechanisms underlying COX-2 upregulation and its 
regulation and impact on airway inflammation. COX-2 has long been regarded as playing a 
pivotal role in the pathogenesis of airway inflammation in respiratory diseases such as asthma 
and COPD. COX-2 can be rapidly and robustly expressed in response to a diverse range of pro-
inflammatory cytokines and mediators. Thus, increased levels of COX-2 protein and prostanoid 
metabolites serve as key contributors to pathobiology in respiratory diseases typified by 
dysregulated inflammation. Bronchodilators, β2-agonists are the front line therapy in bronchial 
asthma. However, it is well-recognized that the β2-AR on human ASM cells is subject to 
heterologous desensitization induced by a COX-2 product, PGE2. These studies aimed to 
investigate the clinical consequences of COX-2-mediated upregulation of PGE2 in ASM cells in 
the context of β2-AR desensitization. 
This was addressed by five projects: 
1. Identifying the possible role of TLR2-induced activation of inflammasome in ASM 
cell cytokine secretion 
 TNFα-induced IL-1β mRNA expression and augmentation by Pam3CSK4 
 Pam3CSK4 potentiates TNFα-induced IL-6 and IL-8 protein secretion, but IL-1β 
is not secreted from ASM cells 
 Neutralization of IL-1β in conditioned media has no effect on cytokine secretion 
 Pam3CSK4 does not affect TNFα-induced NLRP3 and caspase-1 mRNA 
expression in ASM cells 
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This part of the study provides a better understanding of how infectious inflammatory stimuli 
affect pro- and anti-inflammatory mechanisms in ASM cells. Although the TLR2 ligand, 
Pam3CSK4, robustly up-regulated ASM cytokine expression in response to TNFα and 
significantly enhanced IL-1β mRNA expression, we were unable to detect IL-1β in the cell 
supernatants. Thus, we suggested that IL-1β was not secreted and therefore was unable to act in 
an autocrine manner to promote the amplification of ASM inflammatory responses. In 
conclusion, these data demonstrate that the enhanced synthetic function of ASM cells, induced 
by infectious exacerbations of airway inflammation, is NLRP3 inflammasome and IL-1β 
independent. Although NLRP3 is found to be present in human airway epithelium, these results 
prove that this protein is not detected in the nearby ASM bundles, suggesting that activation of 
the NLRP3 inflammasome by invading pathogens may prove cell type specific in exacerbations 
of airway inflammation in asthma. 
2. Investigation of TLR2-induced β2-AR desensitization via COX-2 production 
 TLR2 ligand engagement upregulates TNFα-induced COX-2 mRNA expression 
and increases PGE2 secretion 
 PGE2 induces heterologous β2-AR desensitization as measured by inhibition of 
β2-agonist-induced cAMP production 
 Celecoxib inhibits PGE2 secretion but not COX-2 mRNA expression 
 Pam3CSK4 + TNF cause tachyphylaxis of β2-AR agonists mediating MKP-1 
gene expression and this can be reversed by celecoxib 
This study gives an insight into the functional outcomes associated with TLR2-induced COX-2 
in the context of β2-AR desensitization. Utilizing an in vitro model of bacterial exacerbation in 
ASM cells we showed that activation of TLR2 in the presence of an inflammatory stimulus leads 
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to β2-AR desensitization. This occurs via TLR2 dependent upregulation of COX-2 mRNA 
expression and increased secretion of PGE2. Importantly, PGE2 causes heterologous β2-AR 
desensitization and reduces cAMP and MKP-1 production in response to short-acting 
(salbutamol) and long-acting (formoterol) β2-agonists. Thus, infectious bacterial stimuli act in a 
PGE2-dependent manner to severely curtail the beneficial actions of β2-agonists.  
3. Examination of COX-2 expression and PGE2 secretion by S1P and its effects on β2-
AR desensitization 
 S1P upregulates COX-2 mRNA expression and protein upregulation to increase 
PGE2 secretion from ASM cells 
 COX-2 knockdown by siRNA represses S1P-induced COX-2 mRNA expression, 
protein upregulation and PGE2 secretion 
 TNF enhances S1P-induced COX-2 mRNA expression and protein upregulation 
and increases PGE2 secretion  
 S1P induces heterologous β2-AR as measured by inhibition of β2-agonist-induced 
cAMP production; in a manner independent of adenylate cyclase 
It was shown that S1P plays an important role in the pathophysiology of asthma and also induces 
β2-AR desensitization in bronchial ASM cells and exerts hyporesponsiveness to β2-agonists. 
ASM cells were treated with S1P (1 μM) for up to 24 h and then the temporal kinetics of COX-2 
mRNA expression, protein upregulation and PGE2 secretion were examined. S1P significantly 
enhanced COX-2 expression and PGE2 secretion and this was repressed by the selective COX-2 
inhibitor, celecoxib, the corticosteroid dexamethasone, or siRNA knockdown of COX-2 
expression. In combination with another pro-inflammatory mediator found elevated in asthmatic 
airways, the cytokine TNFα, it was observed that S1P-induced COX-2 mRNA expression and 
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protein upregulation and also PGE2 secretion from ASM cells was significantly enhanced. 
Notably, S1P-induced heterologous β2-AR as measured by inhibition of cAMP production in 
response to the short-acting β2-agonist, salbutamol, and the long-acting β2-agonist, formoterol. 
Taken together, these data indicate that S1P represses β2-adrenergic activity in ASM cells by 
increasing COX-2 mediated PGE2 production, and suggest that this bioactive sphingolipid found 
elevated in asthma may contribute to β2-AR desensitization. 
4. IL-17A increases TNF-induced COX-2 protein stability and augments PGE2 
secretion from ASM cells 
 IL-17A augments TNF-induced PGE2 secretion, but does not increase TNF-
induced COX-2 mRNA expression 
 IL-17A increases TNF-induced COX-2 protein upregulation 
 Proteasome inhibitors increase TNFα-induced COX-2 protein and PGE2 secretion 
 IL-17A enhances TNFα-induced COX-2 protein stability  
 Heterologous β2-AR desensitization as measured by inhibition of β2-agonist-
induced cAMP production in ASM cells: effects of IL-17A ± TNF 
IL-17A plays an important role in respiratory diseases and is a known regulator of pulmonary 
inflammation and immunity. Recent studies have linked IL-17A with exacerbation in asthma and 
COPD. In this study, we showed that IL-17A induces a robust and sustained upregulation of 
COX-2 protein and PGE2 secretion from ASM cells. COX-2 can be regulated at transcriptional, 
post-transcriptional and/or post-translational levels. We have elucidated the underlying 
molecular mechanisms responsible for the sustained upregulation of TNF-induced COX-2 by 
IL-17A in ASM cells and showed that it is not via increased COX-2 gene expression. Instead, 
TNF-induced COX-2 upregulation is subject to be regulated by proteasome, and IL-17A acts to 
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increase TNF-induced COX-2 protein stability by preventing its proteosomal degradation. In 
this way, IL-17A acts to amplify the COX-2-mediated effects of TNF and greatly enhances 
PGE2 secretion from ASM cells. As PGE2 is a multifunctional prostanoid with diverse roles in 
respiratory disease, the experimental results demonstrate a novel function for IL-17A in airway 
inflammation.  
Identifying the role of specific EP receptors 
 Role of EP2 and EP4 receptors in PGE2-induced upregulation of MKP-1 
 Role of EP2 and EP4 receptors in PGE2-induced β2-AR desensitization 
This study aimed to explore the different functional outcomes related molecular pathways 
generated by the diverse functional molecule PGE2. Considering that PGE2 synthesis is initialized 
by COX-2 and then binds with four distinct receptors, EP1-4, each with exclusive expression 
patterns throughout the body; it is predictable that this prostanoid is implicated in many and 
sometimes seemingly opposing functions in humans. PGE2 is a bronchorelaxant via releasing 
cAMP by binding with EP2 and EP4 receptors. MKP-1 is a critical anti-inflammatory protein that 
is produced by cAMP mediated pathways. As a cAMP elevating agent, this study attempted to 
show the effect of PGE2 on MKP-1 mRNA expression directly and for the first time herein, it 
was shown that in ASM cells PGE2 dose dependently induces MKP-1 mRNA expression. 
However, we were unable to antagonize this effect by using specific EP2 and EP4 receptor 
antagonists. This indicates that these receptors might not be involved in this process. In previous 
studies we demonstrated that COX-2 mediated PGE2 is responsible for β2-AR desensitization. 
Further studies were therefore attempted to elucidate the role of the specific receptors 
responsible for this effect. Two different established protocols were followed. According to short 
protocol, it appears that EP2 but not EP4 is associated with β2-AR desensitization. Using the 
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standard protocol, however, these results were not in agreement. The precise mechanism by 
which PGE2 contributes to the inflammatory response by causing β2-AR desensitization has not 
yet been identified, although some preliminary evidences that warrant further work to clarify 
which class of receptor is involved have been provided. 
Collectively, the results gained from these studies have provided answers to the initial research 
aims. It has been established that TLR2 activation by Pam3CSK4 in an in vitro ASM cell model 
does not activate NLRP3 inflammasomes but does induce COX-2 and PGE2 production. It was 
also shown that inflammatory stimuli, S1P and IL-17A, also upregulate COX-2-induced PGE2 in 
this in vitro model. Reduced responsiveness of β2-AR is a characteristic feature in asthma 
exacerbation. Our studies demonstrate that the TLR2 agonist, Pam3CSK4, and S1P cause β2-AR 
desensitization in the presence of TNFα. The study using IL-17A has provided intriguing 
evidence to suggest that TNF-induced COX-2 upregulation is subject to be regulatrd by the 
proteasome, and IL-17A acts to increase TNF-induced COX-2 protein stability. Further, some 
preliminary evidences have been provided to identify the specific role of EP2 and EP4 receptors 
in the context of airway inflammation. The main findings from this thesis are outlined in a 
schematic diagram (Figure 8.1). 
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Figure 8.1 Conclusion schematic of this project’s findings 
 
8.3 Conclusions and future directions 
A growing body of evidence related to TLR2 signalling has demonstrated important relationships 
between these pathways and infectious asthma exacerbation. Activation of TLRs by microbial 
components triggers expression of several genes that are involved in immune responses. The aim 
of this thesis was to identify the signalling cascades that lead to bacteria-induced asthma 
exacerbation. In particular, the involvement of TLR2 receptor activation and COX-2 protein 
upregulation in disease exacerbation has been examined. The experimental results suggest that 
manipulation of TLR pathways, thereby controlling the expression of further inflammatory 
mediators, will provide great therapeutic potential in the treatment of asthma and COPD. 
Evidence has been provided that TLR2 ligand engagement is unable to induce inflammasome 
activation. This proves that inflammasome activation appears to be cell-type specific in airway 
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inflammation. It would be of interest to investigate further crosstalk between airway structural 
cells and inflammatory cells in the context of the functional relevance of the restricted 
localization of the NLRP3 inflammasome in the airways.  
Further, it has been shown that TLR2 engagement increased COX-2 expression and therefore, 
PGE2 release by ASM cells. A previous report suggests that COX-2 products, including PGE2, 
are responsible for rhinovirus-induced β2-AR desensitization (Van Ly et al., 2013). In 
accordance with that, this study supports the premise that bacterial infection directly affects β2-
AR function in a similar manner to viral infection. To date, β2-agonists are considered the first 
line therapy for asthma, and β2-AR present in ASM cells are the most important target of β2-
agonist therapy. However, an increasing body of evidence suggests that several cytokines present 
in the airway microenvironment are some of the most important factors that influence β2-AR 
responsiveness in ASM (Shore and Moore, 2002). This study has shown that, as with TLR2 
agonist, S1P has the potential to repress β2-adrenergic activity via increasing COX-2 mediated 
PGE2 production in ASM cells. However, the study with 1L-17A suggested that due to its 
inability to induce PGE2, IL-17A did not cause β2-AR desensitization.  
The data presented has increased the knowledge of the mechanistic basis for the β2-AR 
dysfunction in asthma and may prove to be an important step in improving the efficacy of these 
agents, as well as provide new ways to discover the roles of bacterial infection in asthma 
pathogenesis and exacerbation. We suggest that more targeted therapies are needed to prevent β2-
AR desensitization in response to viral and bacterial infections. 
According to accumulating research it is obvious that not only COX-2 but also its products, 
prostanoids, play an important role in the pathophysiology of several pulmonary dysfunctions. 
Moreover, prostanoids show their diverse functions, either pro-inflammatory or anti-
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inflammatory, by binding with several receptor subtypes. There are at least eight types and 
subtypes of membrane prostanoid receptor forms characterized in mouse and human, including 
two subtypes of the PGD receptor (DP1 and DP2), four subtypes of the PGE receptor (EP1, EP2, 
EP3, and EP4), the PGF receptor (FP), the PGI receptor (IP) and the TxA receptor (TP) 
(Narumiya and FitzGerald, 2001). Binding of receptor specific ligands with their respective 
receptors can result in varying responses in different cells and tissue types that may be either 
beneficial or deleterious. In brief, PGD2 is a potent bronchoconstictor and vasodilator acting via 
DP1, DP2 and the TP receptor (Johnston et al., 1995; Larsson et al., 2011). PGI2 is capable of 
restraining allergic airway inflammation in mice by inhibiting dendritic cell activation of CD4+ 
Th2 cells, Th2 cell differentiation and eosinophil migration through the IP receptor. Among 
other factors, prostanoid thromboxane A2 (TXA2) is considered to be an inflammatory and 
bronchoconstrictive mediator in asthma and PGF2α plays an important role in pulmonary fibrosis 
(Claar et al., 2015). The activity of PGE2 via signalling through EP2 and EP4 receptors promotes 
the accumulation of cAMP. This leads to smooth muscle relaxation, whereas EP1 and EP3 
receptor activation increases intracellular calcium or decreases cAMP generation that could be 
associated with smooth muscle contraction (An et al., 1993; Coleman et al., 1994; Qian et al., 
1994; Breyer et al., 2001; Vancheri et al., 2004; Kay et al., 2006; Foudi et al., 2008; Machado-
Carvalho et al., 2014; Claar et al., 2015). Our results demonstrate both the inflammatory and 
anti-inflammatory effects of PGE2 by causing β2-AR receptor desensitization and by releasing 
the anti-inflammatory protein, MKP-1, respectively. This could be attributed to the association of 
different EP receptors with various physiological functions. 
The complexity of COX-2 and prostaglandin in the pathogenesis of inflammatory lung diseases 
is well reviewed by Park et al. (Park and Christman, 2006). Up until now the most common way 
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to target COX-2 has been to inhibit its enzymatic activity via non-selective (e.g. NSAIDs) or 
selective inhibitors (such as coxibs). The complete inhibition of COX enzyme with non-selective 
drugs inhibits both COX-1 and COX-2, producing severe side effects by blocking the good 
prostanoids production via COX-1. Taking this into account, a number of selective COX-2 
inhibitors have been discovered but as some COX-2 products also exhibit protective role in 
various circumstances, it is crucial to gain further knowledge about the mechanism of COX-2 
inhibitors in airway cells. 
As the challenge now lies in discovering the potential target to overcome β2-AR desensitization, 
our project aimed to identify a specific receptor mediating the COX-2/ PGE2-induced β2-AR 
desensitization in ASM cells. We propose that selectivity profiling of each receptor subtype is as 
equally important as exploring specific receptor agonists or antagonists with the most targeted 
but least side effects in the context of inflammatory respiratory diseases. Further studies using 
individual prostanoid receptors in knocked-out mice will offer a new avenue for greater 
understanding the impact of COX-2 products in clinically relevant respiratory disease. 
We hypothesised that TLR2 receptor activation may upregulate inflammasomes and COX-2 in 
ASM cells. We found that NLRP3 inflammasomes were not activated in ASM upon TLR2 
ligation. However, our experimental settings cannot rule out the presence of other 
inflmmasomes. This warrants future investigation. Moreover, although earlier report suggests 
that in some in vitro settings a secondary signal is necessary to stimulate active inflammasomes 
secretion (Netea et al., 2009), we didn‟t attempt that in our study. That may explain our negative 
results. Therefore, we believe that there is a wide scope for future experiments in this area. 
Intriguingly, in a parallel study, we found that COX-2 protein is upregulated in ASM cells upon 
TLR2 ligation. Considering the potential role of COX-2 in airway inflammation, we further 
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hypothesized that COX-2 may cause β2-AR receptor desensitization via PGE2 secretion. Our data 
demonstrated that, not only TLR2 ligand, but also S1P, caused β2-AR desensitization via the 
COX-2-dependant PGE2-mediated pathway. Another important inflammatory mediator, IL-17A, 
although having no effect on β2-AR desensitization, induced stabilization of COX-2 protein, 
which is a novel finding. In our studies, we investigated the direct effects of S1P and IL-17A on 
COX-2 upregulation. Previous reports, however, suggest that these inflammatory cytokines can 
be released or have a potential link with infectious asthmatic conditions (Essilfie et al., 2011; van 
Rossum et al., 2014; Lunding et al., 2015; Roos et al., 2015). Thus, further investigations linking 
infection and S1P & IL-17A mediated COX-2 upregulation is necessary. We believe these 
research findings will advance our knowledge in the context of β2-AR desensitisation and merits 
further investigation using contemporary experimental models to translate into clinical outcomes.   
However, the studies performed in this thesis are not out of limitation. In this project, we used 
mimic bacterial infection PAM3CSK4, although it is an established TLR2 ligand, we feel that the 
use of the actual pathogen may strengthen our findings. Moreover, due to rare availability of 
asthmatic cells, we used non-asthamtic ASM cells in our studies. Research findings support that 
there are some intrinsic differences between asthmatic and non-asthmatic cells in terms of cell 
proliferation and expression of various matrix proteins, as well as altered calcium handling 
(Johnson et al., 2001; Johnson et al., 2004; Mahn et al., 2010). This should be considered in 
future studies. 
In conclusion, this thesis provides further understanding of the TLR2 receptor activation and 
COX-2 upregulation in ASM cells. The research carried out explored the role of COX-2, induced 
by TLR2 agonist and some other inflammatory mediators, in β2-AR desensitization. Further, this 
is the first evidence showing IL-17A-induced COX-2 regulation in ASM cells. Overall, we 
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strongly believe that, according to the results of this project, we are now well-positioned to 
unravel some important complexities associated with asthma exacerbation and hopefully develop 
efficacious pharmacotherapeutic strategies to treat respiratory disease without unwanted side 
effects. Hopefully, this will happen in the near future.  
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